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Abstract 
Introduction 
Vaccination is a vital and effective component of communicable disease control. In Australia, a 
publicly funded National Immunisation Program provides free vaccines for children and adults. 
Evaluation of the impact and effectiveness of vaccination programs is necessary for providing an 
evidence base for vaccination policy decision-making. 
Several methods exist to evaluate vaccine impact. The most efficient of these apply analytic 
methods to existing health datasets. In this thesis I use routinely collected and linked data to assess 
aspects of three childhood vaccines funded by the National Immunisation Program: pertussis, 
varicella, and rotavirus. 
Methods 
Routinely collected health outcome data from Queensland, including hospitalisation, emergency 
department presentation, and disease notification data, were linked to vaccination data from the 
Queensland Vaccine Information and Vaccine Administration System. I compared program impact 
in children who received their primary course around the time of switching from whole cell 
pertussis vaccines (wP) to acellular pertussis (aP) vaccines. With the linked data, I calculated the 
current vaccine effectiveness (VE) of aP in Queensland children for preventing pertussis 
notifications and hospitalisations using the screening method. The effectiveness of monovalent 
varicella vaccine (VV) was also calculated adopting a case-control design, with Queensland cases 
matched to controls from the Australian Childhood Immunisation Register. In addition, by 
employing routinely collected national and Queensland health outcome data, I calculated and 
compared varicella and herpes zoster hospitalisation rates before, and after commencement of, 
public VV funding. Finally, rotavirus VE for preventing febrile seizures was estimated similarly 
using the screening method. 
Results and discussion 
I found children primed with wP had substantially lower rates of pertussis in childhood than 
children primed with aP. During the epidemic years of 2009 to 2011, children who received a 
primary course of aP in early childhood had three times the risk of pertussis notification than those 
primed with wP. The differential effectiveness of wP and aP remained when controlled for age and 
receipt of booster doses. Among mixed (wP and aP) primary course recipients, those receiving wP 
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as the initial dose were more protected than those receiving an initial dose of aP. During the 2009 
and 2010 epidemic years in Queensland, aP was highly effective at preventing pertussis in children 
aged 1-<4 years with point VE estimates between 84% and 89% against pertussis notification and 
hospitalisation, respectively. However, similar to findings from the United States, VE waned with 
increasing age, with point VE estimates of 36% to 71% in 2010 among children aged 5-<12 years. 
My findings suggest that priming with a moderately effective wP vaccine is more protective than 
aP, and the nature of the initial vaccine received may be particularly influential in determining long- 
term protection. 
In the first estimate of VE since public funding of VV in Australia, I found a single dose of VV was 
81.9% (95% confidence interval [CI]: 61.8-91.4) effective at preventing varicella hospitalisation 
among children aged 19 months to <6 years. The VV program has led to significant reductions in 
the burden of moderate to severe varicella disease with age-standardised varicella hospitalisation 
rates declining by >70% in 2011-2014 compared to the pre-funded vaccine period 2000-2003. 
However, chickenpox outbreaks continue to occur in childcare centres and schools, even with high 
coverage of a single VV dose. 
Reassuringly, and despite expert predictions, national age-standardised herpes zoster hospitalisation 
rates have not increased significantly after almost nine years of funded VV. Age-specific patterns of 
herpes zoster have however been more varied. Comparing the most recent VV funded period of 
2010/2011-2013/2014 to the pre-vaccine period of 1998/1999-1999/2000, herpes zoster 
hospitalisation rates declined significantly by >50% among children aged <10 years, by 16% among 
70-79 year olds, but in contrast increased by 37% among 40-49 year olds. The lack of increase in 
hospitalisations among older age-groups, despite high vaccine coverage, may indicate that 
exogenous boosting plays a lesser role than immunosenescence in protecting against zoster than 
thought previously. These findings may inform vaccine policy decisions on inclusion of a second 
VV dose, and provide a baseline from which to assess the impact of the soon-to-be publicly funded 
adult zoster vaccine. 
Rotavirus vaccines have had a substantial impact on the large burden of gastroenteritis 
internationally, including in Australia. In agreement with a report from the United States, I was able 
to show rotavirus vaccine also provided the unexpected benefit of being moderately effective in 
preventing febrile seizures in Queensland children, with a VE of 35.8% (95% CI: 26.0-44.2) among 
children aged between 8 months and 2 years, 7 months, at preventing emergency department 
presentations for this condition. 
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Conclusions 
Routinely collected and linked health data are a powerful, resource-efficient tool to evaluate and 
gain insight into the real-world impact and effectiveness of vaccines. Ongoing monitoring of 
vaccine impact and effectiveness following vaccine program implementation provides important 
evidence to support vaccination policy decision-making as longer-term, post-marketing population- 
based surveillance may reveal outcomes unanticipated in pre-licensure vaccine trials. 
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Chapter 1: Introduction 
Vaccination is a vital and effective component of communicable disease control. The National 
Immunisation Program (NIP) is a joint Australian Commonwealth and state/territory government 
public health program providing free vaccines for major vaccine preventable diseases in both 
children and adults, but which is also growing in expense and complexity (1). In 1996, vaccines 
against eight diseases were universally funded at an expense of AUD$13 million per annum (2). 
The NIP included vaccines against 16 diseases costing over AUD$350 million per annum in 2011- 
2012 (3). Inclusion of a new live-attenuated vaccine to prevent herpes zoster (Zoster Vaccine Live 
or Zostavax ®; Seqirus/Merck & Co Inc) in older Australians onto the NIP in late 2016 will further 
increase the program’s cost. 
An integral part of public health interventions of this size should be routine assessment of the 
program’s effectiveness in preventing disease. Assessing vaccine effectiveness (VE) and impact can 
provide a current and locally relevant evidence base for vaccination policy decision-making, whilst 
maintaining confidence in vaccination programs for health practitioners and the community. My 
research therefore aims to contribute to the evidence base by assessing the VE of three vaccines 
included on the NIP: pertussis (whooping cough), rotavirus, and varicella (chickenpox), using 
routinely collected Queensland data. 
Thesis aims 
The aims of the projects contributing to my thesis are described for each of the vaccines studied. 
Pertussis vaccine: 
1. Compare the effectiveness of whole-cell pertussis vaccine and acellular pertussis vaccine primed 
children in Queensland (Chapters 3.1; 3.2; 3.3) 
2. Assess the VE of acellular pertussis vaccine against pertussis notification and hospitalisation in 
children in Queensland in 2009 and 2010 (Chapter 3.4) 
3. Describe the recent pertussis epidemiology of adolescents primed with whole-cell and acellular 
pertussis vaccines (Chapter 3.5) 
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Varicella vaccine: 
1. Assess the VE of a single dose of varicella vaccine against varicella hospitalisation and 
emergency department presentation in children in Queensland (Chapter 4.1) 
2. Assess the impact of the varicella vaccine program on herpes zoster morbidity in Australia 
(Chapter 4.2) 
Rotavirus vaccine: 
1. Review the impact of rotavirus vaccination in Australia and internationally (Chapter 5.1) 
2. Assess the VE of rotavirus vaccine in preventing febrile seizures in Queensland (Chapter 5.2) 
Thesis structure 
My thesis contains three major research components aligned to each one of the three diseases 
studied. In Chapter 2, I provide a brief literature review for each of the vaccines researched: 
pertussis, varicella, and rotavirus, followed by an overview of the methods used in vaccine 
effectiveness assessment. Chapters 3, 4, and 5 address the research aims relating to pertussis 
vaccine, varicella vaccine, and rotavirus vaccine, respectively. Each of these chapters is comprised 
of one or more publications or submitted manuscripts. In addition to a submitted manuscript, 
Chapter 4 contains a section incorporating a research paper that has not been submitted for 
publication. In Chapter 6, I discuss the findings of the preceding chapters, detail the key Australian 
issues in the sphere of vaccine epidemiology research, discuss the clinical and public health 
implications of my research findings, and draw my overall conclusions. 
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Chapter 2: Literature Review and Overview of Methods 
Pertussis 
Pertussis (whooping cough) is a highly contagious respiratory infection caused by the bacterium 
Bordetella pertussis. Pertussis is transmitted through airborne droplets dispersed by coughing or 
sneezing. Up to 90% of susceptible household contacts cases acquire the disease (4). Whilst people 
can develop pertussis at any age, young children, particularly infants younger than 6 months of age, 
are most at risk of severe disease. Hence a major aim of pertussis vaccination strategies is to protect  
this most vulnerable group from disease (5). 
Symptoms of pertussis develop following an average incubation period of 9 or 10 days. The early 
symptoms, during the catarrhal stage, are mild and are indistinguishable from a minor upper 
respiratory infection (4), making early diagnosis difficult. The cough gradually worsens over 1-2 
weeks until reaching the paroxysmal stage. Classic symptoms of the paroxysmal stage include 
coughing paroxysms, which may end in a high-pitched inspiratory ‘whoop’ and can be followed by 
post-tussive vomiting. The inspiratory whoop may be absent in older children, adults, and young 
infants. An infected person may become cyanotic during paroxysms, and infants may have episodes 
of apnoea. The paroxysmal stage commonly lasts between 2-6 weeks. The convalescent stage is 
characterised by a non-paroxysmal cough, which may last for many weeks (4). Even during the 
convalescent stage, subsequent respiratory infections may trigger intermittent paroxysms (6). 
Pertussis can also present as a milder, or even asymptomatic infection, in previously vaccinated 
older children, adolescents, and adults (6). However, even those with mild infection may still 
transmit disease to susceptible individuals (7). 
Apnoea, followed by pneumonia, seizures, and encephalopathy are the most common complications 
in hospitalised infants (6, 8). Young infants, too young to be fully vaccinated, are at the greatest risk 
of complications, including fulminant pertussis, which can include a combination of haemorrhagic 
pneumonia, cardiopulmonary failure, seizures, encephalopathy, and pulmonary hypertension, often 
resulting in death (4). 
Neither natural infection nor vaccination provides life-long immunity (9), with infection-acquired 
immunity estimated to provide 4-20 years of protection and vaccine-induced immunity estimated to 
provide between 4-12 years of protection (9). Although pertussis is a human disease, with no other 
animal reservoir, it remains endemic and one of the least well-controlled vaccine preventable 
diseases, even in communities with high vaccination coverage (5, 6). 
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Globally, pertussis continues to cause a substantial burden of disease, and is ranked among the top 
10 leading causes of childhood mortality, disproportionately affecting children from developing 
countries. Worldwide, over 95% of the estimated 16 million pertussis cases in 2008 occurred in 
developing countries (4) and almost 200,000 children died from the disease (10). 
Prior to the widespread availability of pertussis vaccines from the mid-20th century, pertussis was a 
common cause of morbidity and mortality among infants and children (4). Between the 1920s and 
1940s in the United States (US), pertussis incidence and mortality rates were approximately 150 
and 6 per 100,000 population per year, respectively (4). However, rates of disease greatly declined 
following widespread pertussis vaccination, with a pertussis incidence rate as low as 1.2 per 
100,000 population per year in the 1980s in the US. Pertussis incidence has also greatly declined in 
Australia since mass pertussis vaccination began in the 1950s (11). 
Between 2006 and 2012 in Australia, over 1,800 infants <6 months of age were hospitalised with 
pertussis (at an average rate of 258 per 100,000 population per year), comprising 42% of all 
pertussis hospitalisations (12). During this time 10 unvaccinated infants aged <2 months died from 
pertussis (12). Though most severe in young infants, older children, adolescents, and adults 
comprise most of the pertussis cases in Australia and are important in disease transmission 
dynamics. In Australia, about half of notified pertussis cases are in people ≥15 years (13). A 
literature review found most identified sources of infant pertussis infection in high-income countries 
were household members with 55% (95% CI: 52-58) being a parent, and siblings being another 
common source of infection (14). Furthermore, during the 2008-2012 epidemic in Perth, Western 
Australia, where the highest notification rates were in children <12 years, siblings were also the 
most important source of pertussis infection in infants <6 months of age (6, 15). 
Pertussis vaccination in Australia 
Pertussis vaccination is available to Australian children as part of the NIP (16). However, pertussis 
remains prevalent in Australia, with epidemics occurring every 3-4 years, despite a long-standing 
program with high childhood vaccination coverage (5). 
Vaccination programs for pertussis started in most Australian jurisdictions in 1942, using whole- 
cell pertussis vaccine (wP) (17). Between 1953 and 1998, combined diphtheria, tetanus, and whole- 
cell pertussis vaccine (DTPw), produced locally by the Commonwealth Serum Laboratories, was 
used in Australia (17, 18). During the wP era, the incidence of pertussis dramatically declined (18). 
However, in Australia, as elsewhere, public and health care provider confidence in the wP 
component of the DTPw vaccine waned due to concern about vaccine adverse events (18-21). 
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Subsequently, the less reactogenic diphtheria, tetanus, and acellular pertussis vaccine (DTPa) 
replaced DTPw for booster doses in 1997 and for all doses on the NIP in 1999 (9, 17), with 3 dose 
DTPa coverage at 12 month of age remaining stable at around 92% since 2007 (22-26). Globally, 
high-income countries transitioned from wP to acellular pertussis vaccine (aP) from the 1990s, 
with wP use now largely restricted to lower-income countries (27, 28). 
In addition to the change from wP to aP, there have been numerous changes in the Australian 
pertussis vaccination schedule over time implemented to improve pertussis control (5). At the time 
I commenced working on this thesis (2012), the Australian vaccination schedule for pertussis 
containing vaccines included a three-dose primary vaccination course at 6 weeks, 4 months, and 6 
months of age, followed by a booster at age 4 years, with an adolescent booster of reduced pertussis 
antigen content (dTpa) given between 10 and 15 years of age (5). Several changes in pertussis 
vaccine recommendations and funding have occurred since 2012. The cocooning strategy of 
vaccinating close contacts, particularly parents, to reduce risk of pertussis exposure to infants, was 
recommended in Australia in 2003 (29). In response to the national pertussis epidemic in 2009, 
States and Territories funded time-limited cocooning programs in their jurisdictions (30). As of 
2015, only Victoria and the Northern Territory continue to fund a cocoon program (31). 
Assessments of coverage in the various cocoon programs has not been systematically captured. In 
the only published study to date, maternal coverage in early infancy in the control population of a 
New South Wales case-control study was 51% (32). 
In July 2014, the Queensland Government funded dTpa for women during their third pregnancy, 
and by June 2015, all Australian States and Territory Governments funded maternal pertussis 
vaccination (31). In March 2016, the 18 month DTPa booster was re-instated, funded through the 
NIP following recommendation from the Pharmaceutical Benefits Advisory Committee (PBAC) 
(17, 33). PBAC recommended adding maternal pertussis vaccination to the NIP in July 2016 (34). 
At this time PBAC also requested advice from the Australian Technical Group on Immunisation 
(ATAGI) on the effectiveness of the full pertussis vaccination schedule in order to potentially 
inform a review of the cost effectiveness of these vaccines (34, 35). The request from the 
Department of Health for ATAGI to provide advice on the clinical place and effectiveness of the 
adolescent booster, as part of the overall pertussis vaccine schedule, may signal removal of the 
high school pertussis booster (36). 
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Recent pertussis epidemiology in Australia 
Queensland, along with the rest of Australia, experienced a particularly large and sustained 
pertussis epidemic beginning in 2009. In addition to the unprecedented annual numbers of 
pertussis notifications, there was also a new pattern of disease with the highest pertussis 
notification rates occurring in pre-adolescents, aged between 6 and <12 years in 2010. This was 
despite high primary- course and booster vaccine coverage in children for over a decade (37). 
Since the earliest available records from the Australian Childhood Immunisation Register (ACIR) 
in 1999, over 86%, and generally over 90% of children are ‘fully vaccinated’, a definition that 
includes three doses of a pertussis containing vaccine, at 12 months of age (37). A similar pattern 
of disease was reported in California (38, 39), which, like Australia, had changed from wP to aP in 
the late 1990s (40). In both Queensland and California, the highest notification rates during 2010 
occurred in the first birth cohorts eligible to have been wholly primed with aP. 
Previous acellular pertussis vaccine effectiveness estimates 
A detailed evaluation of global estimates of vaccine effectiveness for the range of pertussis 
vaccines is beyond the scope of this thesis. However, previous investigations found aP to be highly 
effective up to 6 years of age. Studies in Germany (41) and Austria (42) using the screening method 
(discussed in Chapter 3.5) performed soon after the switch from wP to aP, estimated effectiveness 
of three doses of aP in preventing hospitalisation to be 99.8% in children ≤32 months of age and 
92% in children ≤24 months of age, respectively. A case-control study from the United States 
found the VE for preventing pertussis was 95.4% and 96.7% for three and four doses of aP 
respectively, in children aged between 6 and 59 months (43), and a small case-control study in 
Japan found similar estimates for three (95.9%) and four doses (96.9%) of aP for children up to 6 
years of age (44). 
Recent pertussis epidemiology in the United States 
However, studies undertaken in California during the pertussis epidemic in 2010 demonstrated 
waning effectiveness of aP (38, 39, 45). In Marin County, California, VE, assessed using the 
screening method, was 41% and 24% among children aged between 2 and 7 years and 8 and 12 
years, respectively (38). A case-control study conducted in 15 Californian counties found VE for a 
five-dose aP course, declined with time since the fifth dose, from 98.1% at <12 months following 
the fifth dose to 71.2% at ≥60 months after the fifth dose (45). These findings were supported by 
earlier work from Canada which suggested the median time until disease following the last 
vaccination may be shorter in children receiving aP compared to wP (46). In addition to 
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identifying the limited durability of aP vaccines, the evidence from California, indicated the 
change from wP to aP in the late 1990s, contributed to the recent changes in pertussis 
epidemiology. 
The sustained pertussis epidemic beginning in 2009 in Queensland, and the change in 
pertussis notification patterns in the context of a changing pertussis vaccine schedule, 
prompted my investigation into the effectiveness of pertussis vaccines in children in 
Queensland. 
Varicella 
Varicella-zoster virus (VZV) occurs exclusively in humans and manifests as two diseases: 
varicella (chickenpox) and herpes zoster (shingles). During primary VZV infection, which causes 
varicella, the virus migrates to the sensory dorsal root ganglia resulting in latent infection in 70% 
of people (47). VZV may be reactivated, often later in life, causing herpes zoster (shingles), due to 
waning immunity or immunosuppression (47). VZV is a highly contagious airborne infection, 
with secondary attack rates in susceptible household contacts of varicella cases of between 61% 
and 100% (48). Transmission can also occur from cases with herpes zoster, although the risk is 
considerably lower compared to varicella with one study finding approximately a 16% secondary 
attack rate among susceptible contacts under the age of 15 years (49). 
In Australia, varicella is usually a benign, self-limiting childhood disease lasting 5-7 days, 
characterised by fever and a generalised vesicular rash. Severity of infection increases with 
age, with those at the extremes of age and the immunocompromised at greatest risk of 
complications (47). Varicella complications occur in as many as 10% of cases and are most 
commonly due to secondary bacterial skin and soft tissue infections (50). Other complications 
include pneumonia, encephalitis, cerebellar ataxia, hepatitis, and disseminated varicella (47). 
Herpes zoster is a localised, painful dermatomal-vesicular disease. Prodromal pain in the affected 
dermatome precedes the appearance of vesicular skin lesions, which last approximately 10-15 
days (51). Post-herpetic neuralgia (PHN), in which significant pain persists for months following 
the rash, is the most common complication of herpes zoster and can be severely debilitating (51). 
Risk of PHN increases with age and, depending upon the definition used, has been estimated to 
occur in between 7-25% of herpes zoster cases (51). Other complications of herpes zoster include 
secondary bacterial skin infections, herpes zoster ophthalmicus, cutaneous hypersensitivity, nerve 
palsies, pneumonia, meningitis, and disseminated disease (51, 52). 
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Prior to varicella vaccine (VV) introduction in Australia, the peak incidence of varicella occurred 
in the 5-9 year old age group, with 83% of the population infected by 10-14 years of age (53). 
Despite usually being a mild disease, between 2000 and 2002 in Australia, there were on average 
over 1,000 principal diagnosis varicella hospitalisations and almost 10 deaths per year due to 
varicella (54). 
Herpes zoster causes a far greater burden of disease than varicella in Australia. In the absence of 
zoster vaccination, there is a 50% risk of herpes zoster among those living to 85 years of age (55). 
Given that prior to VV introduction, 97% of the Australian population had been infected with 
VZV (53), the population at risk of herpes zoster is and will continue to be great for decades to 
come. In terms of severe morbidity and mortality, herpes zoster was the principal diagnosis for an 
annual average of over 4,500 hospitalisations and 15 deaths between 2000 and 2002 (54). 
The burden of varicella infection (non-hospitalised, hospitalised, and neonatal infections) has 
declined since the inclusion of a single dose of the childhood chickenpox vaccine into the NIP 
in 2005 (56-58). Also funded through the NIP until 2016/2017 was an adolescent catch-up dose 
for children aged 10-13 years without a history of infection or vaccination (58). Prior to 
inclusion in the NIP, the only estimate of VE for VV in Australia came from a chickenpox 
outbreak at a child care centre in Western Australia in 2002 (59). The VE for a single dose of 
VV in this outbreak was 78% (95% CI: 15-94) (59). 
When VV first became available, a single dose schedule was recommended (60). The US 
introduced a single dose of VV as a routine childhood vaccination in 1995, which resulted in a 
dramatic decline in varicella morbidity and mortality (61, 62). However, post-licensure 
surveillance revealed that despite high coverage, a single VV dose did not prevent varicella 
outbreaks in school settings (63). International evidence demonstrates greater protection is 
afforded by two doses of varicella vaccine (64), with some national immunisation advisory 
committees now recommending two doses of varicella vaccine (65, 66). The odds of developing 
varicella among children receiving two VV doses was found to be 95% lower than those 
vaccinated with a single VV dose in the first two and a half years following the recommendation 
of a two-dose VV schedule in the US (67). The impact of the second dose recommendation has 
been demonstrated in the US where varicella incidence has declined by almost 85% between 
2005-2006 (before the second dose was recommended) and 2013-2014 (68). 
Studies have found higher point VE estimates for VV against moderate and severe varicella than 
for varicella of any severity. This is an important issue when considering the additional benefit to 
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be gained from a second dose of VV. A review of 17 post-licensure studies assessing the VE of a 
single dose of Varivax in the United States in 2008 found that one dose of VV was 84.5% 
(median; range, 44% to 100%) effective in preventing all varicella and 100% effective (mean and 
median) in preventing severe varicella (69). A meta-analysis of 27 studies published between 
1995 and 2014 reporting VE of one dose of either of the licensed varicella vaccines, found the 
pooled one dose VE against all varicella and moderate-severe varicella was 81% (95% CI: 78-84) 
and 98% (95% CI: 97-99), respectively (70). 
A recent study has modelled the impact of different vaccination strategies (including two-dose 
strategies as well as the current single-dose strategy with adolescent catch-up until 2015), on 
varicella and herpes zoster incidence in Australia between 2015 and 2050 (71). A two-dose 
strategy with VV at 12 and 18 months of age respectively produced the lowest incidence of 
varicella disease (71). The cost-effectiveness of a second dose declines with increasing first dose 
coverage. If first- dose VV coverage increased to 95% at 24 months of age, from the base case 
scenario of 83%, the incremental benefit of a second dose of VV fell by over half (71). This study 
predicted herpes zoster incidence to increase under all vaccination strategies, however, the 
projected incidence of zoster differed little between strategies (71). 
Uncertainty exists regarding the impact VV may have on the incidence of herpes zoster. It is 
hypothesised circulating varicella may result in exogenous immune-boosting in people that have 
latent varicella infection, thereby providing protection against herpes zoster. This has led to a 
concern that a reduction in circulating varicella resulting from uptake of childhood VV may lead 
to increases in zoster rates, particularly in the elderly (72). 
However, the evidence on whether there has been an increase in herpes zoster due to the 
implementation of childhood varicella vaccination programs is inconclusive (73) with one study 
from the US finding an increase in herpes zoster rates and others reporting stable rates of disease 
(73). Evidence from Canada showed a decline in age-groups targeted for varicella vaccination and 
rates did not change among other age-groups up to 5 years post-funding of the childhood VV (74). 
Other studies have found increasing rates of herpes zoster in the absence of a VV program (75). One 
study examining the incidence of herpes zoster in people over 65 years of age from 1992 to 2010 in 
the US found that age-specific incidence was increasing before introduction of the childhood VV 
program, and that the rate of herpes zoster increase did not significantly change following VV 
introduction (76). In Australia, herpes zoster hospitalisation rates were not found to have increased 
in any age-group when assessed up to June 2010 (58). 
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Despite the single dose childhood VV program being in place since 2005, there have previously been 
no VE calculations for this program at preventing chickenpox in children. I sought to undertake the 
first VE assessment of single dose VV against emergency department (ED) presentation and 
hospitalisation in Australia since its public funding. I also assessed the impact of the vaccination 
program on the burden of varicella and herpes zoster disease. I undertook this assessment to provide 
locally relevant evidence upon which to consider the current single versus a two-dose VV schedule 
for children, and to provide a baseline of single dose effectiveness and impact on varicella and 
herpes zoster for comparison in the event of introducing a second dose, and following introduction 
of the funded herpes zoster vaccine (Zoster Vaccine Live or Zostavax®; Seqirus/Merck & Co Inc) 
for people aged 70 years in November 2016 (77). 
Rotavirus 
Rotavirus is the most common cause of severe gastroenteritis in children <5 years of age 
worldwide, accounting for 5% of deaths in this age group (78). Most of the deaths due to 
rotavirus, estimated in 2013 to exceed 200,000 annually (79), occur in developing countries in 
South-East Asia and sub-Saharan Africa (80). Rotavirus also causes substantial morbidity, with 
an estimated 
2.3 million hospitalisations and 24 million outpatient visits annually among children aged <5 
years (80, 81). The severity of rotavirus is age-dependant with severe infection causing 
dehydration, occurring in young infants and children (82). 
Although deaths are rare in high-income countries such as Australia, the incidence of infection is 
similar to lower income countries, with almost all children having at least one rotavirus infection  
before their 5th birthday (83). Prior to rotavirus vaccine introduction, rotaviruses caused 
considerable morbidity in Australia, resulting in an estimated 10,000 hospitalisations, 22,000 ED 
presentations, and over 110,000 general practitioner (GP) consultations annually among children 
in this age group (84). Moreover, Indigenous people are disproportionately affected by severe 
rotavirus infection, with Indigenous Australian infants five times more likely to be hospitalised 
for rotavirus, and if hospitalised, to have a longer length of stay than non-Indigenous infants (85, 
86). 
In Australia, rotavirus vaccines were added to the NIP childhood schedule in July 2007, with two 
live oral vaccine options. Queensland used a three-dose course of a multivalent vaccine (RV5; 
RotaTeq®, Merck & Co Inc/ CSL Biotherapies), whilst some other states used a two-dose course 
of a monovalent vaccine (RV1; Rotarix®, GlaxoSmithKline), both with strict upper time limits on 
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dose administration (5). Monovalent rotavirus vaccine contains a single, live-attenuated G1P[8] 
human rotavirus strain, which is intended to induce both homotypic and heterotypic protection. In 
contrast, pentavalent rotavirus vaccine contains five human-bovine reassorted rotavirus strains and 
relies more heavily upon inducing homotypic protective immunity (87). 
The ability of the pentavalent and monovalent rotavirus vaccines at preventing severe disease has 
been demonstrated as 85-98% in pre-licensure trials in Europe and the Americas (88-90). Studies 
in low and low middle income countries have also shown that these two vaccines are also 
efficacious at protecting against severe disease (though with reduced efficacy when compared with 
results from the aforementioned high and high middle income regions). Efficacy of 39% was 
reported for the pentavalent vaccine (91) for preventing severe rotavirus gastroenteritis until 
almost 2 years of age in children from low income sub-Saharan countries, while efficacy for two 
doses of monovalent rotavirus vaccine against severe rotavirus gastroenteritis of 49% and 77% 
were observed during the first 12 months of life in infants from Malawi and South Africa, low and 
middle income African countries, respectively (92). Similarly, the efficacy of the pentavalent 
rotavirus vaccine at protecting against severe rotavirus gastroenteritis during the first 21 months of 
life was 43% in Bangladesh and 64% in Vietnam, both low and middle income Asian countries, 
respectively (93). 
In Queensland, assessment of the pentavalent rotavirus VE at preventing hospitalisation for 
rotavirus acute gastroenteritis (RV AGE) and non-rotavirus coded acute gastroenteritis (non-RV 
AGE), in children up to 18 months of age was found to be high (89.3-93.9% for preventing RV 
AGE; 62.2-63.9% for preventing non-RV AGE) (94). Results from the Northern Territory have 
been mixed. The VE was reported to be 85% for the monovalent G1P[8] vaccine at protecting 
against hospitalisation in an outbreak of rotavirus serotype G9P[8] in Central Australia during 
2007 shortly after the vaccine was introduced (95). In contrast, it was not found to provide overall 
effectiveness against hospitalisation in an outbreak of a non-vaccine-related genotype (G2P[4]) in 
2008-2009, raising concerns about the ability of the vaccine to protect against heterotypic strains 
(96). However, the second outbreak was based upon small numbers and a post-hoc analysis 
suggested a protective effect against severe disease in infants in the first, but not second year of 
life. Waning immunity beyond infancy has also been observed in other resource-limited settings 
in sub- Saharan Africa and Southern Asia (97, 98). I therefore undertook a review of the national 
and international literature to describe the post-licensure impact and effectiveness of rotavirus 
vaccines in different settings. 
An unexpected benefit associated with rotavirus vaccine was described recently in a study 
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undertaken in the US, which identified a protective association between rotavirus vaccination and 
febrile and afebrile seizures in children (99). Rotavirus vaccination was found to be associated 
with an 18% to 21% reduction in hospitalisation or ED presentation for seizures in the year 
following vaccination compared to children not receiving rotavirus vaccination (99). Due to 
creation of a large linked dataset for my study to assess the vaccine effectiveness of rotavirus 
vaccine in preventing rotavirus-associated hospital presentations and admissions, I had the 
opportunity to assess the effectiveness of rotavirus vaccine in preventing febrile seizures in an 
Australian context. 
Methods 
VE and impact were assessed using routinely collected health data, while VE was calculated 
through linking several of these health datasets. Data linkage is a primary public health research 
tool that makes a substantial and quantifiable contribution to public health (100). Queensland is 
in a unique position to undertake VE estimation in a timely and resource-efficient manner. As 
one of only two Australian jurisdictions with a local immunisation register, Queensland 
vaccination and health outcome data are able to be readily linked, thereby enabling 
ascertainment of vaccination status of cases of interest. 
Using linked data, the effectiveness of pertussis and rotavirus vaccines at preventing disease 
notification, ED presentation, and hospitalisation, were calculated by the screening method, 
while varicella VE in preventing ED presentation and hospitalisation was assessed using a 
matched case- control method. The comparative effectiveness of aP and wP vaccines was also 
calculated using linked notification and vaccination data. 
The impact of the vaccination programs on pertussis, rotavirus, varicella, and herpes zoster was 
assessed ecologically by analysing unlinked, routinely collected hospitalisation, ED 
presentation, and notification data. 
Data sources 
My research involved multiple vaccination and health outcome datasets. 
The vaccination status of cases was obtained from: 
• The Queensland vaccination register: Vaccine Information and Vaccine Administration System 
(VIVAS). 
The vaccination coverage and vaccination status of controls in the matched case-control 
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analysis were obtained from: 
• The Australian Childhood Immunisation Register (ACIR). 
Health outcome and health-associated data of interest were obtained from: 
• 
• 
• 
• 
• 
• 
• 
The Queensland Notifiable Conditions System, which holds disease notification data; 
The Queensland Emergency Department Information System (EDIS), which holds data on ED 
presentations; 
The Queensland Hospital Admitted Patient Data Collection (QHAPDC), which 
holds hospitalisation data; 
Pathology Queensland, which holds public laboratory testing data; 
Sullivan and Nicolaides Pathology, which holds private laboratory testing data; 
The National Hospital Morbidity database, which holds national aggregate public and 
private hospitalisation data; and 
The Pharmaceutical Benefits Scheme (PBS), which holds data on the national numbers 
of patients receiving pharmaceuticals through the PBS. 
Apart from Sullivan and Nicolaides Pathology (a privately-owned pathology service), the 
National Hospital Morbidity database, and ACIR, all the other datasets used are managed by the 
Queensland Department of Health. The National Hospital Morbidity database and ACIR are 
managed under the Australian Government’s Australian Institute of Health and Welfare and the 
Department of Human Services, respectively. 
The National Centre for Immunisation Research and Surveillance (NCIRS) plays a preeminent 
role in the analysis and reporting of ACIR data (101). ACIR was established in 1996 to record 
details of vaccinations given to children aged <7 years nationally, is a near-complete population 
register with 99% of children included on the register by 12 months of age regardless of 
vaccination status (102). Thus ACIR provides accurate childhood vaccination coverage. VIVAS, 
established in 1996, records all childhood and some adult vaccinations in Queensland and in 
addition, is used to monitor the distribution and use of vaccines in Queensland (103). VIVAS is 
not a population-based vaccination register and only records vaccination encounters, meaning it 
does not include wholly unvaccinated children. However, unlike ACIR, VIVAS data are more 
readily available to link to Queensland health outcome data. Since 30 September 2016, ACIR has 
expanded to become the Australian Immunisation Register, which is designed to be able to record 
vaccinations given to people of all ages (104). 
The Queensland Notifiable Conditions System, is a register containing information about 
people who have been identified in Queensland with a notifiable condition under the Public 
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Health Act, 2005. The register facilitates the control of communicable diseases (105). 
EDIS began operating in 2008 and currently operates in 25 Queensland public hospitals, which in 
2010/2011 were responsible for the large majority (80%) of all non-admitted (ED and outpatient) 
hospital presentations for any cause in Queensland public hospitals. The aim of the data collection 
is to show patterns in presentations to assist in the planning of services and improvement of care 
and clinical outcomes (106). QHAPDC contains data on all separations from Queensland 
hospitals, with identifiable data for public hospitals since 1995 and from private hospitals since 
2007 (106). 
Pathology Queensland collects pathology testing data from public pathology laboratories 
across Queensland through the Auslab laboratory information system. 
Australian state and territories provide data on public and private hospital episodes of care to the 
National Hospital Morbidity database. These data, which have been collected since 1993/1994, is 
publicly available online in aggregated formats (107). 
Managed by the Australian Department of Health, the PBS provides government subsidised 
medicines for all Australian residents with a Medicare card (108). Medicines, such as antivirals are 
listed on the PBS schedule with item numbers, which also specify the indications for the 
prescription of the medicines. Data on PBS claims are available from the Department of Health. 
Commercial sources, such as Hi Connections Pty Ltd, provide analysis of data of all PBS claims 
for a random 10% sample of the population eligible for PBS benefits drawn from the PBS payment 
records. 
Data linkage 
Vaccination data from VIVAS, and health outcome data from the Queensland Government 
datasets listed above were provided to and linked by the Health Statistics Unit of the Queensland 
Department of Health. Identified data were provided to the Health Statistics Unit to enable the 
correct linking of vaccination status to outcome data. The Health Statistics Unit undertook 
probabilistic data linkage, followed by a round of manual linkage to maximise correct record 
linkage. LinkageWiz data matching software, version 5.3 (LinkageWiz Inc, Adelaide, South 
Australia) was used to probabilistically identify potentially matching records. Weighting scores 
were assigned to matching variables, including surname, first name, date of birth, and address. 
Middle- and lower-weighted pairs were assessed individually, and higher-weighted pairs checked 
for false matching related to multiple births. Consistent with recommended practice (109), 
following linkage by the specialised Health Statistics Unit, identifying information was removed 
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and the data are provided in a de-identified form to the researcher. 
Calculation of vaccine effectiveness 
A variety of observational study designs can be used to calculate effectiveness once a vaccine is 
used in the field (110). In this thesis I calculated VE using the screening method and a matched 
case- control method. 
Screening Method 
This method allows for VE to be calculated by comparing the proportion of cases vaccinated 
(PCV) with the vaccine coverage in the general population, also referred to as the proportion of the 
population vaccinated (PPV), using the following equation (111): 
PCV 
VE = 1 - 
1-PCV 
X 
PPV 
1-PPV 
This method has previously been used to assess pertussis vaccine efficacy for preventing 
notified cases in New South Wales (NSW) (112), and more recently, for rotavirus in 
Queensland (94). 
The PCV is ascertained through linking health outcomes data, such as disease notifications, 
with VIVAS data. The PPV is obtained by requesting static vaccination coverage data for the 
relevant population and time period from ACIR. 
Matched Case-Control Method 
Twenty controls and their VV records from the ACIR were matched to each varicella case by 
date of birth, sex, and residence in Queensland. As cases were de-identified, we could not 
exclude the possibility of a case also being selected as one of their own controls. 
We used conditional logistic regression to estimate the odds ratio (OR) for VE at preventing 
hospitalisation and ED presentations. VE estimates and 95% CIs were based on the OR using 
the formula: 
VE = (1 OR) × 100% 
Analysis of vaccine impact 
Using unlinked, routinely collected health outcome and PBS prescription data, I compared the 
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rates of chickenpox and herpes zoster hospitalisations and rates of people receiving prescriptions 
available on the PBS for treating these two conditions (acyclovir, valaciclovir, famciclovir), 
before and at various times after the introduction of VVs into the NIP. Both age-specific and age- 
standardised rates were calculated and then compared through calculation of incidence risk ratios. 
All statistical analyses were undertaken using Stata v13 (StataCorp, College Station, TX). 
Strengths and limitations of vaccine effectiveness and impact assessment 
Pre-licensure vaccine trials are often double-blinded, randomised controlled trials (RCTs) 
involving prospective active monitoring of disease and vaccination status (113). These studies may 
be regarded as providing vaccine efficacy estimates of how the vaccine performs in ideal 
controlled conditions. Once a vaccine is proven to be beneficial and is licensed, RCTs are usually 
neither an ethical nor feasible method of monitoring VE in the population at large. Instead, various 
observational methods may be used to evaluate VE post-vaccine implementation. These methods 
include, but are not limited to cohort studies, case-control studies, the screening method, and 
household contact studies. The strengths and limitations of these observational methods for 
assessing VE have been described previously (110, 114) and are reviewed below. 
In my PhD, I have used both screening method and case-control methods for assessing VE. I 
chose to use the screening method because of the availability of vaccine coverage data from ACIR 
and of the ability to link Queensland vaccination status data from VIVAS to Queensland health 
outcome data. Similarly, I undertook a case-control approach with the involvement of NCIRS, 
due to the ability to select controls from ACIR to match with Queensland cases whose vaccination 
status was obtained from VIVAS. 
Assessing VE using a cohort approach is not readily possible employing routinely collected data 
in Australia. VIVAS is not a population-based register, as it only records vaccination encounters, 
meaning that wholly unvaccinated people are not included in the VIVAS making it inappropriate 
for a cohort design. While ACIR is population-based, identified data from ACIR have not been 
readily available to be linked with health outcome data. 
There are several strengths and limitations of the case-control and screening methods used in this 
thesis. Both methods are resource efficient, particularly in comparison to RCTs or prospective 
observational cohort studies. Using pre-existing data also allows VE assessments to be undertaken 
in a timely manner. This timeliness allows rapid investigation into VE in response to unexpected 
changes in the pattern of disease leading to concern about the effectiveness of a vaccine. A 
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particular strength of using pre-existing immunisation registers in this research is that the 
immunisation status is documented prior to the assessment of the health outcome, and that 
obtaining this value does not rely upon parental recall. However, limitations of using routinely 
collected data include potential lack of completeness and accuracy of the datasets, and reliance on 
the accuracy of data linkage. The strengths and limitations of using routinely collected data and 
linked data for impaxct and effectiveness research is discussed in Chapter 6. 
Post-licensure VE surveillance provides the opportunity to assess how the vaccine is currently 
performing in the local or national population of interest. This may be different to how the 
vaccine performed in other populations or under the strict conditions of a Phase III trial. 
Furthermore, population-based post-licensure VE studies can assess the effectiveness of a vaccine 
in broader age groups, in non-trial populations, over a longer period of time, and in different 
periods of disease incidence. For example, for the VE assessment of aP vaccine in Queensland I 
was able to undertake a rapid analysis in response to the unexpected increase in notified pertussis 
in 2009 and 2010, despite there being high vaccination coverage in the current and preceding 
years. 
In addition, post-licensure VE assessments can both inform and evaluate local changes in 
vaccination schedule. For these reasons, surveillance of VE can play an important role in 
providing locally relevant evidence to support public health vaccination policy decisions. 
The screening and case-control methods of assessing VE share common limitations associated 
with all observational studies. Potential bias and confounding may occur associated with case 
ascertainment and with vaccination status. Unlike RCTs, where confounding variables, both 
known and unknown, are likely to be distributed randomly across groups, vaccinated groups are 
self- selected and non-experimental VE studies are potentially subject to confounding (110). 
Differential case ascertainment in vaccinated and unvaccinated people may occur due to 
differences in health- care seeking behaviour, which if also independently associated with 
vaccination status may cause confounding. Knowledge of vaccination status may influence health- 
care provider testing behaviour, leading to lower ascertainment of cases among vaccinated groups 
and an overestimate of VE. Amelioration of disease through vaccination, such as occurs with 
pertussis, may also lead to a lower incidence of pertussis detection amongst vaccinated individuals 
and an overestimate of VE against milder pertussis infection. Confounding may also occur if 
vaccinated and unvaccinated groups are at differential risk of exposure to infection. 
VEs based upon odds rather than risk ratios will also lead to slight overestimation. However, as 
22 
the incidence of the diseases studied are rare, even during outbreaks, the degree of overestimation 
due to the use of ORs will be small. 
Ascertaining case vaccination status from VIVAS could also lead to overestimation of VE 
by underestimating the proportion of cases vaccinated. Under-reporting of vaccinated 
children to VIVAS, which provides vaccination data to ACIR would led to an underestimate 
of the proportion of the population (or of controls) vaccinated. An underestimate of 
vaccination coverage among the population or controls would also result in overestimating 
VE. There has been no formal validation of VIVAS to assist in quantifying the potential 
degree of bias this may cause. However, cases without complete vaccination status are 
checked frequently on the ACIR as a standard part of public health follow up and VIVAS is 
updated with any additional vaccination records identified on the ACIR. There are also 
financial incentives for parents to ensure their child’s vaccination data are recorded 
correctly on the ACIR, which are likely support completeness and quality of the ACIR data. 
As part of the “No Jab No Pay” legislation, to receive the Family Tax Benefit Part A 
supplement, the Child Care Rebate, and the Child Care Benefit, a child needs to have a 
record on ACIR indicating they are up to date with the childhood vaccination schedule or 
have a specific, documented medical exemption (115, 116). 
Under-reporting of vaccination encounters may lead to small underestimates of vaccine 
coverage, (and vaccination status ascertainment among controls in the case-control study) from 
the ACIR (117). Use of the third dose assumption, where if dose three of the primary course is 
recorded, the previous two doses of a three-dose primary course are assumed to have been 
received, is likely to improve the accuracy of coverage figures (118). 
Finally, I undertook an ecological analysis to assess vaccine impact. Though this analysis has the 
inherent limitations of an ecological approach – that is uncertainty about the causal relationship 
between the vaccine introduction and disease incidence – impact studies offer valuable 
information. Vaccine impact evaluation complements VE assessment, by providing meaningful 
data on the actual change in the burden of disease at a population level, such as the rate of 
hospitalisations for the disease of interest. Quantifying a vaccination program’s impact assists in 
health planning and contributes to estimations of its cost-effectiveness as a public health 
intervention. Unlike VE assessments, vaccine impact incorporates measures of the indirect (or 
herd) vaccine effects on the vaccinated and the non-vaccine targeted population. 
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Evaluating effectiveness 
In 2011-2012, Australia invested $350 million into providing publicly funded vaccines for 
children and adults as part of the NIP (3). However, there is no structured evaluation arm that 
routinely assesses the impact or effectiveness of new or existing vaccines in the Australian 
context. 
With this thesis, I provide an example of how local, routinely collected health data can be used to 
monitor expected benefits, quantify emerging risks, and identify unanticipated outcomes of routine 
immunisation. 
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Chapter 3: Pertussis vaccine effectiveness 
3.1 Number and order of whole-cell pertussis vaccines in infancy and 
disease protection 
This section is presented as a published research letter: 
Sheridan SL, Ware RS, Grimwood K, Lambert SB. Number and order of whole-cell pertussis 
vaccines in infancy and disease protection. JAMA. 2012;308(5):454-6. 
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To the Editor: Due to their lower rate of adverse events, acellular pertussis vaccines (diphtheria- 
tetanus-acellular pertussis; DTaP) replaced whole-cell vaccines (diphtheria-tetanus-whole-cell 
pertussis; DTwP) in many developed countries during the 1990s. DTaP became available in 
Queensland, Australia, in 1996 and replaced DTwP for publicly funded primary course 
immunizations delivered at ages 2 months, 4 months, and 6 months in March 1999. This meant 
children born in 1998 could receive a primary course consisting of only DTwP, only DTaP, or a 
mixed schedule. 
Similar to North America (38), Australia is experiencing a sustained pertussis epidemic (119), with 
the highest incidence rates in Queensland during 2011 in children aged 6 to 11 years. The recent 
changes in pertussis epidemiology may be related to the shift from DTwP to DTaP. To test this 
hypothesis, we compared pertussis reporting rates by primary course vaccination in the 1998 birth 
cohort. 
Methods 
Reporting pertussis cases to the health department is mandatory in Queensland. For children born in 
1998, we calculated pertussis reporting rates in both the pre-epidemic (1998-2008) and outbreak 
periods (2009-2011), by number and order of DTwP doses given before their first birthday. We 
linked data from the Queensland vaccination register (QVR) with case reports of pertussis. The 
QVR is not a population-based register so we could not construct a group of wholly unvaccinated 
children for comparison. Children were censored following initial reporting. We calculated average 
annual incidence rates, incidence rate differences, incidence rate ratios, and 95% confidence 
intervals using Stata version 12 (StataCorp). The Queensland Children's Health Services ethics 
committee approved the study. 
Results 
Of 58 233 children born in 1998 identified in the QVR, 40 694 (69.9%) received at least 3 doses of 
any pertussis-containing vaccine during the first year from a Queensland vaccine service provider 
and were included in the analysis. Overall, 267 first pertussis cases were reported from this cohort 
between 1999 and 2011; 2 second reports were excluded. 
Children who received a 3-dose DTaP primary course had higher rates of pertussis than those who 
received a 3-dose DTwP primary course in the pre-epidemic and outbreak periods (Table 3.1.1 and 
Figure 3.1.1). Among those who received mixed courses, rates in the current epidemic were highest 
for children receiving DTaP as their first dose. This pattern remained when looking at subgroups 
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with 1 or 2 DTwP doses in the first year of life, although it did not reach statistical significance 
(Table 3.1.1). Children who received a mixed course with DTwP as the initial dose had incidence 
rates that were between rates for the pure course DTwP and DTaP cohorts (Table 3.1.1). 
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Table 3.1.1: Counts, average annual incidence-rates, incidence-rate differences and incidence-rate ratios for pertussis notifications between 1999 and 
2011, by number and order of pertussis-containing vaccinesa and pre-epidemic and outbreak periods for children born in 1998. 
Pre-epidemic years (1999 to 2008) 
Primary-course 
(≥3 doses of a pertussis containing 
vaccine <12 months of age) 
Pure course (≥3 doses of a single 
vaccine only) 
DTaP primary-course (n=9,827) 
DTwP primary-course (n=22,956) 
Outbreak years (2009 to 2011) 
Primary-course 
Pure course 
DTaP primary-course (n=9,827) 
DTwP primary-course (n=22,956) 
Mixed course 
1st dose DTaP (n=978) 
1st dose DTwP (n=6,933) 
    Mixed course by number of 
    DTwP 
    1 dose of DTwP only 
    1st dose DTaP (n=549) 
    1st dose DTwP (n=2,501) 
    2+ doses of DTwP 
    1st dose DTaP (n=429)c 
    1st dose DTwP (n=4,432)d 
a 
Notifications Average annual 
      (count) incidence-rateb (95% CI) 
Incidence-rate 
differenceb,e (95% CI) 
Incidence-rate ratio 
(95% CI) 
13 
12 
13.2 (7.0-22.6) 
5.2 (2.7-9.1) 
8.0 (0.0-15.8) 
reference 
Incidence-rate 
differenceb,e (95% CI) 
259.9 (185.7-334.0) 
reference 
295.7 (63.0-528.5) 
88.7 (22.6-154.7) 
2.53 (1.06-6.07) 
reference 
Incidence-rate ratio Incidence-rate ratiof 
                     (95% CI)(95% CI) 
3.29 (2.44-4.46) 
reference 
3.61 (1.79-6.67) 
1.78 (1.20-2.63) 
Notifications Average annual 
      (count) incidence-rateb (95% CI) 
110 
78 
12 
42 
373.1 (306.7-449.7) 
113.3 (89.5-141.3) 
409.0 (211.3-714.4) 
201.9 (145.5-273.0) 
6 
20 
6 
22 
364.3 (133.7-792.9) 
266.6 (162.8-411.7) 
466.2 (171.1-1014.7) 
165.5 (103.7-250.5) 
251.0 (-41.5-543.6) 
153.3 (33.8-272.8) 
352.9 (-20.9-726.8) 
52.2 (-21.4-125.8) 
3.22 (1.15-7.32) 
2.35 (1.36-3.89) 
4.12 (1.47-9.37) 
1.46 (0.87-2.37) 
1.37 (0.45-3.53) 
reference 
2.82 (0.93-7.17) 
reference 
  n=40,694: does not include ineligible records with no vaccination history recorded under 12 months of age (n=6806); vaccination history under 12 months of age not provided by a 
   Queensland vaccine service provider (4129); irregularity of the vaccine dose number or description (191); or less than 3 doses recorded under 12 months of age (6412) 
b 
  Rate per 100,000 per year 
cOnly 2 children had 3 doses of DTwP ≤12 months of age 
dOnly 40 children had 3 doses of DTwP ≤12 months of age 
e 
  Using pure DTwP primary course as reference for rate difference calculations 
f 
  Incidence-rate ratios comparing dose order in mixed course cohorts 
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Figure 3.1.1: Pertussis reporting rates between 1999 and 2011, by primary-course of pertussis vaccination for children born in 1998 
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Comment 
Infant priming with DTwP was associated with a lower risk of subsequent pertussis than DTaP only 
primed children in this cohort. This difference persisted for more than a decade, being evident in 
pre-epidemic and outbreak periods. A primary course using even a moderately effective DTwP 
vaccine may be more protective than DTaP (120). In the pre-acellular era, Australia used a locally 
produced DTwP vaccine with very good to excellent effectiveness (112). Our findings suggest the 
most important factor, in this cohort, may be the initial vaccine received. 
It is unlikely our findings during the current outbreak are the result of detection bias because this 
would require health care–seeking behavior, or the likelihood of laboratory testing or reporting, to 
be associated with the primary course received by children over a decade previously. 
Possible explanations for our findings could include antigenic shifts in circulating Bordetella 
pertussis strains2 or the different immune responses from acellular and whole-cell priming (121). 
The lesser protection provided by DTaP, both as the initial vaccine or full primary course, may be 
due to linked epitope suppression, when the initial exposure locks in the immune response to certain 
epitopes and inhibits response to other linked epitopes on subsequent exposures (122). 
The challenge for future pertussis vaccine development is to address the benefit-risk trade-off 
highlighted by our study, and to develop vaccines that induce long-lasting protection from the first 
dose, without the adverse events associated with DTwP use. 
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3.2 Unexpectedly limited durability of immunity following acellular 
pertussis vaccination in preadolescents in a north American outbreak 
This section is presented as published correspondence: 
Sheridan SL, Ware RS, Grimwood K, Lambert SB. Unexpectedly limited durability of immunity 
following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin 
Infect Dis. 2012;55(10):1434-5. 
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To the Editor: 
We read with interest Witt el al’s recent article on the limited durability of protection following 
acellular pertussis vaccination (DTaP) and we note that disease rates in their study population were 
highest in 12 year olds and was dramatically lower in those 14 years of age and older (see Figure 1 
in (38)). 
We would like to raise with the authors the possibility that the shift from whole-cell pertussis 
vaccine (DTwP) to DTaP as the primary course vaccine, and particularly the initial vaccine, may 
have contributed to the age-specific nature of infection in their patient population. 
Queensland, Australia, which introduced DTaP for the primary course in March 1999, has been 
experiencing a sustained pertussis outbreak since 2009, with a similar peak in late childhood 
notifications of disease. We investigated a cohort of children born in 1998, vaccinated during the 
transition from DTwP to DTaP, and found that receiving a primary course of DTwP was associated 
with a significantly reduced risk of pertussis when compared to receipt of a DTaP primary course 
(123). Receiving DTwP as the first dose in a mixed primary course also appeared to be associated 
with a similar reduced risk of notification. This differential protection persisted for more than a 
decade after receipt of the primary course despite most of the children (84-89%, depending on type 
of primary course) receiving at least two DTaP booster doses (scheduled at 18 months and 4 years 
of age). 
Witt and colleagues state that details on manufacturers of administered vaccines prior to 2002 could 
not be retrieved for the children in their study. However, if acellular pertussis vaccine replaced 
DTwP for the primary course soon after the recommendation from the Advisory Committee on 
Immunization Practices (ACIP) in March 1997 (40), then it is likely that children aged 12 years 
during the period covered by Witt et al’s analysis (March – October 2010), were the first group to 
be exclusively vaccinated with DTaP. If this is the case, then the increase in notification rates in the 
late childhood years, peaking in 12 year olds, would coincide with the first wave of widespread use 
of DTaP for the primary course. 
We would be interested to know whether it is possible for Witt et al to disentangle the influence of 
receiving a booster at 10 to 12 years of age from that of receiving a primary course of DTwP in 
their study population, for example, by comparing rates of pertussis in children who were likely to 
have received both a DTwP primary course (using the ACIP recommendation date as a cut-off) and 
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10 to 12 year booster, with those that were likely to have received a DTaP primary course and 10 to 
12 year old booster. 
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3.3 Reduced risk of pertussis in whole-cell compared to acellular vaccine 
recipients is not confounded by age or receipt of booster-doses 
This section is presented as a published paper: 
Sheridan SL, Ware RS, Grimwood K, Lambert SB. Reduced risk of pertussis in whole-cell 
compared to acellular vaccine recipients is not confounded by age or receipt of booster-doses. 
Vaccine. 2015;33(39):5027-30. 
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Abstract 
Several observational studies provide evidence that acellular pertussis vaccines (aP) are less 
protective against pertussis disease than highly effective whole-cell pertussis vaccines (wP), 
however, concerns have been raised that some of these findings may be confounded by age. By 
undertaking age-stratified and restricted analyses on a cohort of Australian children primed with 
either aP-only, wP-only or mixed pertussis vaccine schedules, we demonstrate that compared to aP 
the association of wP with increased protection from pertussis is not confounded by age, nor by aP 
booster-dose receipt. 
Key words: Pertussis; Whole-cell pertussis vaccine; Acellular pertussis vaccine; Vaccine 
effectiveness; Confounding 
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Background 
Since 2012, several observational studies from the United States (US) and Australia have reported 
the unexpected rapid waning effectiveness of acellular pertussis vaccines (aP) (38, 39, 45, 124-126). 
This occurred in a context of large pertussis epidemics, with a new pattern of highest disease rates 
among pre-adolescents despite high vaccination coverage (38, 39, 124). 
Between 2008 and 2012, Australia experienced its largest and most sustained pertussis outbreak 
since national reporting in began in 1991 (127). In Queensland, Australia (population 4.5 million, 
median age 37 years) (128), the epidemic peaked in 2011, with almost 9000 reported cases (23). 
Pre-adolescent children had the highest pertussis rates, which peaked in 8 year olds 
(570/100,000/year), despite full pertussis vaccination coverage exceeding 80% in this group at 5 
years of age. 
Both the US and Australia replaced whole-cell pertussis vaccines (wP) with aP in the late 1990s, 
and the high pre-adolescent pertussis reporting rates coincided with the first birth cohorts to have 
received purely aP (38, 39, 124). More rapidly waning protection from aP compared to wP has been 
proposed as a contributing factor to this epidemiology, with several studies providing evidence that 
aP vaccines are less protective against disease than wP (123, 129-132). 
In their population-based study in Northern California, Witt and colleagues found those vaccinated 
with wP had a lower risk of pertussis than those vaccinated with aP only (130). However, as their 
study sample involved a wide birth cohort (born from 1990 to 2001) and was not age-stratified or 
age-adjusted (130), concerns were raised that age confounded the study findings (133, 134). These 
concerns have been lessened by studies with narrower birth cohorts. Also, in Northern California, a 
case-control study comparing the relative effectiveness of 4 pertussis vaccine doses administered to 
children <2 years of age at preventing pertussis among teenagers found those who received 4 wP 
doses were substantially more protected from pertussis than those who received 4 aP doses (131). 
Among the strengths of this case-control study was the stratification of analysis by time of year and 
adjustment for gender, race, and medical clinic (131). However, in their study which included 
children born from 1994 to 1999 (aged 10–17 years during the observational period), the authors 
were unable to adjust for age, as age was strongly associated with the type of pertussis vaccine 
received (aP or wP) (131). 
Two population based cohort studies in Oregon and Queensland, Australia, which compared the 
risk of pertussis according to type of pertussis vaccine receipt in 3 and 1 year birth cohorts of 
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children born from 1997 to 1999, and children born in 1998, respectively (123, 129), reduced but 
did not remove the potential for confounding by age. 
In our original study (123), we showed that for Queensland children born in 1998, pertussis 
reporting rates during a pre-epidemic period (1998–2008) and epidemic period (2009–2011) were 
higher in children who received a pure aP, compared to receipt of a pure wP, course. A 5-dose 
childhood vaccination schedule (at 2, 4, 6, 18 months and 4 years of age) was publicly funded for 
these children. To definitively confirm that increased pertussis risk seen in children with an aP 
vaccine history is not due to age confounding, in this report we present a re-analysis of that work 
using three month birth cohorts. We also present an additional analysis to investigate whether aP 
boosting following the primary-course could overcome the differential effectiveness of aP and wP 
priming. 
Methods 
The construction of the cohort under analysis has been described in full previously (123). Briefly,  
reporting pertussis cases to the Queensland Health Department is mandatory. Using the Queensland 
vaccination register (QVR), we initially constructed a cohort of children born in 1998 who before 
12 months of age had received ≥3 doses of any pertussis-containing vaccine from a Queensland 
vaccine service provider. Pertussis case reports within this cohort were linked to the QVR. As the 
QVR does not contain records of children who have not had a vaccination encounter, we were 
unable to construct a group of wholly unvaccinated children for comparison. Only first pertussis 
case reports were included. 
Age-stratified analysis 
In the first analysis, we stratified children born in the cohort described above into four 3 month birth 
cohorts, and categorised the children by the nature of primary-course received: pure DTaP primary 
course (≥3 doses of DTaP <12 months of age) or pure DTwP primary course (≥3 doses of DTwP 
<12 months of age). We excluded mixed DTwP and DTaP recipients from this analysis. Receipt of 
aP boosters was not an inclusion or exclusion criterion. We compared pertussis reporting rates 
between children primed with purely DTaP and purely DTwP within each of the 3 month age 
cohorts, during the Queensland epidemic period of 2009-–2011. 
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Analysis restricted to pertussis booster receipt 
In the second analysis, we restricted the cohort of children born in 1998 who before 12 months of 
age had received ≥3 doses of any pertussis-containing vaccine from a Queensland vaccine service 
provider, to include only children who received exactly two aP childhood booster doses from age 1 
to 6 years. Children who received a childhood booster dose when ≥7 years of age, and/or an 
adolescent booster dose were excluded. We categorised children according to the nature of the 
pertussis primary-course received before 12 months of age. In addition to purely DTaP and purely 
DTwP primary-course recipients, children who received both DTaP and DTwP before 12 months of 
age, were described as mixed primary-course recipients. Mixed course recipients were further 
categorised by the nature of their first pertussis vaccine (DTaP or DTwP), and the number of DTwP 
vaccines received as part of their primary-course (1 or ≥2 doses). We compared 2009–2011 
pertussis reporting rates between children by the nature of primary course received. 
In both analyses we calculated average annual incidence rates and incidence rate ratios (IRR) of 
purely DTaP or mixed course priming compared to purely DTwP priming, with associated 95% 
confidence intervals (CI). Statistical significance was defined as PP < 0.05. All analyses used Stata 
version 12 (StataCorp, College Station, TX). The Children's Health Services District Human 
Research Ethics Committee, Brisbane approved the study. 
Results 
Age-stratified analysis 
Of 58,233 children born in 1998 with a record on the QVR, 32,783 (56.3%) received ≥3 doses of 
purely DTaP or ≥3 doses of purely DTwP before 12 months of age from a Queensland vaccine 
service provider. Approximately 86% of these children also received 2 aP booster doses between 1 
and 6 years of age. There were 188 first pertussis reports among these children during 2009–2011. 
Across each of the four 1998 three month birth cohorts, children primed with DTaP had 
substantially higher rates of reported pertussis compared to those primed with DTwP (Table 3.3.1), 
with point IRRs between 2.5 and 4.5. The association was statistically significant across all three 
month birth cohorts. 
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Analysis restricted to pertussis booster receipt 
Of children born in 1998 identified on the QVR, 34,555 (59.3%) had received two childhood aP 
booster-doses following their primary course. Overall, 212 first pertussis reports occurred among 
this booster-dose restricted cohort. Among these children, reported pertussis rates were highest in 
those primed only with DTaP and in those who received DTaP as the first dose in a mixed vaccine 
primary-course (Table 3.3.1). Compared to children who received a sole DTwP primary-course, 
those primed with DTaP only or who received DTaP as the first dose in a mixed primary-course, 
were at least three times more likely to be reported with pertussis. Analysis of the mixed primary 
course recipients showed that point incidence rates were higher among those who received DTaP as 
the first dose compared to those who received DTwP as the first dose (Table 3.3.1). However, the 
difference did not reach statistical significance when stratified for the number of DTwP doses 
received. Mixed primary course recipients who received only one compared to two doses of DTwP 
had higher point incidence rates. 
Discussion 
Our findings confirm that the increased protection associated with DTwP compared to DTaP 
priming is not confounded by age or receipt of aP childhood boosters. Results after stratification 
into 3 month birth cohorts were significant within each cohort, despite the reduction in population 
size. These findings are similar to those from our original unstratified analysis, where children 
primed with DTaP had a pertussis IRR of 3.3 (95% CI: 2.4-4.5) compared to those primed with 
DTwP during the same epidemic period, 2009–2011 (123). These findings are also consistent with 
findings from the US (129-131). 
Our analysis confirmed the association between the type of pertussis vaccine and protection against 
pertussis disease among much narrower birth cohorts than previous studies (123, 129-131). The 
rapid and complete transition from primary course wP to aP use in Australia and the age-dependent 
nature of pertussis rates makes it difficult to remove potential confounding by age from population- 
based studies. Australia replaced DTwP with DTaP for the primary-course (given at 2, 4 and 6 
months of age) for all infants in 1999. However, in Queensland the transition from DTwP to DTaP 
for priming occurred throughout 1998 and early 1999. This enabled us to minimise the potential for 
confounding by age by comparing pertussis incidence rates between DTaP and DTwP primed 
children among children born in each quarter of 1998. 
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Our second analysis presented here, which restricts the cohort to children who received two 
childhood aP booster-doses in addition to a completed primary-course, provides evidence that the 
differential effectiveness of aP and wP infant priming in protecting children aged 10–13 years is not 
overcome by receipt of childhood aP booster doses. Exclusion of children who received an adult 
diphtheria–tetanus–pertussis acellular vaccine (Tdap) from the analysis cohort removed Tdap 
receipt as a potential confounding factor. Our findings are consistent with those reported by Klein 
and colleagues, who showed that following receipt of Tdap, teenagers who had received four aP 
doses before 2 years of age remained at significantly higher risk than those who had received four 
doses of wP, despite the wP recipients being older and therefore likely to be temporally remote 
from Tdap receipt (131). 
Our study has limitations. It is observational and there was no adjustment for other potential 
confounding factors, such as health care-seeking behaviour. However, to lead to bias, such a factor 
would have to be associated both with the type of primary-course received and reported pertussis 
cases more than 9 years later. Furthermore, it is very unlikely such bias could result in the strength 
of the association found. 
In summary, the findings of our further analyses provide evidence that the greater protection against 
pertussis provided by wP priming, as opposed to aP priming, is not confounded by age or overcome 
by subsequent childhood aP booster-doses. 
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Table 3.3.1: Reported pertussis cases and rates between 2009 and 2011 for children born in 1998 by birth quarter and nature of pertussis vaccines 
received (n=40 694)a 
                                                                                                       Incidence (95% CI)Pertussis vaccine primary courseNo. of reported cases 
                                                                              Average rate per 100,000/yearRate ratio 
                                                         b 
Among the children who received a pure primary course by birth quarter (n=32 783)c 
Jan-Mar 1998 birth quarter 
      Pure DTaP primary course (n=2221)22330.2 (207.0-499.5)2.5 (1.4- 4.6) 
      Pure DTwP primary course (n=6833)27131.7 (86.8-191.6)1 [Reference] 
Apr-Jun 1998 birth quarter 
      Pure DTaP primary course (n=2401)35485.9 (338.7-675.1)3.9 (2.3-6.8) 
      Pure DTwP primary course (n=6653)25125.3 (81.1-184.9)1 [Reference] 
Jul-Sep 1998 birth quarter 
      Pure DTaP primary course(n=2624)32406.5 (278.2-573.4)4.5 (2.4- 8.6) 
      Pure DTwP primary course (n=6222)1791.1 (53.1-145.8)1 [Reference] 
Oct-Dec 1998 birth quarter 
      Pure DTaP primary course (n=2581)21271.2 (168.0-414.3)2.9 (1.3-7.3) 
      Pure DTwP primary course (n=3248)992.4 (42.2-175.3)1 [Reference] 
Among the children who received two booster doses of aP vaccine between 1 and 6 years of age in addition to the primary course (n=34 555)d 
Pure course plus two aP boosters 
      DTaP primary course (n=8574)94365.5 (295.4-447.0)3.0 (2.2-4.2) 
      DTwP primary course (n=19 492)71121.4 (94.8-153.1)1 [Reference] 
Mixed course plus two aP boosters by type of first dose 
      First dose of DTaP (n=813)11451.0 (225.4-805.5)3.7 (1.8-7.0) 
      First dose of DTwP (n=5676)36211.4 (148.1-292.6)1.7 (1.1-2.6) 
Mixed course plus two aP boosters by number of DTwP doses received 
      One dose of DTwP only (n=2556)23300.0 (190.2-449.7)2.5 (1.5-4.0) 
      Two doses of DTwP (n=3933)24203.4 (130.4-302.5)1.7 (1.0-2.7) 
a 
  A primary vaccination course is defined as three or more doses of a pertussis-containing vaccine administered to infants before 12 months of age. All analyses 
exclude records for infants with no vaccination history recorded before 12 months of age (n=6806), those with vaccination history provided by an outside 
source (not a Queensland vaccine service provider; n=4129), those with irregularity of the vaccine dose by number or description (n=192), and those with less 
than three vaccination doses recorded (n=6412). 
b 
  Defined as three or more doses of a single vaccine only. 
c 
  Excludes children who received a primary course containing both DTaP and DTwP (n=7911). 
d 
  Excludes children who did not have exactly two aP childhood booster doses recorded between 1 and 6 years of age (n=6139) 
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3.4 Acellular pertussis vaccine effectiveness for children during the 2009– 
2010 pertussis epidemic in Queensland acellular pertussis vaccine: recent 
epidemiology 
This section is presented as a published paper: 
Sheridan SL, McCall BJ, Davis CA, Robson JM, Hull BP, Selvey CE, et al. Acellular pertussis 
vaccine effectiveness for children during the 2009-2010 pertussis epidemic in Queensland. Med J 
Aust. 2014;200(6):334-8 
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Abstract 
Objectives 
To assess (i) the effectiveness of three, four, or five doses of acellular pertussis vaccine against 
pertussis notification among children aged 1-<4, 5-<8, and 7-<12 years, respectively, by year of 
birth, and (ii) the effectiveness of three doses of acellular pertussis vaccine against pertussis 
hospitalisation for children aged 1-<4 years. 
Design 
Population-based retrospective study using routinely collected notification, hospitalisation, testing 
and vaccination data for descriptive analysis and to assess vaccine effectiveness (VE) by the 
screening method. 
Setting 
Queensland, Australia. 
Population 
Children aged <12 years, in Queensland between 2009 and 2010 were included in VE calculations 
(n=477,776). 
Main outcome measures 
VE against pertussis notification and hospitalisation for children aged 1-<4 years and 5-<12 years, 
by year of birth. 
Results 
VE point estimates against pertussis notification and hospitalisation in children aged 1-<4 years 
were similar in 2009 and 2010, and ranged between 84% and 89%. Point VE estimates against 
notification among children aged 5-<12 years were between 71% and 88% in 2009, and between 
36% and 71% in 2010. Testing, particularly using molecular diagnostic techniques, such as 
polymerase chain reaction (PCR) assays, increased in children between 2009 and 2010. 
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Conclusions 
Acellular pertussis vaccine provided good protection within the first years of priming, but this 
waned with increased age. Changes in pertussis testing behaviour, with greater PCR use and 
heightened awareness may have contributed to increased pertussis notification rates and lower VE 
estimates against notification, due to the identification of milder disease. 
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Introduction 
In Queensland, 2009 and 2010 were epidemic years for pertussis. New patterns of disease emerged, 
with those aged 6-<12 years having particularly high rates of pertussis notification despite high 
primary-course and booster vaccine coverage for over a decade. A similar disease pattern was 
observed in California (135). Evidence from Queensland (123), California (38, 39, 45, 130), and 
Oregon (129) indicates changing from whole-cell to acellular pertussis vaccines in the late 1990s (5, 
40), contributed to recent pertussis epidemiology. In all regions, highest notification rates during 
2010 occurred in the first birth cohorts to receive acellular pertussis vaccine. 
North American studies describe rapid waning of protection following a five-dose course of 
acellular pertussis vaccinations (39, 45, 125). Data from Queensland (123) and Oregon (129) 
showed a primary-course of whole-cell vaccine, or at least the first dose of the primary-course being 
whole-cell vaccine, provided significantly greater protection against pertussis disease than priming 
with acellular pertussis vaccine alone. These findings are supported by earlier work from Canada, 
which suggested the median time until disease following last vaccination may be shorter in children 
receiving acellular than whole-cell pertussis vaccine (46). 
Pertussis vaccination is available to children as part of the publicly-funded National Immunisation 
Program (NIP) (5). Due to adverse events associated with whole-cell pertussis vaccine (21), 
acellular vaccine was introduced into the NIP in 1997, completely replacing the whole-cell vaccine 
by 1999, principally with the three-component acellular pertussis vaccines (Appendix 3.4.1) (5). 
We sought to assess the effectiveness of acellular pertussis vaccine during 2009 and 2010 in 
Queensland. Recognising the potential influence changes in testing patterns may have on pertussis 
notification and vaccine effectiveness (VE) estimates (136), we also investigated pertussis 
notification rates between 2008 and 2010 and laboratory-testing patterns during 2009 and 2010, in 
Queensland children. 
Methods 
Notification and testing patterns 
We obtained confirmed pertussis notifications from the Queensland notifiable diseases database and 
calculated annual age-specific notification rates for children aged <12 years between 2008 and 2010. 
According to the national guidelines (137), confirmed pertussis cases require either definitive 
laboratory evidence; suggestive laboratory and clinical evidence; or both clinical and 
45 
epidemiological evidence. 
Definitive laboratory evidence consists of either Bordetella pertussis isolation by culture or 
detection by nucleic acid amplification tests, such as polymerase chain reaction (PCR) assays.  
Suggestive laboratory evidence is most commonly met through identifying a single high serum IgA 
titre to pertussis antigens, or evidence of seroconversion. Clinical evidence for confirmed cases 
requires a coughing illness lasting ≥2-weeks, or either of (i) coughing paroxysms, (ii) inspiratory 
whoop, or (iii) post-tussive vomiting. Epidemiological evidence consists of contact between two 
people at a time when one is likely to be infectious and the other becomes symptomatic 6 to 20-days 
later, and at least one case in the chain of epidemiologically linked cases is a confirmed case with 
either suggestive or definitive laboratory evidence. 
Two major Queensland pathology providers, Pathology Queensland, the publicly funded laboratory 
service, and Sullivan Nicolaides Pathology, a private company, provided data on pertussis serology 
tests and PCR assays for Queensland residents, undertaken at their laboratories in 2009 and 2010. 
These providers were responsible for approximately 40% of pertussis notifications during the study 
period. We did not include culture results for determining pertussis testing patterns as cultures were 
performed infrequently and mostly on specimens also tested by PCR. We describe testing by 
volume, and type, and results by age and year of test for children aged 1-<12 years. 
Pertussis vaccine schedule and vaccine effectiveness 
We calculated acellular pertussis VE estimates against notification and hospitalisation in 2009 and 
2010. Only children resident in Queensland and born from 1999 onwards were included to restrict 
analysis to those exclusively receiving acellular pertussis-containing vaccine. We excluded second 
notifications or hospitalisations occurring in the same year. We retrieved hospitalisations with a 
pertussis code in any diagnostic field, from all Queensland public and private hospitals (138). Due 
to small admission numbers, VE against hospitalisation was only calculated for children aged 1-<4 
years as a single age-group. 
Changes in the acellular pertussis vaccine type and schedule delivered to Queensland children 
during the study (Appendix 3.4.1) included removing the 18 month booster dose in 2003 and 
introducing an adolescent booster in 2004. Children were considered fully vaccinated if they had 
received the recommended number of pertussis- containing vaccines for their age according to the 
schedule at the time (Table 3.4.1). This meant children in the birth cohorts 2006-2008; 2002-2004; 
and 1999-2001 were fully vaccinated if the received three (primary-course), four (primary-course 
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and 4 year booster), and five (primary-course, 18 month and 4 year booster) doses respectively. 
VE was calculated using the screening method which involves comparing the proportion of cases 
who are vaccinated (PCV) with the proportion of the study population vaccinated (PPV) (111). We 
obtained the vaccination status of cases from the Queensland vaccination register (VIVAS). As 
VIVAS does not include children who have not received any vaccinations, we obtained aggregated 
population coverage figures for Queensland from the national, population-based Australian 
Childhood Immunisation Register (ACIR) for each birth cohort. Vaccinations recorded <2-weeks 
before illness onset were excluded from calculations. The ‘third-dose assumption’ was used in all 
VE calculations. Under this assumption, children are assumed to have received the first two doses of 
a three course series if their third dose is recorded. The validity of this assumption has been 
demonstrated for the ACIR (118). Partially vaccinated children were excluded from PCV and PPV 
calculations. VE was not calculated for children aged <1 or 4-<5 years, as their vaccination status 
changed during the period of analysis due to receipt of either their primary-course or 4 year booster. 
VE estimates, and 95% confidence intervals, were obtained by fitting a logistic regression model 
with the outcome variable as the vaccination status of the case, with birth cohort included as the 
main effect, and with an offset for the log odds of the PPV (111). This model enabled estimation of 
the association between birth cohort and VE. Separate models were constructed for each notification 
year. Sensitivity analyses on diagnostic method (PCR/bacterial culture only versus 
PCR/culture/serology/ clinical and epidemiologically linked diagnoses) and hospitalisation coding 
(principal diagnosis versus any diagnostic field) were performed. Stata version 12 (StataCorp) was 
used for analysis. 
The Children’s Health Services Queensland Human Research Ethics Committee approved this 
study. 
Results 
Epidemiology 
Pertussis notification rates increased substantially from pre-epidemic 2008 levels in both 2009 and 
2010, with children aged 7-<11 years experiencing the highest rates in 2010 (Figure 3.4.1). 
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Figure 3.4.1: Age-specific pertussis reporting rates, Queensland, 2008-2010 
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Testing patterns 
The testing volume and relative contribution of PCR increased in children between 2009 and 2010 
(Figure 3.4.2). The proportion of PCR tests positive for pertussis were highest in the later childhood 
age groups and increased in children aged 6-<12 years between 2009 and 2010 (Figure 3.4.2). The 
proportions of positive serology tests were lower, but followed a similar pattern to PCR (Figure 
3.4.2). In 2010, the proportions of positive PCR tests increased particularly in children aged 6-<11 
years. 
Vaccine effectiveness — notifications 
Almost 2000 notifications and 29 hospitalisations were included in the VE analyses (Appendix 
3.4.2). In 2009, point estimates for three-dose primary-course effectiveness against notification were 
87% and 89%, similar to that for preventing hospitalisation (Table 3.4.1, Appendix 3.4.3). Point VE 
estimates among children aged 5-<11 years who should have received the primary-course, 4 year 
booster, and largely also the 18 month booster, ranged between 71% in the 2000 cohort, and 88% in 
the 2003 birth cohort. 
In 2010 (Table 3.4.1, Appendix 3.4.3), VE point estimates for the younger cohorts receiving the 
primary- course remained high (84% and 85%). VE point estimates were lower for children aged 5- 
<12 years in 2010 compared to 2009. Among these older cohorts, 2010 VE point estimates ranged 
between 70% and 55%, with the exception of the 2002 cohort, which had a VE estimate of 35%. VE 
waned with increasing age in 2009 (p=0.006) and 2010 (p<0.001). 
Restricting analysis to PCR or culture-confirmed cases, all 2009 VE point estimates and most 2010 
VE estimates changed ≤6%, without an overall consistent pattern emerging (Table 3.4.1). However, 
2010 VE estimates for several birth cohorts were substantially lower for PCR/culture diagnosis only. 
The trend of waning VE with age remained significant among PCR/culture confirmed cases (2009: 
p=0.001; 2010: p<0.001). 
Vaccine effectiveness — hospitalisation 
For children aged 1-<4 years, the effectiveness estimates of the three-dose primary-course for 
preventing hospitalisation with any diagnosis of pertussis were 87% and 86% in 2009 and 2010, 
respectively (Table 3.4.1). Restricting analysis to principal diagnoses of pertussis yielded similar 
results. 
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Figure 3.4.2: Count and proportion positive of pertussis tests performed by Queensland Health and Sullivan Nicolaides Pathology laboratories 
in children 1-<12 years of age in 2009 and 2010, Queensland 
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Table 3.4.1: Queensland pertussis notifications (all and PCR/culture positive only) and hospitalisations (all and primary diagnosis only), case and 
population vaccination coverage, and vaccination effectiveness (VE) by birth cohort using the third dose assumption, 2009 and 2010a 
Notifications 
BirthAge, 
Cohortyears 
2009 notifications 
20071–<3 
20062–<4 
20035–<7 
     d 
20026–<8 
20017–<9 
20008–<10 
19999–<11 
2010 notifications 
20081–<3 
20072–<4 
20045–<7 
20036–<8 
     d 
20027–<9 
20018–<10 
20009–<11 
199910–<12 
Hospitalisations 
BirthAge, 
Cohortyears 
Course used for 
VE assessment 
PCV,% 
(number fully 
vaccinated/total)b 
74.6 (50/67) 
71.8 (56/78) 
73.6 (64/87) 
81.6 (71/87) 
77.4 (82/106) 
83.9 (78/93) 
77.8 (63/81) 
80.2 (93/116) 
78.0 (92/118) 
86.2 (131/152) 
86.1 (149/173) 
91.7 (189/206) 
88.6 (164/185) 
88.7 (205/231) 
88.5 (160/181) 
PCV,% 
(number fully 
vaccinated/total)b 
PCR+ only PCV, % PPV,c % 
(number fully 
vaccinated/total)b 
71.4 (40/56) 
66.7 (42/63) 
73.9 (51/69) 
806 (50/62) 
75.7 (56/74) 
86.0 (49/57) 
79.5 (35/44) 
84.2 (80/95) 
76.6 (72/94) 
88.1 (104/118) 
86.2 (119/138) 
94.9 (148/156) 
90.8 (119/131) 
90.4 (142/157) 
86.8 (118/136) 
1° diagnosis only 
PCV,% 
(number fully 
vaccinated/total)b 
66.7 (10/15) 
77.8 (7/9) 
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VE, % 
(95% CI) 
PCR+ VE, % 
(95% CI) 
Three doses 
Three doses 
Four doses 
Four doses 
Five doses 
Five doses 
Five doses 
Three doses 
Three doses 
Four doses 
Four doses 
Four doses 
Five doses 
Five doses 
Five doses 
Course used for 
VE assessment 
95.8 
96.0 
95.8 
94.8 
94.5 
94.7 
94.7 
96.1 
96.0 
95.5 
95.0 
94.5 
94.6 
94.7 
94.7 
PPV,c % 
87.0 (77.5–92.5) 
89.4 (82.6–93.5) 
87.7 (80.1–92.3) 
75.5 (57.8–85.7) 
80.3 (68.9–87.5) 
71.2 (49.9–83.4) 
80.3 (66.7–88.3) 
83.5 (73.9–89.5) 
85.4 (77.5–90.6) 
70.3 (53.0–81.3) 
67.3 (49.6–78.7) 
34.7 (-7.2–60.3) 
55.3 (29.6–71.6) 
56.2 (34.2–70.9) 
57.1 (32.4–72.8) 
VE, % 
(95% CI) 
89.0 (80.3–93.8) 
91.7 (85.9–95.1) 
87.4 (78.5–92.7) 
77.0 (56.7–87.8) 
82.0 (69.4–89.4) 
66.0 (28.3–83.9) 
78.1 (54.5–89.5) 
78.2 (62.1–87.4) 
86.5 (78.3–91.6) 
64.7 (38.3–79.8) 
67.0 (46.4–79.7) 
-8.6 (-121.2–46.7) 
43.3 (-2.7–68.7) 
47.5 (10.6–69.1) 
63.1 (39.4–77.5) 
1° diagnosis only 
VE, % (95% CI) 
2009 hospitalisations 
2006–2007 1–<4 
2010 hospitalisations 
2007–2008 1–<4 
Three doses 
Three doses 
75.0 (15/20) 
77.8 (7/9) 
95.9 
96.1 
87.1 (65.6-95.3) 
85.6 (30.9-97.0) 
91.4 (74.9-97.1) 
85.6 (30.9-97.0) 
a 
  VE not calculated for children <1 year of age in 2009 and 2010, and for the birth cohorts of 2004-2005 in 2009 and 2005-2006 in 2010, as the 
vaccination status of these cohorts was changing during the period of analysis due to receipt of either their primary-course or 4 year booster. 
b 
  Where PCV is the proportion of cases vaccinated. Fully vaccinated defined as (i) receipt of dose three for 2006 to 2008 birth cohorts; (ii) receipt of 
dose three and the 4 year booster for 2002 and 2003 birth cohorts; and (iii) receipt of dose three, the 18 month booster and 4 year booster for 1998 to 
2001 birth cohorts. Total = fully vaccinated + unvaccinated. 
c 
  Where PPV is the proportion of population vaccinated. Fully vaccinated / total proportions from the ACIR. 
d 
  Approximately one quarter of this cohort was eligible for the 18 month booster. 
52 
Discussion 
The primary-course of acellular pertussis vaccine was highly effective in protecting children aged 1- 
<4 years against pertussis notification and hospitalisation in Queensland during the epidemic years 
of 2009 and 2010. These VE estimates are similar to findings for predominantly whole-cell pertussis 
vaccine in the late 1990s from NSW, where VE was 85% for children aged 2-<5 years (112). 
However, our findings indicated protection waned with increasing age following receipt of the 4 
year booster and is consistent with the waning protection observed in the United States (39, 45, 
125). The decline in VE point estimates in 2009, from 88% in children aged 5-<7 years to 71% and 
81% among children aged 8-<10 and 9-<11 years, respectively, is similar to 2010 findings from 
California, where VE progressively declined from 95% to 71% for children 1-≥5 years after their 
fifth pertussis vaccine dose (recommended at age 4-6 years) (45). Overall, higher whole-cell VE 
estimates of 87% for children aged 5-<9 years, and 78%, for children aged 9-<14 years, were found 
in NSW between 1996 and 1998 (112). This agrees with evidence showing the whole-cell vaccine 
used previously in Australia provided greater duration of protection against pertussis than acellular 
vaccine (123). Despite the waning protection provided by acellular pertussis vaccine, until low- 
reactogenic pertussis vaccines providing sustained high-level protection are developed, we should 
ensure high coverage with current vaccines is maintained. 
As the screening method is very sensitive to small changes in coverage estimates, the accuracy of 
PPV estimates is important. Our study benefitted from obtaining PPV values from the ACIR, which 
registers approximately 99% of Australian children by 12 months of age (102). Previous validation 
of ACIR data indicates the most likely inaccuracy is PPV will be underestimated (117), which, in 
isolation, may result in underestimating VE. A limitation affecting this study is that in the context of 
very high vaccination coverage, modest changes in PCV can lead to marked changes in VE 
estimates. Due to regional variation in immunisation coverage (estimated to be largely <2%), our 
lack of geographical stratification may have biased state-wide VE estimates in either direction. 
Additionally, the small numbers of hospitalisations provide low precision for VE estimates against 
severe disease. The value of this method is in providing a broad overview of effectiveness and 
changes in VE over time (139). 
VE point estimates were lower, particularly among the older age groups during 2010 compared to 
2009. We are unable to explain the isolated low VE point estimate of 35% in 2010 among children 
born in 2002. Whilst there is evidence of increasing circulation of vaccine-mismatched strains 
(119), we believe vaccine-driven selection pressure is unlikely to account for such rapid and uneven 
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changes in VE estimates between 2009 and 2010, as this would require circulating pertussis strains 
to vary with childhood age-group and change very rapidly over time. 
Changes in diagnostic testing behaviour, due to the expanded availability and increased awareness 
of PCR (136), may have contributed to lowering VE estimates in 2010. Whilst we cannot be certain 
of the laboratory-testing data generalisability, the high proportion (~40%) and state-wide coverage 
increases the likelihood that they are broadly representative of pertussis testing in Queensland. 
Based on these data, use of the more sensitive, less invasive PCR method for pertussis testing has 
increased rapidly in Queensland with increased testing in 2009 and 2010 occurring particularly in 
younger age-groups. Before the widespread availability of PCR, clinicians may have been less 
likely to seek laboratory-confirmation involving venepuncture, particularly for milder illness in 
children. Publicity about pertussis during the epidemic may have increased clinician testing for 
pertussis, with a recent study reporting a 40% increase in testing between April 2009 to March 2010 
and April 2010 to March 2011 (140). 
Increased awareness, testing and detection of milder disease, against which the vaccine may be less 
effective, may have resulted in lowering VE estimates (141). Increased testing is likely to have 
contributed substantially to high notification rates during the epidemic. However, the high and 
increasing proportion of pertussis tests positive between 2009 and 2010 in older children, suggests 
the disease burden was truly greatest and increasing in 2010 among children aged 7-<11 years, 
consistent with notification patterns, and with waning protection following a four or five-dose 
acellular pertussis vaccine course. Through differential healthcare usage, older children may be less 
likely to have milder disease diagnosed, leading to relatively high and stable VE estimates. A likely 
consequence of increased pertussis incidence among older children is increased transmission, which 
will have the greatest impact upon infants. 
In the era of predominant PCR use and heightened awareness, pertussis notification rates even 
during non-epidemic periods are likely to be substantially higher, and VE estimates for preventing 
notification may be consistently lower than recorded previously. This change in testing behaviour, 
leading to the identification of milder disease, may require a recalibration of what are considered 
baseline notification rates, and will need to be considered when interpreting future VE estimates. 
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Appendix 3.4.1: Table 3.4.2: Summary of schedule changes for pertussis-containing vaccines 
in Queensland, 1999-20118 
Date 
Pre-March 1999 
Description of schedule change 
Locally produced Diphtheria-tetanus-whole-cell pertussis 
vaccine (DTPw; Triple Antigen, Commonwealth Serum 
Laboratories [CSL], Australia), used for routine pertussis 
immunization at 2, 4, and 6 months, and 18 month and 4 to 5 year 
boosters 
Diphtheria-tetanus-acellular pertussis vaccine (DTPa; Infanrix, 
SmithKline Beecham Biologicals, Rixensart, Belgium) (3- 
component pertussis) and (DTPa; Tripacel, CSL/Pasteur Merieux 
Connaught, Toronto, Ontario, Canada) (5-component pertussis) 
introduced for 2, 4 and 6 month primary-course vaccines 
(replacing whole-cell pertussis vaccine). DTPa continued to be 
provided for 18 month and 4 to 5 year booster vaccines 
Diphtheria-tetanus-acellular pertussis-hepatitis B vaccine 
(DTPaHepB; Infanrix-hepB, SmithKline Beecham Biologicals) 
(3-component pertussis) replaced DTPa for 2, 4 and 6 month 
vaccines 
18 month booster (DTPa) removed from schedule 
Diphtheria-tetanus-acellular pertussis adolescent/adult 
formulation booster (dTpa; Boostrix, GlaxoSmithKline 
Biologicals) (3-component pertussis) introduced for 15 to 17 year 
olds 
Diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis 
vaccine (DTPaIPV; Quadracel, Aventis Pasteur, Toronto, 
Ontario, Canada) (5-component pertussis) replaced DTPaHepB 
for 2, 4 and 6 month vaccines 
Diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis 
vaccine (DTPaIPV; Infanrix-IPV, GlaxoSmithKline Biologicals) 
(3-component pertussis) replaced DTPaIPV (5-component) for 2, 
4 and 6 month vaccines 
Diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated 
poliomyelitis vaccine-Haemophilus influenzae type b (Hib) 
(DTPa-hepB-IPV-Hib; Infanrix-hexa, GlaxoSmithKline 
Biologicals) (3-component pertussis) replaced DTPaIPV (3- 
component) for 2, 4 and 6 month vaccines 
Recommendation for 2 month primary-course DTPa-containing 
vaccine to be given at 6 weeks of age in response to pertussis 
epidemic 
March 1999 
May 2000 
September 2003 
January 2004 
November 2005 
July 2006 
March 2008 
September 2010 
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notifications 
For children born 
(n=669) 
For children born 
(n=1460) 
For children born 
     2006‐7 
     (n=22) 
For children born 
     2007‐8 
     (n=11) 
• 
   nd• 2 notification for a child 
• 
• 
• 
child in the same year 
(n=2) 
• 
• 2nd hospitalisation for a 
(n=599) 
(n=9) 
Appendix 3.4.2: Figure 3.4.3: Flow diagram showing distribution of children for inclusion in the analysis of pertussis reports and hospitalisations 
in 2009 and 2010, Queensland 
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Appendix 3.4.3: Figure 3.4.4: Pertussis vaccine effectiveness against reporting by birth cohort in 2009 and 2010, Queenslanda 
a 
  VE not calculated for children <1 year of age in 2009 and 2010, and for the birth cohorts of 2004-2005 in 2009 and 2005-2006 in 2010, as the 
vaccination status of these cohorts was changing during the period of analysis due to receipt of receipt of either their primary-course or 4 year booster. 
b 
  Approximately one quarter of this cohort was eligible for the 18 month booster. 
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3.5 Waning vaccine immunity in teenagers primed with whole-cell and 
acellular pertussis vaccine: recent epidemiology 
This section will be presented as a published review: 
Sheridan SL, Frith K, Snelling TL, Grimwood K, McIntyre PB, Lambert SB. Waning vaccine 
immunity in teenagers primed with whole-cell and acellular pertussis vaccine: recent epidemiology. 
Expert Rev Vaccines. 2014;13(9):1081-106. 
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Summary 
The recent epidemics of pertussis (whooping cough) in parts of the United States and Australia have 
led to the largest numbers of annual cases reported in over half a century. These epidemics 
demonstrated a new pattern of incidence, with particularly high rates of disease among pre- 
adolescents and early adolescents. These high rates of pertussis coincided with the first cohorts to 
have been vaccinated with purely acellular pertussis (aP) vaccine, which replaced whole-cell 
pertussis (wP) vaccine in the later 1990s in the US and Australia. Studies undertaken during these 
epidemics provide new evidence of the rapid waning of aP and relatively greater and longer-term 
effectiveness of wP vaccine. The initial dose of pertussis vaccine appears to have particular 
importance in determining future protection. This evidence will be reviewed together with the 
immunobiology associated with both vaccines, and the implications for pertussis control discussed. 
Introduction 
Pertussis (whooping cough), caused by the bacteria Bordetella pertussis, continues to be an 
important cause of global morbidity and mortality. In 2008, pertussis infection was responsible for 
an estimated 16 million cases worldwide, 95% occurring in developing countries, and 
approximately 195,000 child deaths (10). Whilst low income countries with sub-optimal vaccine 
coverage have the greatest burden of disease, there has been a recent resurgence of pertussis 
reported from several high income countries with long-standing high vaccination coverage (27, 
136, 142). In the United States (US), over 48,000 cases of pertussis were reported during 2012, the 
highest annual figure since 1955 (143). Whilst the factors contributing to the increase in pertussis in 
the US, Australia and similar countries are complex, increased reporting driven by access to more 
sensitive diagnostic tests and the replacement of whole-cell (wP) with acellular pertussis (aP) 
vaccines are both likely to be important contributors (144). Here we review the evidence for 
differential effectiveness of wP, aP and mixed wP-aP vaccine courses, with a particular focus on 
evidence for waning effectiveness of aP vaccines in pre-adolescents and teenagers, among whom 
pertussis incidence was unexpectedly high during the recent epidemics in the US and Australia. The 
immunobiology underlying the differential effectiveness of pertussis vaccines will also be 
discussed. 
Introduction of pertussis vaccines and transition from wP to aP vaccines 
The first pertussis vaccines to be developed in the early 20th century used suspensions of whole 
killed B.pertussis bacteria and are referred to as wP vaccines. These vaccines became widely 
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available in combination with diphtheria and tetanus toxoids (DTwP) in the 1940s and 1950s in the 
US, United Kingdom (UK) and other developed countries (4, 145). With routine childhood DTwP 
vaccination, pertussis disease dramatically decreased. After decades of vaccine use, annual reported 
pertussis incidence in the US had declined by 99% by the 1970s (146). While still a small fraction 
of the pre-vaccine era incidence (147), there have been regional increases in reported pertussis 
incidence since the 1980s, with a pronounced resurgence between 2009 and 2012 in several 
countries, most notably, the US and Australia (27, 136, 142). 
Concerns in many developed countries emerged first in the 1970s and increased in the 1980s and 
1990s over high rates of local and systemic adverse events associated with whole-cell pertussis 
vaccines (148). This led in some areas to substantially reduced vaccine coverage and increased 
incidence (145, 149). In response to these concerns, aP vaccines containing up to five purified 
B.pertussis antigens, and associated with significantly fewer adverse reactions than wP vaccines 
were developed (21, 150). 
aP vaccines, in combination with diphtheria and tetanus toxoids (DTaP) were first introduced in 
Japan in 1981 (151), and replaced DTwP in the 1990s in many high income countries. In the US, 
DTaP was recommended for the 15-18 month and 4-6 year old booster doses in 1992, and for the 
primary doses at 2, 4, and 6 months of age in 1997 (40). Similarly, in Australia, DTaP replaced the 
18 month and 4-5 year old booster doses in 1997 and for the primary 2, 4 and 6 month courses in 
1999 (5). 
In many developing countries, widespread wP vaccine uptake began after inclusion of the vaccine 
in the World Health Organization (WHO) Expanded Programme on Immunization in 1974 (152). 
In 2012, global coverage with three doses of a diphtheria, tetanus and pertussis containing vaccines 
was estimated to be 83%, with pertussis mortality continuing to decline (153). Due to the 
substantially greater expense of aP vaccines, historically costing ≥10 times than wP vaccines (154), 
aP vaccines are not affordable for many lower income countries, where multivalent vaccines 
containing wP continue to be the predominant vaccine in use (155). 
Recent epidemiology of pertussis in US and Australia 
Resurgent pertussis has been reported in several developed countries in North America, Australia 
and Europe (142, 143, 156). Between 2010 and 2012 there have been large outbreaks in several 
regions of the US including California, Wisconsin, Oregon and Washington, with the emergence of 
a changed age-specific pattern of disease: high rates of disease among pre-adolescents and 
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adolescents, many of whom were fully vaccinated (129, 135, 157, 158). Across the US in 2012, 
>48,000 pertussis cases were reported, the highest number in 57 years (Figure 3.5.1) (143). Whilst 
infants continued to have the highest rate of reported disease, children 7-10 years old had the 
second highest reporting rates followed by adolescents (143). 
Figure 3.5.1: Reported pertussis cases in the United States: 1922-2013* (143) 
*2013 data are provisional 
Similarly, during the recent epidemic of 2009-2011 in Australia, a new pattern of particularly high 
rates of notified pertussis among 5-14 year olds emerged (159). In the state of Queensland, the 
highest age-specific notification rates in the recent epidemic, higher even than those in infants, 
occurred among children 6-11 years old (123, 124). In both the US and Australia, the high 
notifications rates in these age-groups corresponded with the first birth cohorts who received aP 
vaccines for both their primary-course vaccinations and booster doses. This occurred in a context of 
high vaccine coverage, leading to concern about the duration of protection provided by aP.  
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Other factors contributing to pertussis vaccine failure and resurgence of pertussis 
Other factors, apart from the relatively more rapid waning of protective immunity from aP 
compared to wP vaccine and skewing of the pertussis immune responses in children due to the use 
of aP in early childhood, potentially contribute to pertussis vaccine failure and the resurgence in 
reported pertussis (160). 
Higher reported rates of pertussis may have occurred due to increased and more sensitive pertussis 
testing, particularly using PCR (140, 147), as a result of greater physician and public awareness. 
Increased PCR use, possibly contributed to by the relative acceptability of obtaining a respiratory 
sample for PCR analysis versus phlebotomy in children, and the rapidity of obtaining PCR results 
in comparison to culture, is likely to have led to increased pertussis. This may also contribute to 
greater detection of milder disease, against which pertussis vaccines appear less effective. Detection 
and misclassification of B.parapertussis as B.pertussis, due to non-specific PCR assays, has been 
suggested to contribute to inflated reports of pertussis incidence and apparent vaccine failures (141). 
However, this does not appear to apply for several of the recent US studies investigating aP vaccine 
that used assays that can distinguish between B.pertussis and B.parapertussis (38, 39, 130, 131). 
Recent genetic changes have been detected in pertussis bacteria, with a dramatic increase in 
pertactin-deficient strains in the US and Australia (161, 162). It has been hypothesised that these 
changes in the pathogen are due to adaptation in response to vaccine selection pressure, and that this 
may be contributing to the resurgence in pertussis. However, despite pertactin being a specific 
antigenic target of the marketed DTaP vaccines it is currently unknown whether aP vaccines are 
less effective against such strains or whether they are more pathogenic (162). 
Another contributing factor might be that aP vaccines are less protective than wP vaccines against 
asymptomatic infection, with the consequence of greater transmission of asymptomatic or infection 
in aP vaccinated populations. In baboons aP vaccination prevented disease after challenge but did 
not reduce the period of colonization compared to naïve animals, and did not prevent transmission 
to other non-vaccinated baboons (163). Baboons vaccinated with wP cleared were protected against 
disease and cleared the infection more rapidly than both naïve and aP vaccinated animals (163). 
Immunobiology of pertussis vaccines 
Infection with B.pertussis provokes a complex and as yet incompletely understood immune 
response. B.pertussis produces a range of pathogenic toxins and virulence factors that aid infectivity 
and help the organism evade immune responses (164). Both innate and adaptive systems are 
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activated by natural pertussis infection, and cellular and humoral responses are required to clear 
infection and provide protection against subsequent infection. 
Both wP and aP vaccines provide protection against pertussis disease via multiple cellular and 
humoral immune responses (165-167). Variations in contained vaccine antigens and preparation 
methods result in stimulation of different immune components (164). wP vaccines contain whole 
bacteria killed by either heat or formalin (168). The immune response to wP vaccines more closely 
mimics that following natural infection than the immune responses elicited by aP vaccines, but wP 
vaccines are also more reactogenic (164-166). In contrast aP vaccines contain highly purified 
pertussis toxin, alone or in combination with up to four additional purified pertussis antigens in 
varying concentrations (168). 
Humoral immunity 
High titres of antibodies are produced to a range of antigens following vaccination with both aP and 
wP vaccines but the humoral responses are distinct (164-166, 168, 169). Antibodies block 
adherence to mucosal surfaces, facilitate opsonisation and directly neutralise pertussis toxins (164). 
The stimulation of antibodies of different subclasses and antigenic specificities might influence 
vaccine efficacy. For example, the efficient complement-mediated killing mediated by toxin- 
specific IgG3 subclass antibodies has been associated with enhanced clearance of pertussis (169). 
Pertussis toxin (PT), a component of both aP and wP vaccines is recognized as having strong IgE- 
adjuvantising properties (170). aP vaccination stimulates serum IgE production to both pertussis 
toxins and co-administered antigens such as tetanus and diphtheria toxoids (121, 165, 171). Booster 
doses of aP further enhance the IgE response (171). In contrast, vaccination with wP, which also 
contains PT, down-regulates IgE production (170). This is believed to be due to bacterial cell wall 
antigens such as lipopolysaccharide (LPS) which are present in wP, absent in aP, and which are 
thought to have T helper 1 (Th1) adjuvantising/Th2 down-regulating properties (170). Unlike 
natural infection neither wP nor aP vaccines induce pertussis-specific IgA production, thought to be 
an important contributor to mucosal protection against pertussis (164). 
Although high antibody titres correlate with better protection against pertussis it has not been 
possible to determine a protective titre for any single antibody to pertussis (164-166, 172, 173). The 
reason why no antibody titre, either alone or combination, reliably correlates with immunity might 
be explained by the inherent heterogeneity and redundancy in the immune response to pertussis 
involving a complex interplay of both humoral and cellular mechanisms. 
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Cellular immunity 
The importance of cell-mediated immunity to pertussis is increasingly recognized (164, 167, 171, 
174). Both CD4 (Th1, Th2, and Th17) and CD8 T cells specific to various pertussis toxins are 
produced after natural infection or vaccination (174, 175). In particular, CD4 (Th) cells are central 
to effective immune responses to pertussis and are vital to immune functions other than promoting 
antibody production (167). Murine models have demonstrated that CD4-deficient mice cannot be 
effectively immunized against pertussis, whilst CD8-deficient mice can (176). Further, T cell 
deficient mice can clear pertussis infection if passively transfused with pertussis-primed CD4 cells, 
but not with CD8 cells (176). Pertussis infection induces a potent Th1 response that is necessary to 
clear infection (175). In a baboon model, both those primed with wP and previously infected 
animals had a strong pertussis specific Th17 and Th1 response, whereas those vaccinated with aP 
had a Th1/Th2 response. These immune responses were associated with the greater ability to clear 
B.pertussis from the airways and interruption of transmission among wP primed baboons compared 
to aP primed animals (163). 
Vaccination with wP and aP, which contain different antigens, promote differential development of 
either Th1 or Th2 cells (164). In general, early infant immune systems have an inherent Th2 bias as 
a legacy of the in utero state (167, 177, 178). Gradually, Th1 responses become increasingly 
prominent during infancy, as indicated by an improved ability of T cells to produce interferon 
gamma (IFNγ), an important immunoregulatory cytokine (176, 178). Vaccines given in infancy 
have the potential to delay or promote the IFN secreting ability of infants (121, 178). A temporary 
maturational delay in Th1 function, more specifically in the production of IFNγ, may occur after aP 
vaccination (121). Th2 skewing of infant immune responses following priming with aP vaccines 
may result from the combined effect of the Th2-biased phenotype at birth, together with the 
presence of alum (in some aP products) and PT which both have Th2-stimulating properties, and the 
absence of cell wall-derived Th1-stimulating ligands in aP vaccines (170, 179, 180). 
In contrast, wP vaccines contain a multitude of bacterial antigens including LPS, and induce 
secretion of the pro-inflammatory cytokines tumour necrosis factor alpha (TNFα), interleukin (IL)- 
12 and IL1β from macrophages in turn promoting a Th1 response (164). Th1 cells produce 
cytokines including IFNγ, which help activate phagocytes and promote opsonizing antibody 
production, which play an important role in pertussis immunity (164). aP vaccines do not contain a 
complete range of pertussis antigens and instead stimulate IL10 production by macrophages 
inducing a more Th2-dominant response (164). Th2 cells secrete IL5 and IL13, which promote the 
production of neutralizing antibodies as well as non-neutralising IgE antibodies (121, 164). 
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The type of pertussis vaccine used for primary vaccination might also influence infant cellular and 
cytokine responses to mitogens and bystander antigens. Infants vaccinated with an aP vaccine have 
a Th2 skewed (IgE stimulating) response to co-administered antigens such as tetanus toxoid, and a 
reduced ability to secrete IFNγ in response to other antigens, such as phytohaemagglutinin (PHA) 
(121). By the time they are 12 months old, children who received primary vaccination with aP still 
demonstrated a mixed Th2/Th1 response to pertussis toxins although global Th2 bias appears to 
normalize (181). Booster doses of aP vaccine given to older children primed with aP vaccine in 
infancy boost the Th2 skewed response to pertussis and tetanus toxins, but do not appear to promote 
IgE production to common food and aero-allergens (170, 171, 180). 
Waning of immunity to pertussis 
The longevity of immune responses to pertussis vaccination may be influenced by vaccine type in 
addition to the frequency of natural boosting. It is widely recognized that in children antibody levels 
decline rapidly after vaccination, yet they are still protected from severe disease (165, 168, 172). 
Long-lived effector memory T cells and central memory T cells are produced following vaccination 
with both aP and wP vaccines (182, 183). Memory T cells are able to proliferate and produce 
cytokines in response to pertussis antigens many years after vaccination and may be key to long- 
lived pertussis immunity (183). The quality and magnitude of memory T cell responses differs 
depending on whether primary vaccination was with an aP or wP vaccine, with evidence suggesting 
longer lasting immune responses are induced with wP vaccines (183). 
A recent study examined differences in memory T cell proliferation and cytokine secretion in 
children primed with an aP and wP vaccine (183). Thirteen and 11 children were primed in infancy 
with aP and wP vaccines, respectively, and all received an aP booster dose (containing PT and 
filamentous haemagglutinin) at age 5.5-8.2 years (183). Time since booster vaccination was 
significantly longer for the wP vaccine group at 4.8 years, compared with 2.7 years for the aP 
vaccine group) (183). Nevertheless, wP-vaccine primed children had higher cytokine responses and 
similar CD4 and CD8 proliferative responses following stimulation with pertussis antigens 
compared with aP vaccine primed children (183). 
Antigen specific memory B cells are also produced following vaccination with both aP and wP 
vaccines (184). A recent cross sectional study compared differences in long-term immune responses 
between 6 year old children who received primary vaccination with an aP vaccine (n=61) or with a 
Dutch wP vaccine (n=61) (184). All children received an aP preschool booster at 4 years of age. 
Memory B cell numbers, IgG levels and T cell cytokine responses to the pertussis antigens PT and 
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PRN were evaluated. Although the aP booster improved the pertussis immune response in both 
groups, aP-primed children had higher pertussis specific memory B cell numbers, IgG levels and 
avidity before and shortly after the booster compared to wP-primed children, and also higher 
pertussis specific IgG 2 years after the booster. Pre-booster levels of Th1 cells were higher in aP- 
primed children but waned more quickly than in wP-primed children with sustained levels at 2 
years post booster only detected in wP-primed children (184). 
A further study examined immune responses pre and post aP vaccine booster in older children (10- 
14 years old) primed with either aP or wP vaccines (185). The interval since the preceding dose of 
pertussis vaccine was at least 4 years, and on average was longer for the wP-primed group (185). 
The aP booster induced robust humoral and cell mediated immune responses in both groups (185). 
Cellular responses were similar in each group, however, PT-specific antibody responses were 
higher in the wP-primed group both pre and post booster (185). 
In summary, children primed with aP vaccines appear to have good humoral responses up to two 
years after booster aP vaccination, but responses among aP vaccine-primed children appear to 
decline more rapidly in adolescence compared with wP vaccine-primed individuals (184, 185). In 
addition, memory T cell responses appear more robust in children primed with wP vaccines (183, 
184). Given the known qualitative differences in the immune responses generated by aP versus wP 
vaccine priming, the significance of the transient Th2 skewing observed after aP vaccine priming on 
the quality and magnitude of memory immune responses needs further research (181). 
Additionally, among mixed vaccine recipients, the nature of the initial dose received may have a 
particularly important influence on the longer-term immune response and protection. Cherry and 
colleagues investigated the antibody responses to pertussis antigens in children who had pertussis 
following previous vaccination (i.e. were vaccine failures) and unvaccinated pertussis cases (122). 
Children were found to have more robust antibody responses to antigens that were presented in the 
vaccine they had received than to antigens not contained in the vaccine. The authors hypothesised 
that this may be explained by linked epitope suppression, where the initial exposure locks in the 
immune response to certain epitopes and inhibits response to other linked epitopes on subsequent 
exposures (122). 
wP and aP efficacy and effectiveness 
Comparative trials of aP and wP vaccines, undertaken in the 1990s prior to the widespread 
introduction of aP vaccine, provide the most robust evidence for the relative efficacy of these 
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vaccines. Observational studies undertaken following the routine introduction of wP and aP 
vaccines provide expanded evidence of the effectiveness of each under real-world conditions. 
Whilst the efficacy studies provide essential information, there are several points to consider when 
interpreting the available evidence. Multiple wP and aP products exist, including many wP vaccines 
produced by local national manufacturers. Efficacy and effectiveness studies have been undertaken 
on only a few of the wP products and show that efficacy varies substantially between them (186). 
Likewise efficacy varies between aP products. A 2011 Cochrane review found aP vaccines 
containing ≥3 components provide greater protection than aP vaccines with fewer components 
(120). Thus when considering the comparative effectiveness of aP and wP vaccines, the 
heterogeneity in products needs to be considered. Considering the limited and variable efficacy and 
effectiveness data available for wP vaccines the Cochrane review concluded that ≥3 component aP 
were more effective than low-efficacy wP vaccines but may be less effective than the highest- 
efficacy wP vaccines (120). 
Efficacy and effectiveness studies for aP and wP vaccines have varied in design, case definition, 
case ascertainment, vaccination schedule and period of follow up, limiting the ability to directly 
compare results between studies (186). Reported results frequently reflect vaccine efficacy against 
more severe disease, as was the WHO case definition of pertussis in use at the time of these studies 
was ≥21 days of paroxysmal cough and one or more of the following: positive culture for 
B.pertussis, or serological evidence of Bordetella-specific infection by a significant rise in antibody 
(including PHA, IgG, IgA, and PT IgG), or household contact with a B.pertussis confirmed case 
(187). Whilst use of case definitions based on classic symptoms of pertussis provides consistency 
across studies, vaccine efficacy against such disease may overstate the ability of the vaccine to 
prevent milder and more common forms of pertussis. 
Major studies reporting absolute wP and aP vaccine efficacy using the WHO or similar case 
definition are summarised in Table 3.5.1. Among these studies, vaccine efficacy estimates of 3 
doses of ≥3 component DTaP were 78%-89% over mean follow up periods of 17-35.6 months (165, 
166, 188, 189). Efficacy estimates of the same vaccines using more inclusive case definitions, 
including laboratory-confirmed pertussis with up to 7 days of cough, were 62%-81% (165, 166, 
188, 189). The variable efficacy of wP vaccines was also demonstrated in these trials. Two studies 
reported the Connaught Laboratories DTwP vaccine to have particularly low efficacy (36% and 
48%); this was substantially lower than the efficacy of some of the comparator aP vaccines (165, 
190) and that observed for wP vaccines produced by other manufacturers which had efficacies 
≥92% (188, 189, 191, 192). 
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Table 3.5.1: DTaP/DTwP efficacy summary table: (modified from (4)) 
                Study designCase definitionStudyVaccination 
location, year,schedule 
reference(months) 
Sweden, 1991 Double-blind3, 5, 12≥7 days of paroxysmal 
(193)randomizedcough plus infection 
                placebo-controlledconfirmed by culture, 
                studyserology or epi link to 
                                    culture-confirmed case 
Italy, 19922, 4, 6Double-blind,≥21 days of paroxysmal 
(165)randomized,cough plus infection 
                controlled studyconfirmed by culture or 
                                    serology 
Sweden, 1992 
(166) 
Double-blind, 
randomized, 
controlled study 
≥21 days of paroxysmal 
cough plus infection 
confirmed by culture, 
PCR or serology; or epi 
link to culture-confirmed 
case 
≥21 days cough with 
paroxysms, whoop, or 
vomiting, plus infection 
confirmed by culture or 
serology; or epi link to 
culture-confirmed case 
≥21 days of paroxysmal 
cough plus infection 
confirmed by culture or 
serology; or epi link to 
culture-confirmed case 
2, 4, 6 
Surveillance method 
Active: Telephone call 
monthly 
Passive: Parents 
instructed to report 
Active: Telephone call 
monthly 
Passive: Parents 
instructed to report 
Active: Telephone call 
6-8 weekly 
Passive: Parents 
instructed to report 
Mean duration 
of follow up 
(months) 
17.5 
    Vaccine(s) evaluated 
(pertussis antigens in DTaP) 
DTaP: 1-component (PT) ‘Certiva’ 
Vaccine efficacy 
(95% CI) 
71% (63-78) 
17 DTwP: Connaught Laboratories, US 
DTaP: 3-component (PT, FHA, PRN) 
‘Infanrix’ SmithKline Beecham, Belgium 
DTaP: 3-component (PT, FHA, PRN) 
‘Acelluvax’ Chirion Biocene, Italy 
DTwP: Connaught Laboratories, US 
DTaP: 2-component (PT, FHA) SmithKline 
Beecham, Belgium 
DTaP: 5-component (PT, FHA, PRN, FIM2, 
FIM3) ‘Tripacel’ Connaught Laboratories, 
Canada 
DTwP: Wyeth-Lederle 
36.1% (14.2-52.1) 
83.9% (75.8-89.4) 
84.2% (76.2-89.7) 
48.3% (37.0-57.6) 
58.9% (50.9-65.9) 
85.2% (80.6-88.8) 
21-23.5 
Germany, 
1991 (188) 
Double-blind, 
randomized for 
DTaP and DTwP 
arms, and 
nonrandomized, 
unblinded DT 
group 
Double-blind, 
randomized for 
DTaP and DTwP. 
Absolute efficacy 
based on nested 
case-contact study 
using 
nonrandomized 
DT/no vaccine 
group that was 
unblinded 
Household contact 
study. Vaccine 
3, 4.5, 6, 15- 
18 
Active: Telephone call 
2nd weekly 
Passive: Parents 
instructed to report 
35.61 
DTaP: 4-component (PT, FHA, PRN, FIM2) 
‘ACEL-IMUNE’ Lederle/Takeda, Wyeth- 
Lederle Vaccines and Pediatrics, US 
2, 4, 6 Active: Field worker 
visit weekly 
21 DTwP: Pasteur Mérieux Sérums and 
Vaccines, France 
DTaP: 2-component (PT, FHA) ‘Triavax’ 
Pasteur Mérieux Sérums and Vaccines, 
France 
Senegal, 1990 
(192) 
3 doses: 93% (83- 
97) 
4 doses: 93% (88- 
96) 
3 doses: 78% (60- 
88) 
4 doses: 85% (77- 
91) 
92% (81-97) 
74% (51-86) 
Germany, 
1992 (189) 
≥21 days of paroxysmal 
cough plus infection 
3, 4, 5 mo Active: Following 
identification of case 
23 mo DTwP: SmithKline Beecham, Belgium or 
Behringwerke, Germany 
97.6% (83.1-99.7) 
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assignment not 
randomized; 
parents and 
physicians 
responsible for 
initial case 
detection not 
blinded. Study case 
investigators were 
blinded 
Germany, 
1993 (191) 
Prospective, 
unblinded, 
nonrandomized 
case-control study 
confirmed by culture or 
serology 
Child <2 years of age 
with ≥21 days of 
paroxysmal cough plus 
2, 4, 6 
household, weekly 
interviews for ≥28 days 
and final interview 56 
days after onset of 
pertussis symptoms in 
every suspected case 
Passive: Initial case 
household detection: 
Paediatrician report of 
contact from case 
household 
Passive: Physician 
report of study 
participant contact 
DTaP: 3-component (PT, FHA, PRN) 
‘Infanrix’ SmithKline Beecham, Belgium 
88.7% (76.6-94.6) 
n/a DTwP: Behringwerke, Germany 
DTaP: 2-component (PT, FHA) ‘Tripedia’ 
Biken, Japan 
96% (71-100) 
93% (63-99) 
                                       infection confirmed by 
                                       culture or epi link to 
                                       culture-confirmed 
                                       household case 
DT: Diphtheria and tetanus toxoid vaccine; DTaP: Diphtheria and tetanus toxoid, acellular pertussis vaccine; DTwP: Diphtheria and tetnus toxoid, whole-cell pertussis vaccine; PT: Pertussis 
toxin; FHA: filamentous hemagglutinin; PRN: pertactin; FIM: fimbrial protein; epi link: epidemiological link 
1 
  follow up began at 6.5 months of age 
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Longer-term aP and wP efficacy 
While the original pertussis vaccine efficacy trials were of limited duration, unblinded follow-on 
studies provided longer-term vaccine efficacy estimates (Table 3.5.2). These studies suggested 
efficacy of the 3- and 4-component aP vaccines studied remained high for up to 6 years following a 
3- or 4-dose course. An Italian study found the efficacy of a 3-dose primary course of two 3- 
component aP vaccines in infancy to be 86% for children aged 3-6 years, against laboratory- 
confirmed pertussis associated with ≥21 days of spasmodic cough (194). Including laboratory- 
confirmed pertussis with any cough lasting ≥7 days gave point estimates of vaccine efficacy of 
76%-78% (194). Follow up of a German efficacy trial found 3-doses of a 4-component DTaP with a 
single booster dose provided 89% efficacy for preventing physician diagnosed pertussis 1-9 years 
after the last pertussis dose, without evidence of waning (195). The comparative DTwP arm 
experienced similar overall protection with 92% efficacy over the same period (195). 
In contrast, follow up of the Senegalese efficacy trial found 3-doses of 2-component aP vaccine had 
a lower point estimate of vaccine efficacy than a wP vaccine, but not the wP vaccine, protection 
waned significantly with increasing age (196). aP vaccinated children ≥30 months of age had a 
relative risk of pertussis of 2.27 (95% CI: 1.28-4.03) compared to those ≤18 months of age, whereas 
no significant change in risk occurred among wP vaccinated children of the same ages (196). No 
efficacy studies, prior to the replacement of wP with aP vaccines, evaluated a 5-dose course of aP. 
wP vaccine effectiveness 
Population-based studies undertaken following the establishment of pertussis vaccination programs 
provide evidence on the effectiveness of wP vaccines (Table 3.5.3). Whilst study differences limit 
the comparison of estimates across studies, they provide useful information about vaccine 
effectiveness in real-world contexts, against notified disease. The three vaccines, including two 
locally produced wP vaccines (112, 197), assessed in the 5 studies described in Table 3, were 
generally ≥80% effective for at least the first 4 years following the last dose (112, 197-200). Across 
the studies, effectiveness point estimates declined with increasing age, consistent with waning 
protection (112, 197-200). In one study vaccine effectiveness remained ≥80% for up to 8 years 
following the last dose (199), while other studies indicated more rapid waning of protection with 
age with vaccine effectiveness <50% 7 years after vaccination (198). The two studies, which 
reported effectiveness in epidemic and non-epidemic periods, found the point vaccine effectiveness 
lower in epidemic contexts (197, 199). 
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Table 3.5.2: DTaP/DTwP longer-term efficacy summary table: 
Study location,Study designCase definition 
year, reference 
Italy, 1995-1998 Unblinded≥ 21 days of spasmodic 
(194)prospectivecough plus infection 
                  longitudinal studyconfirmed by culture or 
                  follow on from (165)serology 
                  Study designCase definitionStudy location, 
year, reference 
Germany, 1995- UnblindedPhysician based 
2000 (195)prospectivediagnosis 
                  longitudinal study 
                  follow on from (188) 
Vaccination 
schedule (months) 
2, 4, 6 
Surveillance method 
Active: Telephone call 
monthly 
Passive: Parents 
instructed to report 
Surveillance method 
Active: Questionnaires 6- 
9 months 
Passive: Parental report 
Vaccine evaluated 
(pertussis antigens in DTaP) 
DTaP: 3-component (PT, FHA, PRN) 
‘Infanrix’ SmithKline Beecham (Belgium) 
DTaP: 3-component (PT, FHA, PRN) 
‘Acelluvax’ Chirion Biocene (Italy) 
Vaccine evaluated 
(pertussis antigens in DTaP) 
DTwP: Wyeth-Lederle 
Age group 
3-6 years 
3-6 years 
Years after 4th 
dose 
1-2 
3 
4 
5 
6 
7-9 
1-9 (overall) 
1-2 
3 
4 
5 
6 
7-9 
1-9 (overall) 
Vaccine effectiveness 
(95% CI) 
86% (79-91) 
86% (79-91) 
Vaccine effectiveness 
(95% CI) 
100% (-) 
93% (65-99) 
91% (51-98) 
86% (39-97) 
97% (74-100) 
82% (10-96) 
92% (84-96) 
100% (-) 
100% (-) 
77% (15-94) 
74% (4-93) 
96% (65-99) 
75% (-22-95) 
89% (79-94) 
Vaccination 
schedule (months) 
3, 4.5, 6, 15 
DTaP: 4-component (PT, FHA, PRN, 
FIM2) ‘ACEL-IMUNE’ Lederle/Takeda 
(Wyeth-Lederle Vaccines and Pediatrics, 
US) 
DTaP: Diphtheria and tetanus toxoid, acellular pertussis vaccine; DTwP: Diphtheria and tetnus toxoid, whole-cell pertussis vaccine; PT: Pertussis toxin; FHA: filamentous hemagglutinin; 
PRN: pertactin; FIM: fimbrial protein; epi link: epidemiological link 
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Table 3.5.3: Summary of selected DTwP effectiveness studies 
StudyStudy designVaccine evaluated 
location, year 
United 
Kingdom 
(UK), 1977- 
1987 (198) 
Longitudinal study in 
discrete general practice 
community 
Wellcome, UK 
Vaccination schedule Case definition Age group 
3, 4.5-5, 8.5-11 mo ≥21 days of paroxysmal cough, often 
with vomiting and whooping 
1 year 
2 year 
3 year 
4 year 
5 year 
6 year 
7 year 
1 year 
2 years 
3 years 
4 years 
5 years 
6 years 
7 years 
8 years 
9 years 
6-11 mo 
1-4 years 
5-14 years 
8-23 mo 
2-4 years 
5-8 years 
9-13 years 
UK, 1989 
(199) 
Population based study on 
surveillance data, 
screening method 
Wellcome, UK 3, 4.5-5, 8.5-11 mo Notified cases with ≥21 days of 
paroxysmal cough 
UK, 1995- 
1997 (200) 
Population based study on 
surveillance data, 
screening method 
Population based, 
screening method 
Wellcome, UK 2, 3, 4 mo Notified cases with culture- 
confirmation 
Australia, 
1996-1998 
(112) 
CSL Limited,1 
Australia 
2, 4, 6, 18 mo and 4-5 
years2 
Pertussis notifications to Health 
Department3 
Poland, 1996- 
2001 (197) 
Population based study on 
surveillance data 
Nationally 
produced whole- 
cell vaccine, Poland 
2, 3-4, 5, 16-18 mo Notified pertussis cases with culture- 
confirmation or detection of IgM 
antibodies by ELISA 2-5 years 
6-9 years 
Vaccine effectiveness 
(95% CI) 
Of 3 doses 
100% 
96% 
89% 
84% 
52% 
54% 
46% 
Non-epidemicEpidemic 
95%94% 
92%88% 
93%86% 
93%87% 
90%93% 
95%84% 
91%79% 
85%85% 
78%48% 
95.8% (89.4-98.1) 
91.8% (86.6-95.0) 
75.8% (63.8-86.8) 
Of ≥3 doses 
91.0% (85.5-94.4) 
84.5% (78.3-88.9) 
86.5% (82.7-89.5) 
77.6% (71.7-82.3) 
Of 3 or 4 doses 
Non-epidemicEpidemic (2001) 
(1996) 
97.3% (92.4-99.0) 73.5% (52.3-85.3) 
84.9% (54.5-95.0) 68.9% (54.7-78.6) 
DTwP: Diphtheria and tetnus toxoid, whole-cell pertussis vaccine 
1Whole-cell vaccine (CSL) accounted for the great majority of pertussis vaccines used. DTaP was funded for 4 th and 5th dose in 1998. 
2 
  4-5 year dose introduced in 1994 
3Notifiable pertussis requires confirmed by culture; or with serological evidence plus a history of a clinically compatible illness; or an illness lasting ≥2 weeks with paroxysms of coughing, 
inspiratory whoop without other apparent cause, and/or posttussive vomiting; or a cough illness lasting ≥2 weeks plus an epi link to a laboratory confirmed case. 
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Effectiveness of adolescent/adult aP vaccines 
aP vaccines with reduced antigen content, combined with tetanus and reduced-dose diphtheria 
(Tdap) were introduced for use in adolescents and adults in response to an increase in reported 
pertussis among adolescents and adults despite high childhood pertussis vaccination coverage (201). 
Tdap was recommended for 11-12 year olds in the US in 2005 (202), and for 15 year olds in 2004 in 
Australia (5). 
Table 3.5.4 summarises an efficacy trial and three field studies from the US and Australia 
evaluating the protection provided by the adolescent/adult pertussis booster. The randomized 
double-blind trial of a reduced content 3-component GlaxoSmithKline aP monovalent vaccine 
undertaken in the US among 15-65 year olds, found an efficacy against laboratory-confirmed 
pertussis of 92% (95% CI: 32-99) over a median of 22 months (203). The precision of the vaccine 
effectiveness estimate is limited by the small number (n=10) of cases. Whilst there was no 
information provided on previous pertussis vaccination history, except the absence of a pertussis 
vaccination in the 5 years prior to the study, it is likely that a large proportion of subjects received 
wP vaccine earlier in their life and had not received aP vaccine previously. 
A US study undertaken during an outbreak at a school found Tdap vaccine effectiveness to be 
70.6% (95% CI: -110.3-95.9) against laboratory-confirmed disease among children ≥11 years of 
age (204). Given the timing of the study in relation to the recommendation for an adolescent booster 
in the US, it is likely that the effectiveness estimate was for protection within the first year of 
receiving Tdap (202). Unfortunately, the findings of this study are also limited by small numbers 
with only 25 confirmed cases. 
An Australian field evaluation of the 3-component Tdap (Boostrix, GlaxoSmithKline, Rixensart, 
Belgium), among high school students aged 12-19 years in 2005, found vaccine effectiveness, 
adjusted for potentially confounding factors, to be 85.4% (95% CI: 83.0-87.5) for laboratory- 
confirmed notified cases (205). Similar to previous studies, vaccine effectiveness was measured 
within two years of Tdap receipt, and almost all students would have received DTwP for some or all 
of their prior childhood vaccinations. 
The type of initial doses of vaccine and primary course of vaccine might have an influence on the 
responses elicited by booster doses, and therefore effectiveness of Tdap following wP vaccination 
in childhood may differ from the effectiveness of Tdap following aP priming. A recent case control 
study undertaken among members of a healthcare organization in Northern California in 2006- 
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Table 3.5.4: Summary of selected Tdap efficacy and effectiveness studies1 
StudyStudy designVaccine evaluatedVaccination 
location,(pertussis antigens in schedule 
yearaP booster vaccine) 
US, 1997-Randomized3-component (PT,Single monovalent 
1999, (203)double-blindFHA, PRN)reduced content 
               controlledmonovalent vaccine,acellular pertussis 
               studyGlaxoSmithKlinevaccine without 
                                Biologicalsreceipt of pertussis 
                                                        vaccine in the 
                                                        previous 5 years 
NorthernCase controlBoth 3- and 5-Tdap receipt ≥11 
California,studycomponent Tdapyears of age 
US, 2006-vaccines: ‘Boostrix’ 
2011 (206)(PT, FHA, PRN), 
                                GlaxoSmithKline, 
                                Rixensart, Belgium; 
                                and ‘Adacel’ (PT, 
                                FHA, PRN and 
                                FIM2&3), Sanofi 
Pasteur, Swiftwater, 
PA 
3-component (PT, 
FHA, PRN) 
‘Boostrix’ 
GlaxoSmithKline, 
Rixensart, Belgium 
Median duration of 
follow-up / time since 
Tdap receipt 
Median duration of 
follow-up: 22 mo 
Case (and control) definition 
Cough illness lasting ≥5 days 
with culture, PCR or 
serological confirmation2 
Age group Vaccine efficacy/ effectiveness (95% 
CI) 
92% (32-99)3 Healthy 15-65 
year olds 
Among recipients of 
Tdap, % vaccinated 
within 2 years of 
PCR test by 
subgroup: 
aP 92% 
wP 62% 
Pre-vaccine 58% 
Cases: PCR positive for 
pertussis 
Controls 1: PCR negative for 
pertussis 
Controls 2: Demographically 
matched (including age), with 
membership of the same 
healthcare organisation 
≥11 years of 
age & 
according to 
prior 
vaccination of: 
aP only 
wP only 
none (pre- 
vaccine era) 
PCR negative 
controls 
Matched controls 
57.6 (34.1-72.7) 
68.3 (45.8-81.5) 
24.1 (-58.7-63.7) 
74.4 (60.4-83.4) 
63.6 (37.3-78.9) 
26.7 (-65.4-67.5) 
New South 
Wales 
(NSW), 
Australia, 
Jan-Dec 
2005, (205) 
Virgin 
Islands, US, 
Sep-Dec 
2007, (204) 
                                                                                                           Cough illness plus culture≥11 years of68.3% (-126.4-95.6) compared to non- 
                                                                                                           confirmed pertussis; or coughageTdap recipients who had received ≥4 
                                                                                                           lasting ≥14 days with ≥1 ofdoses of DTwP/DTaP doses 
                                                                                                           whoop, post-tussive vomiting, 
                                                                                                           and paroxysmal cough, plus 
                                                                                                           positive PCR or serological 
                                                                                                           test result 
Tdap: tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine; aP: acellular pertussis vaccine; wP: whole-cell pertussis vaccine; DTaP: Diphtheria and tetanus toxoid, acellular 
pertussis vaccine; DTwP: Diphtheria and tetnus toxoid, whole-cell pertussis vaccine; PT: Pertussis toxin; FHA: filamentous hemagglutinin; PRN: pertactin; FIM: fimbrial protein 
Time since Tdap 
receipt: likely to have 
been ≤22 months of 
study completion 
Population 
based study of 
high school 
students in 
several NSW 
health regions 
using the 
screening 
method 
Cohort study 
during school 
outbreak 
Tdap receipt May- 
Dec 2004 
Time since Tdap 
receipt: likely to have 
been ≤20 months of 
study completion 
Notified to the NSW health 
department based on 
serological or PCR 
confirmation 
12-19 year 
olds 
85.4% (83.0-87.5) 
Not specified4 ≥4 doses of
DTwP/DTaP with 
4th dose given >4 
years of age and 
Tdap ≥11 years of 
age5
74 
1 
2   see also reference (207) in Table 5 
  Active surveillance of twice monthly phone calls 
3 
  Adjusted for duration of cough 
4 
  Two Tdap vaccines (3-component and 2-component) licensed in the US at the time of the study 
5 
  Tdap adolescent booster recommended in 2006 (202) 
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2011, assessed Tdap effectiveness following childhood vaccinations of aP-only, wP-only, or no 
priming with pertussis vaccines (for people born in the pre-vaccine era) (206). Cases, identified by 
pertussis polymerase chain reaction (PCR), were compared against both PCR test negative controls 
and demographically matched controls from the same healthcare organization. Tdap was found to 
provide moderate, and statistically significant protection among those who had received aP-only 
vaccinations (vaccine effectiveness of 58% or 74% depending upon control group), and for people 
vaccinated with wP-only in childhood (vaccine effectiveness of 68% or 64%), compared to those 
who had not received Tdap but received the same type of pertussis vaccinations in infancy (206). 
Among the pre-vaccine era subset, effectiveness estimates were 24% or 27% depending upon 
control group, however, neither was statistically significant (206). Whilst the vaccine effectiveness 
estimates between aP and wP recipients were similar, the effective follow-up time among aP-only 
vaccine recipients was shorter, so it is uncertain whether the longer-term effectiveness of Tdap 
varies with the type of vaccine received in infancy. Among the aP subset, 92% received Tdap <2 
years prior, compared with only 62% and 58% among those in the wP and pre-vaccine era subsets 
respectively (206). 
Evidence of waning protection from aP 
Studies from the US were the first to identify the rapid waning of protection provided by 5 doses of 
aP in the context of the recent outbreaks (Table 3.5.5). Witt and colleagues assessed vaccine 
effectiveness during the 2010 epidemic among children aged 2-18 years who were members of a 
single large healthcare system in Northern California (38). The incidence of laboratory-confirmed 
pertussis was highest among children 8-12 years old. Vaccine effectiveness was calculated twice 
using the screening method including and excluding partially vaccinated children (38, 208). In both 
analyses, vaccine effectiveness was found to be unexpectedly low. 
Excluding partially vaccinated children, the effectiveness of age-appropriate vaccination compared 
to being unvaccinated was 64% (95% CI: -61-92) for 2-7 year olds and -33% (95% CI: -230-47) for 
8-12 year olds (208). Whilst the authors were unable to identify which vaccines were administered 
prior to 2002, given the that the healthcare system ceased use of DTwP in 1999 (130), many 
vaccinated children aged 8-12 years-old including all <10 years old would have received 3- or 5- 
component DTaP exclusively. The effectiveness estimates suggested rapid waning of protection 
following boosting and inadequate control of pertussis of the existing schedule in this well 
vaccinated population (coverage = 88-94%). Vaccine effectiveness was substantially higher among 
adolescents 13-18 years old (79%; 95% CI: 73-84). The authors suggested this may be due to 
improved protection provided by boosting with Tdap (38), although an additional consideration is 
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Table 3.5.5: Summary of recent aP effectiveness studies 
                Study designVaccines in useStudy 
location, year 
Oregon, US,PopulationNot specified1 
2012 (207)based cohort 
Vaccination 
schedule 
2,4,6,15-18 
mo, 4-6 
years, Tdap 
at 11-12 yrs 
Case definition 
Confirmed according to the Council of State and Territorial 
Epidemiologists’ 1997 case definition that requires a cough illness 
of any duration, with a positive culture; or a cough lasting ≥2 
weeks with paroxysms of cough, inspiratory whoop, or post- 
tussive vomiting, accompanied by (i) a PCR positive result or (ii) 
epidemiological inkage to a confirmed case (209). 
Age-group 
6-14 mo 
15-47 mo 
4-6 yrs 
7-10 yrs 
11-12 yrs 
13-16 yrs 
17-19 yrs3 
Marin County, 
Northern 
California, 
US, 2010 (38) 
Population 
based, 
screening 
method 
Australia, 
2005-2009 
(126) 
Matched case- 
control study 
3-component (PT, FHA, 
PRN) (GlaxoSmithKline, 
US) and 5-component (PT, 
FHA, PRN, FIM2&3) 
(Sanofi Pasteur, US) and 
prior to 1999 DTwP 
Almost exclusively 3- 
component (PT, FHA, 
PRN) GlaxoSmithKline 
acellular pertussis vaccines 
Vaccines in use 
Not specified1 
2,4,6,15-18 
mo, 4-6 
years 
≥1 week of cough associated illness or intimate contact with a 
pertussis case, plus a positive PCR 2-7 yrs 
8-12 yrs4 
Vaccine effectiveness (95% 
CI) 
3 doses: 
86% (72-93) 
4 doses: 
95% (92-97) 
5 doses2: 
89% (81-94) 
83% (72-90) 
Tdap receipt: 
65% (46-78) 
47% (19-65) 
66% (30-84) 
4-5 doses: 
64% (-61-92) 
5 doses: 
-33% (-230-47) 
2,4,6 mo 
Study 
location, year 
15 Californian 
counties, 
California, 
US, 2010 (45) 
Study design 
Case-control 
study 
Vaccination 
schedule 
2,4,6,15-18 
mo, 4-6 
years 
Notified cases which required either (i) definitive laboratory 
evidence (detection by PCR or isolation by culture) or (ii) 
suggestive laboratory evidence (single point serology) plus a 
coughing illness lasting ≥2 weeks with either paroxysms, 
inspiratory whoop or posttussive vomiting 
Case definition 
All suspected, probable and confirmed cases among children aged 
4-10 years. Clinical cases defined as cough lasting ≥2 weeks with 
paroxysmal cough, inspiratory whoop, or posttussive vomiting. 
Confirmed cases defined as cough plus culture confirmation; or 
clinical case plus either a positive PCR test result or an epi link to 
a confirmed case. Probable cases were clinical cases without 
laboratory confirmation or an epi link. Suspected cases defined as 
cough with positive PCR result or cough with ≥1 other sign and 
an epi link to a confirmed case. 
Case definition 
1 yr 
2 yrs 
3 yrs 
Years since 5th 
DTaP dose 
<1 
1 
2 
3 
4 
≥5 
Overall <1-≥5 
Time since 5th 
DTaP dose 
Per year after 
the 5th dose 
3 doses: 
79.2% (75.0-82.8) 
70.7% (64.5-75.8) 
59.2% (51.0-66.0) 
Vaccine effectiveness (95% 
CI) 
98.1% (96.1-99.1) 
95.3% (91.2-97.5) 
92.3% (86.6-95.5) 
87.3% (76.2-93.2) 
82.8% (68.7-90.6) 
71.2% (45.8-84.4) 
88.7% (79.4-93.8) 
Study 
location, year 
Northern 
California, 
US, 2006- 
2011 (39) 
Study design Vaccine in use 
Not specified1 
Vaccination 
schedule 
2,4,6,15-18 
mo, 4-6 
years 
Case-control 
study 
Children 4-12 years of age who were positive for pertussis and 
negative for parapertussis on PCR testing and who received a 
dose of DTaP at 47-84 months of age (considered the 5th dose) 
before the PCR test was performed. 
Odds Ratio (OR) or Risk 
Ratio (RR) of pertussis (95% 
CI) 
OR 1.42 (1.21-1.66) 
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Minnesota and 
Oregon, US, 
2002-2010 
(125) 
                                                                                                                                                                                          Oregon RRYears since 5th Minnesota 
                                                                                                                                                      DTaP doseRR 
                                                                                                                                                      1referencereference 
                                                                                                                                                      21.9 (1.3-2.9)1.3 (0.6-2.8) 
                                                                                                                                                      32.6 (1.7-3.8)1.5 (0.7-3.7) 
                                                                                                                                                      43.2 (2.1-4.8)1.7 (0.8-3.7) 
                                                                                                                                                      56.1 (4.1-8.9)2.6 (1.2-5.6) 
                                                                                                                                                      68.9 (6.0-13.0) 4.0 (1.9-8.4) 
aP: acellular pertussis vaccine ; Tdap: tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine; DTaP: Diphtheria and tetanus toxoid, acellular pertussis vaccine; PT: Pertussis 
toxin; FHA: filamentous hemagglutinin; PRN: pertactin; FIM: fimbrial protein 
1 
  Both 3- (PT, FHA, PRN) and 5-component (PT, FHA, PRN, FIM2, FIM3) aP vaccines, and a 3- and 5-component Tdap boosters licenced during the study period 
2or 4 doses if 4th dose received >4 years of age 
3 
  The primary course in this age-group is likely to be wP 
4 
  Vaccine effectiveness may not be exclusively for DTaP, as DTwP was not retired from use until 1999 
Cohort study 
of children 
born 1998- 
2003 who had 
5 DTaP doses 
2,4,6,15-18 
mo, 4-6 
years 
Not specified1 Cases ≤ 15 years identified from statewide surveillance. Cases 
required either culture confirmation with a cough of any duration; 
or a cough lasting >2 weeks with paroxysmal cough, inspiratory 
whoop, or posttussive vomiting, plus either a positive PCR result 
for pertussis or an epi link to a laboratory confirmed case. 
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the predominance of childhood vaccination with DTwP rather than DTaP among adolescents aged 
≥13 years old. 
Given the uncertainty about the type of vaccines received prior to 2002, it is uncertain to what 
degree the estimates presented for the 8-12 year age-group reflects the effectiveness of exclusive 
vaccination with aP vaccine, and for the 13-18 year age-group reflects the effectiveness of wP 
vaccination. The small number of cases and the high vaccination coverage also contributes to 
uncertainty of the vaccine effectiveness estimates. Additionally, as the age-groups were not 
structured according to the recommended immunization schedule, the definition of fully vaccinated 
varies within single assembled age-cohorts (210). 
Klein and colleagues also undertook a case-control study within the same integrated healthcare 
system in Northern California to assess the duration of protection following 5 doses of DTaP (39). 
They enrolled PCR positive cases and both PCR test-negative and demographically matched 
controls aged 4-12 years between 2006 and June 2011. The authors found significantly increased 
odds of acquiring pertussis each year after receipt of the 5th DTaP dose (odds ratio (OR) 1.42; 95% 
CI: 1.21-1.66) (39). The results indicate that even if DTaP provides initially very high protection, 
protection from DTaP wanes rapidly. 
In another case control study undertaken across 15 Californian counties in 2010 by Misegades and 
colleagues, the vaccine effectiveness of 5 doses of DTaP was assessed by increasing time since 5th 
vaccination (45). The effectiveness of 5 doses was found to progressively decline from 98.1% (95% 
CI: 96.1-99.1) <1 year after the 5th dose to 71.2% (95% CI: 45.8-84.8) >5 years following the 5th 
dose of DTaP (45). 
Tartof and colleagues assessed the risk of acquiring pertussis following 5 doses of DTaP in two 
large cohorts of children in Oregon and Minnesota born between 1998 and 2003 (125). They found 
the relative risk of pertussis increased progressively in both cohorts with increased time since the 5th 
dose. Compared to the risk in the first year following the 5th dose, the relative risk of pertussis was 
8.9 (95% CI: 6.0-13.0) in Minnesota and 4.0 (95% CI: 1.9-8.4) in Oregon by the 6th year after 
receipt of the 5th dose (125). 
A further statewide, population-based study from Oregon investigated the effectiveness of DTaP 
and Tdap in those aged <20 years in the epidemic year of 2012 (207). Using the statewide 
reportable disease database and immunization system, the authors assessed vaccine effectiveness 
based on age-specific pertussis attack rates among those fully vaccinated and unvaccinated. The 
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effectiveness of 4 doses of aP was 95% (95% CI: 92-97) among 15-47 month-olds, whilst among 7- 
10 year olds, 5 doses was 83% (95% CI: 72-90) effective (196). Tdap effectiveness was 65% (95% 
CI: 46-78) among 11-12 year olds, 47% (95% CI: 19-65) among 13-16 year olds, and 66% (95% 
CI: 30-84) among teenagers aged 17-19 years old (207). Many of those ≤16 years of age were likely 
to have received aP for their childhood vaccines due to being born during or following the transition 
to aP, whilst those ≥17 years old are likely to have been primed with wP in early childhood. Liko 
and colleagues suggest that the greater protection among 17-19 year olds compared to 13-16 years 
olds might be attributable to wP priming enhancing the booster effect of the Tdap (207). 
A nationwide age-matched case control study undertaken in Australia investigated the duration of 
protection provided by 3 doses of DTaP vaccine without a booster dose among children up to 4 
years old. Vaccine effectiveness reduced significantly from 79.2% (95% CI: 75.0-82.8) among 1 
year olds to 59.2% (95% CI: 51.0-66.0) among 3 year olds (126). These results were substantially 
lower than those reported previously for DTwP among 2-4 year olds (112, 126). 
Outcome of a mixed wP-aP primary course in infancy in current teenagers 
Four recent studies from the US and Australia explore the effect of mixed wP and aP pertussis 
vaccination on children and adolescents who were vaccinated during the transition from wP to aP 
vaccines (Table 3.5.6). 
A retrospective cohort study undertaken using routinely collected pertussis surveillance and linked 
vaccination data in the state of Queensland, Australia, investigated the differential effectiveness of 
pertussis vaccines by comparing pertussis incidence rates among a single year birth cohort, by the 
nature of pertussis vaccine primary-course received (123). The nature of the change-over to DTaP 
from DTwP meant that children born in 1998 received either a purely DTwP primary-course, a 
purely DTaP primary-course or a mixed primary-course containing both DTwP and DTaP. 
Incidence rates for children, based upon the nature of their primary-course of pertussis vaccination 
were calculated and compared between a non-epidemic period of 1999-2008 and an epidemic 
period of 2009-2011. This approach had the advantage that identified cases were subject to the same 
diagnostic tests during comparison periods. Of the 40,694 children in the cohort, 56.4% were 
primed with DTwP-only, 24.1% with DTaP-only, and 19.4% with a mixed combination of DTwP 
and DTaP in their first year of life. 
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Table 3.5.6: Summary of recent studies comparing aP and wP vaccine effectiveness by nature of the vaccines received 
LocationVaccination course of comparative groupsPertussis casesBirth cohortStudyIncidence over the studyRisk Ratio (95% 
                (age duringperiodperiod per 100,000CI)/ (p-value) 
                study period)(average annual incidence) 
Population-based cohort studies 
                                   2009-3 pertussis doses <1 year of ageQueensland, 1998 (10-13 
                                        21Pure DTaP primary course (n=9,827)1101119.4 (373.1)3.29 (2.44-4.46)2011years)Australia 
                                                     Pure DTwP primary course (n=22,956)78339.8 (113.3)1(123) 
                                                                               st 
                                                     Mixed primary course, 1 dose acellular (n=978)121227.0 (409.0)3.61 (1.79-6.67) 
                                                                               st 
                                                     Mixed primary course, 1 dose whole-cell (n=6,933)42605.8 (201.9)1.78 (1.20-2.63) 
            33 pertussis doses <1 year of ageOregon, US1997-1999 (0- Apr 1997- 
                                                     1st dose acellular (n=120,712)243201.3 (13.2)2.15 (1.40-3.30)(129)15 years)Jul 2012 
                                                      st 
                                                     1 dose whole-cell (n=24,569)2393.6 (6.1)1 
                                                 ≥5 pertussis doses starting <1 year of age, with Tdap at age ≥10 years 
                                                 of age 
                                                     1st dose acellular (n=86,105)6575.5 (5.0)2.54 (1.02-6.36) 
                                                      st 
                                                     1 dose whole-cell (n=16,800)529.8 (2.0)1 
                                                 5 pertussis dosesNorthern1990-2001;1 Jan 
California,aP only (n=31,676)249786.1 (133.8)8.57 (p<0.0001)[8-20 years of2006-15 
    3≥1 wP (n=13,084)1291.7 (15.6)1age as of 15Nov 2011US (130) 
                                                 6 pertussis dosesMay 2010], 
                                                     aP only (n=35,495)134377.5 (64.3)3.55 (p<0.0001)(4-21 years) 
                                                     ≥1 wP (n=14,106)15106.3 (18.1)1 
Case-control study 
                                                                                                                                                   Odds Ratio (95% CI)LocationBirth cohortVaccination course of comparative groupsStudy 
                                                                                                                           Compared with PCR-negativeCompared with health care(age duringperiod 
                                                                                                                           controlssystem matched controlsstudy period) 
                1994-19994 pertussis doses <2 years of ageNorthernJan 2010- 
                              4California,aP only5.63 (2.55-12.46)6.27 (2.97-13.21)(10-17 years)Dec 2011 
    3Mixed wP and aP3.77 (1.57-9.07)3.12 (1.35-7.20)US (131) 
                                                     wP only11 
                                                 4 pertussis doses <2 years of age without Tdap 
                                                     aP only for 1st 4 doses9.92 (1.31-75.31)16.28 (2.26-117.49) 
                                                                    st 
                                                     wP only for 1 4 doses11 
                                                 4 pertussis doses <2 years of age with Tdap 
                                                     aP only for 1st 4 doses4.85 (1.92-12.21)4.74 (1.99-11.32) 
                                                                    st 
                                                     wP only for 1 4 doses11 
  aP: acellular pertussis vaccine; wP: whole-cell pertussis vaccine; DTaP: Diphtheria and tetanus toxoid, acellular pertussis vaccine; DTwP: Diphtheria and tetnus toxoid, whole-cell pertussis 
  vaccine; DTaP: Diphtheria and tetanus toxoid, acellular pertussis vaccine 
  1 
    Vaccination schedule for this birth cohort: Primary course - 2, 4, 6 months (aP replaced wP in 1999); booster doses - 18 months, 5 years (aP replaced wP in 1997); Tdap booster - 15 years 
  (introduced in 2004) (5). 
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2 
3   Study period was 1999-2011, only the epidemic period of 2009-2011 presented above   Vaccination schedule: Primary course - 2, 4, 6 months (aP replaced wP in 1997); booster doses - 18 months, 4-5 years (aP replaced wP in 1992) (40); Tdap booster - 11 years (introduced in 
2005) (202). 
4 
  The study included 138 PCR-positive cases, 899 PCR-negative controls, and 54,339 health care system matched controls. 
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Notification rates for all children were low during the non-epidemic period, when they were aged 
<11 years, and increased more than 20-fold during the epidemic period, during which period they 
were 10-13 years of age. Despite changes in diagnostic tests during these periods, when compared 
to recipients of the purely DTwP primary-course, children primed only with DTaP were twice as 
likely to be identified as cases during the non-epidemic period (relative risk (RR) 2.53; 95% CI 
1.06-6.07) and three times more likely during the epidemic period (RR 3.29; 95% CI 2.44-4.46) 
(123). Among mixed primary-course recipients, those whose first dose was DTwP had an 
intermediate risk of pertussis notification (RR 1.78; 95% CI 1.20-2.63) compared to children 
primed only with DTwP or DTaP, whereas those whose initial dose was DTaP had the highest risk 
of pertussis (RR 3.61; 95% CI 1.79-6.67) (123). Sensitivity analysis restricting the cohort to 
children who had received at ≥2 DTaP boosters gave similar estimates, supporting greater 
effectiveness of wP priming (data not shown) (211). 
To investigate whether the order in which DTwP doses were received was a factor independent of 
the number of DTwP doses in a mixed primary course, recipients were further categorised by 1 only 
or ≥2 DTwP vaccines received in the first year of life and the nature of the first vaccine (DTaP or 
DTwP). Among children who received only 1 dose of DTwP, those whose initial dose was DTaP 
had a relative risk of 1.37 (95% CI: 0.45-3.53) for acquiring pertussis compared to whose first dose 
was DTwP. Among children receiving ≥2 DTwP doses, those whose first dose was DTaP had a 
relative risk of 2.83 (95% CI: 0.93-7.17) (123). Whilst not statistically significant the results 
suggest that the type of vaccine received first may have an independent influence on long-term 
protection. 
Liko and colleagues undertook a similar but larger cohort study in Oregon, of >195,000 children 
vaccinated during the transition from wP- to aP-priming (129). Using statewide surveillance and 
immunisation data for children born 1997-1999, they compared the incidence of reported pertussis 
between April 1997 and July 2012 among children who received aP vaccine as their first dose with 
those who received wP vaccine as the first dose. Consistent with the Australian findings, they found 
children primed with aP had the highest rate of pertussis (129) (Table 6). Likewise pertussis rates 
were significantly lower among children whose initial dose was DTwP, regardless of whether they 
completed their vaccination course or had received a Tdap booster (129). 
Also similar to the Queensland findings, Liko et al found the risk of pertussis in this cohort 
diverged according to vaccination history at 10 years of age. Among children receiving ≥5 pertussis 
vaccinations starting in the first year of life, the incidence of pertussis ≥10 years of age among 
children who began with DTaP was 114.5 per 100,000 compared to 45.0 per 100,000 for those 
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starting with DTwP (RR 2.55; 95% CI 1.34-4.84) (129). Among the subset of children who had 
received Tdap after turning 10 years old, the incidence was lower (75.5 and 29.8 per 100,000 for 
children beginning with DTaP and DTwP respectively), but the relative risk remained similar (RR 
2.54; 95% CI 1.02-6.36) (129). This suggests that although Tdap boosting reduces the risk of 
pertussis, there is a persistent advantage from DTwP priming with respect to response to subsequent 
aP boosters. 
In order to assess whether pertussis risk among 10-17 year olds during a 2010-2011 outbreak was 
differentially associated with type of pertussis vaccine received, Klein et al undertook a case control 
study among children born between 1994 and 1999 who received 4 pertussis vaccinations before 
turning 2 years old in a managed care setting in Northern California (131). PCR positive cases were 
compared with two control groups: PCR negative children and age-matched controls sampled from 
the same healthcare organization. The risk of pertussis was assessed according to the nature of the 
first 4 vaccines received – DTaP-only, DTwP-only or a combination of DTaP and DTwP. In the 
PCR-negative control group analysis, the adjusted risk of pertussis was significantly greater among 
DTaP recipients (OR 5.63 95% CI 2.55-12.46) and DTaP/DTwP mixed recipients (OR 3.77; 95% 
CI 1.57-9.07) compared to DTwP recipients. Results of the age and healthcare facility-matched 
controls yielded similar results (DTaP vs DTwP OR 6.27; 95% CI 2.97-13.21; and DTaP/DTwP vs 
DTwP OR 3.12; 95% CI 1.35-7.20), confirming that the association was not explained by 
confounding due to age. The authors also found that with each DTaP dose received in place of a 
DTwP dose before 24 months of age, individuals on average had a 40% increased risk of pertussis 
compared to recipients of 4 DTwP doses (131). 
Among those who had not received Tdap, the odds of pertussis among DTaP recipients compared to 
DTwP recipients was almost ten times greater (OR 9.92; 95% CI: 1.31-75.31), with the relative 
benefit of DTwP persisting even among those who were subsequently boosted with Tdap (OR 4.85; 
95% CI: 1.91-12.21) (131). 
When considering the apparent protection afforded by mixed vaccine schedules, it is likely that the 
most received wP for their first dose given that these children were born as wP was being replaced 
by aP. Among mixed course recipients, the increased protection associated with increasing numbers 
of doses of wP vaccine might only occur among those who began with wP as their first dose. Whilst 
interpretation is limited by small numbers, the Queensland results appeared to indicate there was no 
advantage in receiving more than one dose of wP vaccine if the initial vaccine was aP (123). 
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A third large retrospective cohort study comparing the protection provided by a prior pertussis 
vaccination including ≥1 wP, with purely aP vaccination, was undertaken by Witt and colleagues 
among members of the same integrated healthcare organisation in Northern California as their 
previous study (130). The cohort included almost 190,000 people who were 8-20 years old during 
the 2010 Californian epidemic and had received 5- or 6-doses of pertussis vaccine. Subjects were 
born 1991-2001, and therefore included people who had received wP and/or aP vaccines (130). 
Among patients who had 5 doses of pertussis vaccine the risk of pertussis among purely aP 
recipients was over 8 times higher (RR 8.57; p<0.0001) than those who received ≥1 dose of wP 
vaccine. The difference between risk was partially attenuated by receipt of a 6th dose of aP, however 
the risk of pertussis was still over three times higher among recipients of 6-doses of aP vaccine (RR 
3.55; p<0.0001) compared to those receiving ≥1 wP vaccine among their 6 doses (130). Witt el al, 
described these results as confirming profoundly enhanced protection and long-lasting from 
pertussis among people who had ever received a dose of wP vaccine compared to people that had 
only received aP (130). However, it is not clear from that study whether benefit was confined to 
only those receiving the first dose as a wP vaccine. 
Whilst in the Australian and US, wP-priming appears to have provided higher protection than aP 
against pertussis, this may not be universally the case. In countries that previously used poorly 
efficacious wP vaccine, it is not known whether wP-priming bestows greater or less protection than 
aP. 
The future for pertussis control 
Several strategies to control the resurgence of pertussis have been raised relating to changes in the 
schedule of existing vaccines, improvements to existing vaccines, and the development of 
completely new pertussis vaccines (144). 
Changes to the pertussis vaccination schedule 
Potential strategies to control pertussis with the existing vaccines include re-introduction of wP 
vaccine, maternal pertussis vaccination, neonatal vaccination, vaccination of newborn contacts 
(cocoon strategy), and more frequent boosters with aP vaccine (144). 
Re-introduction of the formerly used wP into countries which have transitioned to using aP vaccines 
is unlikely (144), though consideration for using wP for the first dose, given that it appears to prime 
for better immune responses to subsequent doses of aP has been raised (147). It is unknown whether 
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the reactogenicity of wP vaccines would be acceptable today. Re-introduction of wP would risk 
increasing pertussis incidence as a result of lower vaccine uptake. The recent Cochrane review 
found non-completion of the primary series due to adverse events is significantly lower for aP than 
wP vaccines (120). In such a circumstance, declining vaccine coverage may outweigh the advantage 
of increased effectiveness of wP. Importantly, while aP vaccines may be less effective than high 
efficacy wP vaccines, they are still highly effective against disease in the short-term, including 
infancy, when children are most vulnerable. 
Maternal vaccination has been recommended in the US and elsewhere (5, 212, 213) to provide 
protection to the newborn infant. Vaccination of other close contacts, as well as mothers of newborn 
infants, described as the cocoon strategy has also been recommended, although this may not be cost 
effective in some contexts (214). Neonatal vaccination is another potential way to provide 
protection against infants, though further research may be needed to determine that this would not 
misdirect the immune system (215). 
Greater frequency of aP boosters is another strategy, though the optimal timing of boosters is 
uncertain (120), and may well differ according to the initial vaccines received in childhood, with 
those who have received purely aP vaccine possibly requiring more frequent boosting to maintain 
protection. 
Improvements to existing vaccines and development of completely new vaccines 
The development of wP vaccines with detoxified lipopolysaccharide, which considerably 
contributed to the reactogenicity of wP vaccines, has been suggested (141). A whole-cell vaccine 
with reduced endotoxicity due to chemical extraction of lipo-oligosaccharide from the outer 
membrane, has demonstrated, in a mouse model, greatly reduced endotoxin related toxicity without 
loss of potency and with similar Th1/Th2 responses compared to a currently used DTwP (216), 
potentially providing a future alternative to currently available wP or aP vaccines. 
Suggested changes to aP vaccines to increase their effectiveness whilst retaining their low 
reactogenicity include the inclusion of additional antigens and the use of a new adjuvant that may 
drive a Th1 response (144). Genetic inactivation of PT, or use of a milder chemical in the 
inactivation of PT has been suggested, as genetically inactivated PT has been shown to provide 
higher antibody levels than formalin-inactivated products (144, 217). 
A live attenuated nasal pertussis vaccine, BPZE1, has undergone a Phase 1 trial in adult humans, 
and was found to be safe, able to transiently colonise the nasopharynx, and able to induce immune 
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responses in colonised individuals, allowing the vaccine to undergo further clinical development 
(218). However, reformulated vaccines are unlikely to become available in the immediate future, 
with challenges including expensive, large and prolonged trials to provide safety and efficacy data, 
in order to meet regulatory requirements (144). 
Research has an important role in improving pertussis control. As identified by Poland (160), areas 
where further knowledge is required include understanding more comprehensively the determinants 
of long-term protective immunity, elucidating whether and to what extent newly emerging pertussis 
strains compromise current aP vaccine effectiveness, research on the long-term effects of Th1 
versus Th2 immune response skewing in infants by different pertussis vaccines, research to guide 
recommendations on the frequency of adolescent/adult pertussis boosters, and research to support 
the development of pertussis vaccines providing high and long-lasting protection with low 
reactogenicity. Until such vaccines are available, the best way to control pertussis is to ensure high 
coverage with the existing vaccines. 
Low-middle income countries using wP 
In light of the recent evidence demonstrating aP to be less enduringly effective than high-efficacy 
wP, the transition from wP to aP in countries currently using wP may stop (144). Based on the 
experience of wP vaccines in India, and due to the recent evidence of superior priming with wP, the 
Indian Academy of Pediatrics has recommended staying with the current immunisation policy of 
using only wP in the national Universal Immunisation Program (219). Following review of the 
evidence on pertussis, the Strategic Advisory Group of Experts (SAGE) on Immunization, in their 
meeting in April 2014, recommended countries currently using wP vaccines should continue using 
wP vaccines for early infant vaccination (220). 
Currently, the pentavalent DTwP, hepatitis B and Haemophilus influenzae type b (DTwP- 
HBV/Hib) vaccine is the standard combination vaccine used in low-income countries (219) with 
separate administration of oral polio vaccine (OPV) (155). It is predicted that inactivated polio 
vaccine (IPV) would replace the live OPV following the last cases of polio, and that IPV will be 
used for several years to ensure polio eradication (155). Whilst an IPV-containing hexavalent 
vaccine (included with DTwP-Hep B/Hib) would be ideal in such a circumstance, enabling a 
simplified routine immunisation schedule, and reduced delivery costs, the only currently available 
hexavalent IPV-containing vaccine includes aP (155). Furthermore, an IPV-containing combination 
vaccine with wP, which would be affordable for low and middle income countries and removes the 
concern about the long-term effectiveness of aP, is not expected before 2020 (10). Among the 
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technical and logistical challenges of producing a DTwP-HBV-IPV/Hib vaccine is the use of 
thiomersal in the bulk wP process, used by many manufacturers to kill the pertussis bacteria and 
inactivate pertussis toxin. However, thiomersal also causes loss of antigenicity of IPV (155). 
Uncertainty about how many years an IPV containing hexavalent vaccine would be required for, 
may also be a barrier to investing in this vaccine (155). Potential alternatives to a hexavalent 
vaccine in low income countries may be separate IPV and DTwP –HBV/Hib vaccines provided at 
the same time, described as the “5 plus 1” strategy (155). The advantage of this strategy is the 
availability of the existing pentavalent vaccines and that both the pentavalent and the IPV vaccines 
are able to be supplied in multi-dose form using different (and otherwise incompatible) 
preservatives (155). 
Expert commentary 
Despite well-established vaccination programs and high vaccination coverage in many countries, 
pertussis still causes disease globally. In several developed countries, pertussis incidence has 
increased, with the replacement of wP with aP likely to be one factor contributing to this 
resurgence. Cohorts solely vaccinated with aP appear to be most vulnerable, compared to those who 
received schedules using wP exclusively or mixed wP/aP schedules. The long-lasting influence 
initial vaccines have on future protection from pertussis suggests that the epidemiology of pertussis 
will evolve as cohorts of aP-only vaccinated people become older. There are several possibilities for 
new pertussis vaccines, but until more effective and low reactogenic become available, other 
strategies are required to control pertussis in countries where pertussis is resurgent and aP vaccine is 
in use. Whilst durability of effectiveness appears less than with wP, aP vaccines still provide 
substantial short term protection against severe disease, particularly as a primary course. In order to 
protect those most vulnerable from disease, as well as to reduce the burden of illness throughout the 
population, timely and high vaccine coverage is required, with appropriately timed and targeted 
boosters. Further research is needed to determine the optimal timing of booster doses in different 
contexts. The timing of boosters may need to change with the vaccination history of the population; 
for example, cohorts vaccinated solely with aP may require more frequent boosting than wP primed 
cohorts. Primary focus should also remain on protecting the most vulnerable, infants under one year 
of age, particularly those too young to be vaccinated. Thus strategies such as maternal vaccination, 
and timely vaccination of infants have an important role in pertussis control programs. 
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Five-year review 
Both aP and wP vaccines are likely to remain in the places they are currently in use. As new 
formulations of pertussis vaccines are unlikely to be available within the next 10 years, maintaining 
high coverage with existing vaccines will be vital for disease control. As has occurred in several 
countries recently, targeted booster doses (such as for women in their third trimester), and more 
frequent boosters of aP, particularly in countries that only use aP, may be recommended. National 
recommendations for boosters may be made according to the local epidemiology. The recent 
changes in pertussis epidemiology in the US and Australia, may occur in other developed countries 
which have changed from an effective wP vaccine to aP vaccines at a later time than the US and 
Australia. Pertussis epidemiology in aP-using countries such as the US and Australia is likely to 
evolve with the increasing age of the aP only vaccinated cohorts, who may require more frequent 
boosters to maintain protection than wP primed cohorts. 
Key issues 
• 
• 
Whilst variability has been demonstrated among both wP and aP vaccines, highly efficacious 
wP vaccines provide longer-term protection than aP vaccines 
In the US and Australia priming with wP appears to be more effective than priming with aP, 
both prior to and following aP booster vaccinations. aP boosters do not neutralise the advantage 
provided by wP priming. 
• The differential effectiveness of not only priming in early childhood, but of aP boosters later in 
life by the type of vaccine used for priming, has implications for future patterns of age-specific 
pertussis incidence and the appropriate timing of booster vaccinations to provide protection. 
• The nature of the first pertussis vaccine received appears to be particularly important in 
determining long-term protection, with a highly effective wP as an initial vaccine providing 
superior protection than a course commencing with aP. 
• The immunobiology underlying the differential effectiveness between aP and wP vaccines is 
incompletely understood. However, wP, more similar to natural infection stimulates a mixed 
Th1/Th2 response, whereas aP priming stimulates a predominantly Th2 response. 
• The importance of the initial dose of vaccine on longer-term protection may be related to linked 
epitope suppression, where the initial exposure locks in the immune response to certain epitopes 
and inhibits response to other linked epitopes on subsequent exposures. 
• Ecological and other observational study evidence on the differential effectiveness of wP and aP 
primed children indicate the replacement of wP by aP in the US and Australian contexts, 
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contributed to recent pertussis epidemiology, particularly the high incidence of disease of fully 
aP primed pre-adolescents and adolescents. 
• Whilst aP vaccines wane more rapidly than wP vaccines, both aP and wP provide a high level of 
protection against disease shortly after priming, thereby providing very good protection to 
vaccinated infants. 
• Evidence from a baboon model found aP vaccine did not prevent asymptomatic infection in aP 
vaccinated baboons or transmission from aP vaccinated baboons to unvaccinated baboons. In 
contrast, wP vaccinated baboons cleared infection more rapidly. 
• 
• 
New pertussis vaccines or new formulations of current vaccines are unlikely to be available 
within the next 10 years. 
Maintaining high vaccination coverage and appropriately timed and targeted boosters remains 
central to pertussis control. 
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Chapter 4: Varicella vaccine effectiveness and impact 
4.1 Impact and effectiveness of varicella vaccine on varicella in 
Queensland manuscript 
This section is presented as a submitted paper: 
Sheridan SL, Quinn HE, Hull BP, Ware RS, Grimwood K, Lambert SB. Impact and effectiveness of 
childhood varicella vaccine program in Queensland, Australia. 
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Abstract 
Background: In November 2005, Australia introduced a publicly funded single dose of varicella 
vaccine for children aged 18 months. We describe the impact of this program on varicella 
hospitalisations in Queensland and provide the first assessment of single-dose varicella vaccine 
effectiveness in Australia since the program commenced. 
Methods: Age-standardised varicella hospitalisation rates were calculated for 2000 to 2014 and 
pre- and post-public funding period rates compared. Case-control studies were conducted to 
investigate the association between vaccine receipt and both varicella hospitalisations and 
emergency department presentations. Cases were matched to controls from a population-based 
register by date of birth and state of residence. Vaccine effectiveness was calculated as (1 – odds 
ratio) X 100%. 
Results: Compared to the pre-funded period (2000-2003), age-standardised varicella hospitalisation 
rates declined by more than 70% in 2011-2014 with varicella principal diagnosis rates declining 
from 5.7 to 1.6 per 100,000 population per year. Varicella vaccine effectiveness at preventing 
hospitalisation with a principal diagnosis of varicella among children aged 19 months to 6 years 
was 81.9% (95% confidence interval: 61.8-91.4), while for emergency department presentations 
among children aged 19 months to 8 years it was 57.9% (95% confidence interval: 48.5-65.5). 
Conclusions: In Australia, the single-dose varicella vaccination program has substantially reduced 
varicella morbidity. The single-dose varicella vaccine schedule is moderately-to-highly effective 
against hospitalisation, but appears less effective against emergency department presentations. 
Keywords 
varicella, varicella vaccine, vaccine-effectiveness 
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Introduction 
Australia began public funding of varicella vaccine (VV), as part of the National Immunisation 
Program in November 2005, with the inclusion of a single-dose at 18 months of age (221). The 
program also included a time-limited, catch-up dose for 10-13 year olds in Queensland who were 
unimmunised through either varicella vaccination or prior disease (221). Previous ecological studies 
have described the impact of the publicly funded varicella program in Australia, with significant 
reductions in national varicella hospitalisations in both vaccine age-eligible children and vaccine 
age-ineligible adults (58), and on national neonatal varicella incidence (56), suggesting direct and 
indirect protection. To date, there have been no vaccine-effectiveness (VE) estimates of VV in 
Australia during the public funding era. 
The monovalent VVs, Varivax (Merck & Co., Inc, Whitehouse Station, NJ, USA) and Varilrix 
(GlaxoSmithKline, Rixensart, Belgium), became available in Australia in 2000. In late 2003 a 
single-dose of VV was recommended, but not publicly funded, at 18 months of age (29). With the 
commencement of public funding, Queensland initially used both Varivax and Varilirix between 
November 2005 and June 2006. Subsequently, only Varilrix was used in the public program until 
July 2013, when the quadrivalent measles, mumps, rubella, and varicella vaccine (MMRV), Priorix- 
Tetra (GlaxoSmithKline, Rixensart, Belgium), replaced VV at age 18 months (5). In Queensland, 
the adolescent catch-up dose was undertaken through school-based immunisation of 13 year olds 
from 2007 (222). 
The aim of this study is to describe vaccination uptake and the impact of the single-dose program 
on varicella hospitalisations in Queensland between January 2000 and December 2014 and, for the 
first time, investigate the VE of a single dose of VV against hospitalisation and emergency 
department (ED) presentation in Queensland among children aged from 
19 months to 8 years of age. 
Methods 
We analysed unlinked hospitalisation data (2000-2014) and then conducted a matched case-control 
study using data-linkage to identify the vaccination status of cases. The case-control study included 
children aged up to 8 years who were eligible for publicly funded VV between January 2006 and 
June 2013 in Queensland, Australia. 
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Data sources 
VV coverage for children aged 24 months in Queensland between 2007 and 2014 was obtained 
from published immunisation coverage reports (22-26) and other published literature (58) using 
data from the Australian Childhood Immunisation Register (ACIR). The ACIR is a near- complete 
population register with 99% of children included on the register by age 12 months regardless of 
vaccination status (102). ACIR data were used to identify controls and their vaccination status in 
the case-control study. 
Vaccination coverage data for eligible adolescents from school-based VV programs between 2007 
and 2014 were provided by the Queensland Health Department. The coverage reported through the 
school-based program is likely to underestimate the true coverage achieved as adolescents were also 
able to receive the catch-up VV from their family doctor (223). Unfortunately, we do not know the 
extent to which adolescents receive VV from a family doctor, and therefore the degree to which VV 
coverage among adolescents is underestimated. 
Queensland public and private hospitalisation episodes coded for varicella or its complications 
(International Statistical Classification of Diseases, 10th Revision, Australian Modification [ICD-10- 
AM] codes B01.0-B01.9) in any diagnostic field between January 2000 and December 2014, were 
retrieved from the Queensland Hospital Admitted Patient Database (224). Mid-year Queensland 
population estimates between 2000 and 2014, were obtained from the Australian Bureau of Statistics 
(225) in order to calculate hospitalisation rates. 
Paediatric ED presentations with the ICD-10-AM code B01.9 (varicella without complication) were 
obtained from the Emergency Department Information System (EDIS). EDIS operates in 25 
Queensland public hospitals, which in 2010/2011 were responsible for 80% of all non-admitted (ED 
and outpatient) hospital presentations for any cause, in Queensland public hospitals. 
Vaccination records of hospitalised and ED cases were retrieved from the Queensland vaccination 
register (Vaccination Information and Vaccination Administration System; VIVAS). VIVAS is not 
a population-based vaccination register and only records vaccination encounters, meaning it was not 
inclusive of wholly unvaccinated children. 
Analysis 
Hospitalisation patterns 
Average annual age-specific varicella hospitalisation rates, directly age standardised to the 2014 
population, and 95% confidence intervals (CIs) were calculated for time-periods corresponding to 
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when VV was licensed, but not recommended (2000-2003); when VV was recommended, but not 
publicly funded (2004-2005); and two periods when VV was publicly funded (early: 2007-2010; 
late: 2011-2014). To allow time for initial program implementation, the first year of the funded 
program was not included in the analysis. 
Crude and age-specific incidence rates were calculated for hospitalisations where varicella was 
recorded as the principal diagnosis or in any diagnostic field using Poisson regression. Directly age- 
standardised rates were calculated using the 2014 population. Incidence rate ratios (IRRs) and 95% 
CIs were calculated, comparing age-specific and age-standardised rates in the vaccine-funded 
period to those in the vaccine-licensed period. 
Vaccine effectiveness 
We calculated the VE of VV in preventing hospitalisation with varicella in the principal diagnostic 
and any diagnostic field, and in preventing ED presentation for varicella in Queensland using a 
matched case-control method. This method was used previously to assess VE of pertussis vaccine in 
Australia (126). 
We included cases born after 01 July 2004, and therefore eligible for funded VV, and who were at 
least 19 months old at hospitalisation or ED presentation. Only children attending hospital between 
January 2006 and June 2013 with their first varicella hospitalisation or ED presentation during the 
study period were included. 
To determine the vaccination status of cases, the Queensland Health Data Linkage Unit linked 
vaccination records from VIVAS to ED presentation and hospitalisation data using LinkageWiz 
probabilistic data matching software, v5.3 (LinkageWiz Inc, Adelaide, South Australia). Weighting 
scores were assigned to matching variables, including surname, first name, date of birth, and 
address. Middle- and lower-weighted pairs were individually assessed, and higher-weighted pairs 
checked for false matching related to multiple births. 
Twenty controls and their VV records from the ACIR were matched to each case by date of birth 
(either the same day, or one day on either side of the case’s date of birth), sex, and residential 
jurisdiction. As cases were de-identified, we could not exclude the possibility of a case also being 
selected as one of their own controls. 
Vaccination was considered valid if it was received at least 42-days before illness onset among 
cases and 14-days before the case’s disease onset for controls. Cases were excluded if their 
symptoms began within 42-days of being vaccinated to ensure VV-associated rashes were not 
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misclassified as varicella cases in our study. 
We used conditional logistic regression to estimate the odds ratio (OR) for VE in preventing 
hospitalisation and ED presentations among children aged 19 months to 6 years and 
19 months to 8 years, respectively. VE in preventing hospitalisation was calculated for children 
aged to 6 years as there were no vaccine eligible hospitalised cases older than this. We also 
undertook analysis stratified by the age-groups: 19 months-2 years, 3-4 years, and 
5-6 years for hospitalisation; and 19 months-2 years, 3-4 years, and 5-8 years for ED presentation. 
VE estimates and 95% CIs were based on the OR using the formula: 
VE = (1 – OR) x 100%. All statistical analyses were undertaken using Stata v13 (StataCorp, 
College Station, TX). 
The Queensland Health Central Health and Medical Research Ethics Committee and the University 
of Queensland Human Research Ethics Committee approved this study. 
Results 
Vaccine coverage 
Before VV was recommended in late 2003, national coverage of children at age 24 months was 
9.7%, reaching 20.9% by the end of the pre-funding period in 2005 (58). VV coverage among 
children aged 24 months in Queensland increased steadily from 81.8% in 2007 to 87.1% in 2012 for 
monovalent VV, and to 91.4% for MMRV in 2014 (22-26). The uptake of the school-based 
immunisation program targeting 13 year olds also increased from 32% in 2007 to 52% in 2014 
(223). 
Vaccine impact 
Annual numbers of all-age hospitalisations where varicella was coded in the principal or in any 
diagnostic field declined annually between 2006 and 2012, with a small increase in admissions in 
2013 and 2014 (Figure 4.1.1). The average age of those admitted with a principal diagnosis of 
varicella increased over time from <15 years between 2000 and 2003 (2000: 7 years, 2001: 14 
years, 2002: 6 years, 2003: 12 years), to 34 years in 2014. Coinciding with the overall reduction in 
varicella hospitalisations since 2007, the seasonal patterns of winter-spring varicella hospitalisation 
peaks have also become less pronounced (Figure 4.1.2). 
Between 2000 and 2012, annual age-standardised rates for principal and any diagnosis varicella 
hospitalisations showed a pattern of general decline, with a more consistent pattern of decline 
between 2007 and 2012 (Figure 4.1.3). Following 2012, the annual age-standardised hospitalisation 
rates slightly increased and remained steady in 2014. 
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Figure 4.1.1: Principal and non-principal diagnosis varicella hospitalisations, and median age for principal diagnosis varicella admissions, 
Queensland, 2000 – 2014 
97 
Figure 4.1.2: Principal diagnosis varicella hospitalisations, Queensland, 2000 to 2014 
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Figure 4.1.3: Annual age-standardiseda rates for principal and any diagnosis varicella hospitalisations, Queensland, 2000 – 2014 
a 
standardised to 2014 
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Compared to the VV licensed period of 2000-2003, varicella hospitalisation rates were substantially 
lower during the funded VV periods of 2007-2010 and 2011-2014 (Table 4.1.1). Average annual 
hospitalisation rates further declined in all age-groups in 2011-2014, compared to 2007-2010, 
though the difference did not always reach significance. 
Across all vaccine time-periods, there remained a general pattern where the highest varicella 
hospitalisation rates occurred among infants aged <1 year, followed by 1-4 year olds. Despite being 
too young to be vaccinated, the impact of the vaccination program was greatest in infants, with 
average annual hospitalisation rates in this age-group progressively decreasing between the VV 
licensed period and the 2011-2014 VV funded period from 50 to 11 per 100,000 per year. 
Between the VV licensed and the 2011-2014 funded periods, average annual varicella 
hospitalisations significantly decreased in all those aged <40 years. There were no significant 
changes in varicella hospitalisation rates in people aged >40 years. Compared to the VV licenced 
period, age-standardised varicella hospitalisation rates declined >70% in the 2011-2014 VV funded 
period with principal diagnosis rates declining from 5.7 to 1.6 per 100,000 population per year 
(Table 1). 
Vaccine effectiveness 
Overall VE for VV preventing hospitalisations with a principal diagnosis of varicella among 
children aged 19 months to 6 years was 81.9% (95% CI: 61.8-91.4). VE against hospitalisation 
where varicella was recorded in any diagnostic field was similar (Table 4.1.2). When stratified by 
age-group, point VE estimates were progressively lower with increasing age, and therefore, time 
from the recommended immunisation time point, although these differences were not statistically 
significant. 
VE against ED presentation among children aged 19 months to 8 years was 57.9% (95% CI: 48.5- 
65.5) (Table 4.1.2). Unlike VE against hospitalisation, point VE estimates were progressively 
higher with increasing age, although the differences were again not statistically significant. 
Discussion 
With high vaccination coverage, the single-dose VV program has reduced substantially the burden 
of severe varicella illness in all age groups <40 years in Queensland, due to both direct and indirect 
protective effects. This finding is consistent with national ecological findings (58). The median age 
of people hospitalised with varicella did increase, however, reassuringly there was no increase in 
the incidence of varicella hospitalisations in those aged >40 years. Varicella hospitalisations have 
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Table 4.1.1: Varicella hospitalisations between 2000 and 2014, by vaccine policy period, in Queensland Australia 
Age (years) 
Vaccine licensed period 
(2000-2003) 
Vaccine recommended period 
(2004-2005) 
Varicella hospitalisation 
  Vaccine funded period 
  (early: 2007-2010) 
Vaccine funded period 
(late: 2011-2014) 
Average annual 
hospitalisations 
Principal varicella diagnosis 
<124 
1-456.8 
5-925.8 
10-1919.8 
20-2935.3 
30-3929 
40+20 
All ages210.5 
Age- 
standardised to 
2014 
Any varicella diagnosis 
<130.7 
1-486 
5-939.3 
10-1928.3 
20-2952 
30-3939.5 
40+34.5 
All ages310.3 
Age- 
standardised to 
2014 
       a 
         Confidence interval (CI) 
Average annual 
rate 
(95% CI)a 
49.8 (40.3-60.8) 
28.8 (25.2-32.8) 
9.9 (8.1-12.0) 
3.8 (3.0-4.7) 
7.0 (5.9-8.2) 
5.4 (4.4-6.4) 
1.3 (1.0-1.6) 
5.8 (5.4-6.1) 
5.7 (5.3-6.1) 
Average annual 
hospitalisations 
Average annual 
rate 
(95% CI) 
32.3 (22.3-45.4) 
18.6 (14.7-23.3) 
5.8 (4.0-8.3) 
3.0 (2.1-4.2) 
4.7 (3.5-6.2) 
5.9 (4.6-7.5) 
1.3 (1.0-1.8) 
4.4 (3.9-4.8) 
4.3 (3.8-4.8) 
Average annual 
hospitalisations 
Average annual 
rate 
(95% CI) 
16.5 (11.8-22.4) 
6.1 (4.6-7.9) 
5.2 (3.9-6.7) 
1.9 (1.4-2.6) 
2.9 (2.2-3.6) 
2.7 (2.1-3.5) 
1.4 (1.2-1.7) 
2.6 (2.4-2.8) 
2.6 (2.3-2.8) 
Average annual 
hospitalisations 
Average annual 
rate 
(95% CI) 
10.8 (7.1-15.8) 
3.5 (2.4-4.9) 
1.4 (0.8-2.2) 
1.8 (1.3-2.4) 
0.9 (0.6-1.4) 
2.4 (1.9-3.1) 
1.0 (0.8-1.2) 
1.6 (1.4-1.8) 
1.6 (1.4-1.8) 
2011-2014 
vaccine funded 
period compared 
to vaccine 
licensed period 
Rate ratio 
(95% CI) 2011- 
2014 
0.22 (0.14-0.34) 
0.12 (0.08-0.17) 
0.14 (0.08-0.24) 
0.47 (0.32-0.69) 
0.14 (0.08-0.21) 
0.45 (0.33-0.62) 
0.78 (0.57-1.07) 
0.27 (0.24-0.31) 
0.28 (0.24-0.32) 
16.5 
38 
15.5 
16.5 
25 
33.5 
23 
168 
- 
10 
14 
14.5 
11.3 
17.5 
16.5 
27.3 
111 
- 
6.8 
8.8 
4.3 
10.8 
6.3 
15.3 
21 
73 
- 
63.8 (53.0-76.1) 
43.6 (39.2-48.5) 
15.1 (12.8-17.6) 
5.4 (4.5-6.5) 
10.3 (8.9-11.8) 
7.3 (6.2-8.5) 
2.2 (1.9-2.6) 
8.6 (8.1-9.1) 
8.4 (7.9-8.9) 
24 
58.5 
25.5 
27 
38.5 
42.5 
40 
256 
- 
47.1 (34.7-62.4) 
28.6 (23.7-34.3) 
9.6 (7.1-12.6) 
4.9 (3.7-6.4) 
7.2 (5.7-9.0) 
7.5 (6.0-9.3) 
2.3 (1.9-2.9) 
6.6 (6.0-7.2) 
6.6 (6.0-7.1) 
13 
21.5 
20.8 
14 
25.5 
24 
58.3 
177 
- 
21.4 (16.0-28.1) 
9.3 (7.5-11.5) 
7.4 (5.9-9.2) 
2.4 (1.8-3.1) 
4.2 (3.4-5.1) 
4.0 (3.2-4.8) 
3.1 (2.7-3.5) 
4.2 (3.9-4.5) 
4.1 (3.8-4.4) 
8.8 
15 
7.5 
13.3 
8.5 
19.3 
37.8 
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- 
14.0 (9.8-19.5) 
6.0 (4.6-7.7) 
2.5 (1.7-3.5) 
2.2 (1.6-2.9) 
1.3 (0.9-1.8) 
3.1 (2.4-3.8) 
1.8 (1.5-2.1) 
2.4 (2.2-2.6) 
2.4 (2.2-2.6) 
0.22 (0.15-0.32) 
0.14 (0.10-0.18) 
0.16 (0.11-0.24) 
0.40 (0.29-0.56) 
0.12 (0.08-0.18) 
0.42 (0.31-0.55) 
0.81 (0.64-1.03) 
0.28 (0.25-0.31) 
0.28 (0.25-0.32) 
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Table 4.1.2: Varicella vaccine effectiveness estimates against hospitalisation and emergency department presentation in Queensland, 
Australia 
Age at 
hospitalisation/ 
ED presentation 
Principal diagnosis hospitalisation 
Number ofNumber of 
CasesControls 
(%(% 
vaccinated)vaccinated) 
21 (23.8)420 (71.9) 
10 (60.0)200 (84.0) 
4 (75.0)80 (77.5) 
35 (40.0) 
a 
Estimated VE 
(95% CI)b 
a Any diagnosis hospitalisation Number ofNumber of 
CasesControls 
(% vaccinated)(% vaccinated) 
35 (34.3) 
17 (52.9) 
8 (62.5) 
60 (43.3) 
700 (74.1) 
340 (82.9) 
160 (84.4) 
1200 (78.0) 
Estimated VE 
(95% CI) 
83.9 (66.0-92.3) 
78.1 (38.2-92.2) 
69.1 (-37.3-93.1) 
80.7% (66.4-88.9) 
Emergency department presentation 
Number ofNumber ofEstimated VE 
CasesControls(95% CI) 
(% vaccinated)(% vaccinated) 
265 (67.9) 
144 (70.8) 
93 (66.7) 
5292 (80.1) 
2880 (86.5) 
1860 (87.2) 
10032 (83.3) 
49.6% (33.5-61.8) 
61.9% (44.6-73.8) 
70.8% (54.0-81.5) 
57.9% (48.5-65.5) 
19m-2y 
3-4y 
5-6y 
5-8y 
19m-6y 
19m-8y 
89.4% (69.6-96.3) 
74.4% (-6.5-93.8) 
12.7% (-769.6-91.2) 
81.9% (61.8-91.4) 700 (76.0) 
b 
502 (68.5) 
Vaccine effectiveness (VE); Confidence interval (CI) 
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declined progressively from the initial vaccine funded period of 2007-2010 to 2011-2014 
consistent with maturation of the vaccination program and improved coverage. Continued 
monitoring of varicella outcomes will be important to identify if the burden of varicella 
disease continues to decline or remains stable at 2011-2014 levels. 
Importantly, this study also reports the first VE estimates of a single VV dose in Australia 
since commencement of the publicly funded vaccination program in 2005. The VE of 82% 
(95% CI: 62-91) in preventing hospitalisation where varicella is the principal diagnosis 
among children aged 18 months to 6 years indicates a high degree of protection provided by a  
single-dose of VV against moderate-to-severe disease. This point estimate is lower than VE 
point estimates for moderate and severe varicella reported in 19 other post-licensure studies, 
which range between 86% and 100% (47), though the 95% CI of our findings overlaps with 
the range of the other post-licensure study VE point estimates. However, comparisons 
between study findings are limited by different definitions to describe disease severity and 
variations in the age-groups of study subjects. Comparing VE against hospitalisation in 
different settings will be limited by regional variations in hospital practices, disease 
management, laboratory testing, and hospital admission policies, access to primary 
healthcare, referral patterns, healthcare-seeking behaviour, and cultural attitudes of the local 
population (226). 
Our VE point estimates of a single-dose of VV in preventing ED presentation were generally 
lower than those for hospitalisation, consistent with VV being less effective in preventing 
milder disease. Vaccinated varicella cases may be more likely to present to ED for diagnosis 
due to the atypical clinical presentation rather than due to severity of disease. Conversely, 
cases with milder varicella disease, more likely to be associated with vaccination, may be 
less likely to present to ED. We have no way of knowing if the sample of cases presenting to 
ED is representative of all cases of the same severity with regard to vaccination status. This 
may introduce a bias which limits a direct comparison of our finding of VE in preventing ED 
presentation (or seeking care at ED) with other published estimates of VV preventing 
varicella of any severity. A further limitation to our VE findings against ED presentation is 
that we had information on approximately 80% of ED presentations in Queensland. It is 
possible that the other approximately 20% of ED presentations, which were more likely to 
occur in regional and remote areas, may differ due to differences in health seeking behaviour 
and other socioeconomic characteristics, such that our VE findings against ED presentation 
may not be generalisable to all of Queensland. 
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The VE of 58% (95% CI: 49-66) in preventing ED presentation among children aged 19 
months to 8 years, was also lower than most VE point estimates reported internationally in 
preventing varicella of any severity (47). The point estimate of VE for a single-dose of VV 
preventing disease of any severity found in a varicella outbreak at an Australian childcare 
centre prior to public funding of 78% (95% CI: 15.4-94.5) (59), was also higher than our VE 
point estimates in preventing ED presentation. In a summary of post- licensure effectiveness 
studies, the median VE of a single VV dose against any varicella was 84% for Varivax and 
80% for Varilrix (47). However, VE of 44% and 20% have been reported for a single-dose of 
Varivax (227) and a single-dose of Varilrix (228), respectively, in daycare centre outbreaks. 
The pattern of decline of VE point estimates in preventing hospitalisation with increasing 
age, while not statistically significant, is consistent with waning of vaccine-acquired 
immunity reported during the single dose program in the United States (229). We are 
unsure why the VE point estimates for ED presentation showed the opposite, albeit non- 
significant, pattern of increasing with older age-groups. It may be that in our setting, 
younger children with breakthrough infection are more likely to generate an ED 
presentation, increasing the proportion of cases who are vaccinated, thereby reducing 
measured VE in younger age- groups. 
While the single VV dose program has led to substantial reductions in varicella-associated 
morbidity, varicella transmission has not been interrupted and, despite high vaccine coverage, 
varicella outbreaks in childcare centres and schools continue to occur (personal 
communication: Angela Wakefield, Advanced Epidemiologist, Communicable Diseases 
Branch, Queensland Health) as happened in the United States during their single-dose 
program (63). Due to their ongoing varicella outbreaks, a second-dose of VV was 
recommended for children in the United States (65). Since this recommendation, two-doses of 
VV have been shown to provide greater protection than one-dose (67), with varicella 
incidence, hospitalisations, and outbreaks all having declined (230, 231). Over 2.5 years the 
VE of two-doses of VV in preventing varicella was 98% compared to 86% VE of a single- 
dose, and a relative VE in two versus one-dose recipients of 95% (67), similar findings to a 
recent meta-analysis of international studies on varicella VE (232). 
A second dose of VV not only reduces risk of infection and interrupts virus transmission 
(232), it also appears to lower subsequent risk of developing zoster (67). However, the cost- 
effectiveness and incremental benefits of a second-dose needs to be considered in context 
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with funding of all drugs. In 2007, a second-dose of VV was considered and rejected by the 
Pharmaceutical Benefits Advisory Committee, the national body which advises on the public 
funding vaccines and other drugs in Australia (233). 
Recent modelling has been undertaken in Australia comparing four different varicella 
vaccination strategies, two of which involved an early childhood dose and, for differing 
lengths of time, a catch-up dose at age 12 years (234). The other two strategies involved an 
early childhood-dose and a second-dose, one at 18 months, the other at 12 years of age. The 
modelling suggested that two-doses of VV given at ages 12 and 18 months would result in 
the lowest varicella morbidity, and that the current strategy of an infant dose and a time- 
limited catch-up dose would result in the highest varicella incidence. However, the projected 
incremental benefit of the second-dose at 18 months of age would fall by 70% if single-dose 
coverage increased from 83% to 95% (234). In July 2013, the second MMR vaccine in the 
Australian schedule (previously given at age 4 years) was removed and brought forward to 
18 months of age, with MMRV replacing VV as the publicly funded vaccine. As anticipated 
(234), with this change in schedule there has been a further increase childhood varicella- 
containing vaccine coverage at 24 months of age in Queensland, from 87.1% in 2012 for 
VV to 91.4% for MMRV in 2014 (25, 26). 
In Australia, the single-dose VV schedule is moderately to highly effective against 
hospitalisation, but in our setting, appears less effective against ED presentations. Varicella 
notifications – where in place – and continuing childcare and school-based outbreaks with 
substantial breakthrough infection highlight the weaknesses in a single-dose strategy. 
Improving single-dose coverage in Australia is important in the current circumstances, but 
modelling suggests that, even with coverage as high as 95%, this option is still less able to 
control disease than any two-dose scenario. A two-dose schedule is therefore the best 
pathway to minimise breakthrough disease and to interrupt virus circulation. Research to 
better capture the costs of breakthrough disease, and other impacts, is required to inform 
future cost-effectiveness assessments, and subsequently, re-evaluation of the incremental cost 
benefits of supporting a publicly funded two-dose VV program in childhood. 
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4.2 Impact of the single dose publicly funded childhood 
varicella vaccination program on herpes zoster in Australia 
Introduction 
Australia commenced public funding of childhood varicella vaccine (VV) for the prevention 
of chickenpox in November 2005 with a single dose of VV at 18 months of age (221). The 
program also included a time-limited, single catch-up dose of VV for unimmunised 12-13 
year olds with no history of prior varicella infection or immunisation (221). Globally, single 
dose and, to a greater degree, two-dose childhood VV programs have been effective in 
reducing the burden of chickenpox (58, 230, 231). However, it has been hypothesised that 
high VV coverage, achieved through vaccination programs, may result in an increase in the 
incidence of herpes zoster (HZ) due to a reduction in exogenous boosting among people with 
a history of chickenpox (72). 
HZ causes significant cost to the community (235) and in Australia is responsible for a 
greater burden of disease than chickenpox (236). Modelling of the impact of VV has 
predicted an increase in HZ disease in older people in the medium term (71, 237-239). As the 
majority of HZ occurs in people aged ≥50 years, with incidence and severity increasing with 
age (240), the predicted increases in HZ could led to substantial increases in the burden of 
disease and healthcare costs. In order to prevent HZ among those at high risk, the Australian 
Government has recently announced public funding for a live-attenuated zoster vaccine 
(Zoster Vaccine Live or Zostavax; Seqirus/Merck Sharp & Dohme [Australia] Pty Ltd), 
hitherto named Zostavax, for people aged 70 years, with a five year catch-up program for 
people aged 71-79 years, to commence in November 2016 (241). 
Reassuringly, an analysis of national data from Australia found age-standardised 
hospitalisations rates for HZ were lower in the first 4.5 years of the VV program compared to 
the 1.5 years immediately preceding vaccine licensure (58). Another recent study comparing 
age-specific Australian HZ hospitalisation rates up to 6.5 years post VV public funding found 
rates remained stable in all age-groups, except aged ≥80 years, in whom there had been a 
significant increase compared to the pre-vaccine funded period (242). Non-admitted patient 
data sources in Australia (242) and other countries (243-245) provide evidence of increasing 
HZ incidence rates more broadly across age-groups, however, they also show that the 
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increasing trend preceded the VV programs, complicating the assessment of what role VV 
may have on increases in HZ rates (246). 
The aims of this study were to (i) extend the analysis of HZ hospitalisation and HZ antiviral 
therapy prescription patterns to >8 years post-introduction of the single dose VV program, 
(ii) investigate the potential impact of VV on zoster incidence from the most recently 
available data, and (iii) provide a baseline of HZ patterns prior to the public funding of 
Zostavax. 
Methods 
Data sources 
We obtained annual national aggregate public and private hospitalisation data for HZ between 
July 1998 and June 2014 from the National Hospital Morbidity database (247). All episodes 
where HZ or its complications (codes B02-B02.9 in the International Classification of 
Diseases, 10th Revision, Australian Modification) in the principal diagnostic field were 
obtained, aggregated by five year age-group. 
The Australian Government provides subsidised medicines to all Australian residents through 
the Pharmaceutical Benefits Scheme (PBS). Three antiviral medicines are available through 
the PBS for treatment of HZ: Famciclovir (PBS item numbers 08002E and 08897G), Aciclovir 
(01052J), and Valaciclovir (08064K). Antiviral medicines with these item numbers may only 
be used in patients with HZ and must be prescribed within 72 hours of rash onset. Annual age- 
specific national numbers of patients receiving HZ treatment through the PBS were estimated 
from all PBS claims for a random 10% sample of the population eligible for PBS benefits 
drawn from the PBS payment records between July 2003 and June 2015 (data from 
Department of Human Services, analysis provided by HI Connections Pty Ltd). 
The Queensland Health Central Health and Medical Research Ethics Committee and the 
University of Queensland Human Research Ethics Committee approved the study on national 
HZ hospitalisations and prescription of antiviral therapy for HZ. 
107 
Analysis 
We calculated annual age-specific rates for HZ hospitalisation and for the estimated patients 
receiving PBS subsidised HZ antiviral therapy using annual population estimates from the 
Australian Bureau of Statistics (248). Rates were calculated for time-periods broadly 
corresponding to the pre-vaccine period (1998/1999-1999/2000); to when VV was licensed, 
but not recommended (2000/2001-2003/2004); when VV was recommended, but not publicly 
funded (2004/2005-2005/2006); and two periods when VV was publicly funded (early: 
2006/2007-2009/2010; late: 2010/2011-2013/2014). Crude and age-specific incidence rates 
were calculated for hospitalisations using Poisson regression. Incidence rate ratios (IRRs) and 
95% CIs were calculated for age-specific and age-standardised rates between the pre-vaccine 
and late vaccine-funded periods. 
All statistical analyses were undertaken using Stata v13 (StataCorp, College Station, TX). 
Results 
Across the study period, hospitalisations and rates of antiviral therapy receipt for HZ 
increased with age (Figures 4.2.1 and 4.2.2). Although the crude rate of principal diagnosis 
HZ hospitalisations increased by approximately 14% between the pre-vaccine period of 
1998/1999-1999/2000 and 2010/2011-2013/2014, there was no change in age-standardised 
rates over the same periods (Table 4.2.1). 
When comparing the same pre- and late post-vaccine time periods, HZ hospitalisation rates 
significantly declined among children <10 years of age, many of whom were eligible to 
receive VV (Table 4.2.1). Among 40-49 year olds average annual principal HZ diagnosis 
hospitalisation rates increased significantly across these periods from 3.4 to 4.6 per 100,000 
per year. In contrast, HZ hospitalisation rates were significantly lower among 70-79 year olds 
and hospitalisation rates among people ≥80 years of age remained stable when comparing the 
late post-vaccine period with the pre-vaccine period. 
In contrast to the annual age-specific hospitalisation rates (Figure 4.2.1), the estimated rates 
of patients receiving PBS subsidised antiviral medication for HZ increased more rapidly and 
substantially in all age-groups (Figure 4.2.2, Table 4.2.2). 
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Figure 4.2.1: Annual age-specific principal diagnosis herpes zoster hospitalisation rate, July 1998 to June 2014, Australia 
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Figure 4.2.2: Annual estimated age-specific rates of patients receiving Pharmaceutical Benefits Scheme subsidised herpes zoster therapy, 
July 2002 to June 2015, Australia 
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Table 4.2.1: Hospitalisations in which herpes zoster was the principal diagnosis, July 1998 to June 2014, by vaccine policy period, Australia 
Age-group 
(years) 
Approximate pre-vaccine period 
(1998/1999-1999/2000) 
Crude average hospitalisation values 
Counts Rate (95% CI) 1 
Approximate vaccine licensed period 
(2000/2001-2003/2004) 
Crude average hospitalisation values 
Counts Rate (95% CI) 
Approximate vaccine recommended 
period (2004/2005-2005/2006) 
Crude average hospitalisation values 
Counts Rate (95% CI) 
Early vaccine funded period 
(2006/2007-2009/2010) 
Crude average hospitalisation values 
Counts Rate (95% CI) 
Late vaccine funded period 
(2010/2011-2013/2014) 
Crude average hospitalisation values 
Counts Rate (95% CI) 
Incidence rate 
ratio (95% CI) 
2010/2011- 
2013/2014 vs 
1998/1999- 
1999/2000 
00-04 
05-09 
10-19 
20-29 
30-39 
40-49 
50-59 
60-69 
70-79 
80+ 
All ages 
Age 
standardised 
22 
39 
36 
47 
83 
92 
167 
264 
587 
577 
1911 
- 
1.7 (1.2-2.3) 
2.9 (2.3-3.6) 
1.4 (1.1-1.7) 
1.7 (1.4-2.1) 
2.8 (2.4-3.3) 
3.4 (2.9-3.9) 
8.0 (7.2-8.9) 
18.4 (16.9-20.1) 
53.4 (50.4-56.5) 
110.3 (104.0-116.8) 
10.2 (9.9-10.5) 
11.8 (11.4-12.2) 
27 
37 
48 
37 
85 
105 
184 
268 
565 
671 
2026 
- 
2.1 (1.8-2.6) 
2.8 (2.3-3.2) 
1.8 (1.5-2.1) 
1.4 (1.2-1.6) 
2.9 (2.6-3.2) 
3.7 (3.4-4.1) 
7.9 (7.3-8.5) 
17.7 (16.6-18.7) 
49.2 (47.2-51.2) 
111.3 (107.1-115.6) 
10.5 (10.2-10.7) 
11.6 (11.3-11.8) 
22 
25 
53 
38 
73 
127 
200 
320 
581 
739 
2176 
- 
1.7 (1.2-2.3) 
1.9 (1.4-2.5) 
1.9 (1.6-2.3) 
1.4 (1.1-1.7) 
2.5 (2.1-2.9) 
4.3 (3.8-4.8) 
7.9 (7.2-8.7) 
19.3 (17.8-20.8) 
50.0 (47.2-53.0) 
108.6 (103.1-114.3) 
10.9 (10.5-11.2) 
11.7 (11.3-12.0) 
13 
22 
56 
40 
83 
120 
209 
359 
537 
830 
2266 
- 
0.9 (0.7-1.2) 
1.6 (1.3-2.0) 
2.0 (1.7-2.3) 
1.3 (1.1-1.6) 
2.7 (2.4-3.0) 
4.0 (3.6-4.3) 
7.9 (7.3-8.4) 
19.0 (18.0-20.0) 
44.8 (42.9-46.8) 
109.2 (105.5-113.0) 
10.8 (10.5-11.0) 
11.3 (11.0-11.5) 
6 
18 
50 
67 
87 
146 
259 
441 
591 
958 
2620 
- 
0.4 (0.2-0.6) 
1.3 (1.0-1.6) 
1.7 (1.5-2.0) 
2.0 (1.8-2.3) 
2.8 (2.5-3.1) 
4.6 (4.3-5.0) 
9.1 (8.5-9.6) 
19.9 (19.0-20.9) 
45.1 (43.3-47.0) 
112.0 (108.5-115.6) 
11.6 (11.4-11.8) 
11.7 (11.5-12.0) 
0.22 (0.12-0.37) 
0.44 (0.32-0.62) 
1.27 (0.96-1.69) 
1.20 (0.94-1.53) 
0.97 (0.80-1.17) 
1.37 (1.16-1.63) 
1.13 (1.00-1.28)1 
1.08 (0.98-1.19) 
0.84 (0.79-0.91) 
1.02 (0.95-1.09) 
1.14 (1.10-1.18) 
0.99 (0.96-1.03) 
1Per 100,000 population per year 
2 
Lower 95% CI is 0.9953 
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Table 4.2.2: Estimated patients on Pharmaceutical Benefits Scheme (PBS) subsidised antiviral therapy for herpes zoster (HZ), July 2002 to June 2015, 
Australia 
Age-group 
(years)1 
Average annual 
number of patients 
on PBS HZ 
antiviral therapy 
00-19 
20-29 
30-39 
40-49 
50-59 
60-69 
70-79 
80+ 
All ages 
Age 
standardised 
1 
Average annual rate of 
patients on PBS HZ 
antiviral therapy (95% CI) 
2002/2003 – 2005/2006 
74.9 (73.8-76.1) 
181.4 (178.9-184.0) 
245.7 (242.9-248.6) 
310.6 (307.5-313.8) 
520.6 (516.1-525.1) 
784.9 (778.1-791.8) 
915.8 (907.1-924.6) 
911.5 (900.0-923.1) 
339.5 (338.2-340.8) 
480.6 (478.6-482.7) 
Average annual 
number of 
patients on PBS 
HZ therapy 
4290 
6408 
8045 
10595 
14470 
15813 
12455 
7673 
79748 
- 
Average annual rate of 
patients on PBS HZ 
antiviral therapy (95% CI) 
2006/2007-2009/2010 
77.9 (76.7-79.1) 
214.9 (212.2-217.5) 
265.4 (262.5-268.3) 
349.9 (346.6-353.3) 
545.2 (540.7-549.6) 
834.9 (828.4-841.4) 
1039.8 (1030.7-1048.9) 
1010.1 (998.9-1020.5) 
378.8 (377.5-380.1) 
527.1 (525.0-529.1) 
Average annual 
number of patients 
on PBS HZ 
antiviral therapy 
5118 
9586 
11448 
14864 
19768 
21978 
16720 
10438 
109920 
- 
Average annual rate of 
patients on PBS HZ antiviral 
therapy (95% CI) 
2010/2011-2014/2015 
88.7 (87.6-89.8) 
288.9 (286.3-291.5) 
361.4 (358.5-364.4) 
470.6 (467.3-474.0) 
685.5 (681.3-689.8) 
977.9 (972.1-983.7) 
1253.0 (1244.5-1261.5) 
1206.3 (1195.9-1216.7) 
483.3 (482.0-484.6) 
647.9 (646.0-649.8) 
Incidence rate ratio 
(95% CI) 2010/2011- 
2014/2015 vs 
2002/2003 -2005/2006 
1.18 (1.16-1.21) 
1.59 (1.57-1.62) 
1.47 (1.45-1.49) 
1.52 (1.50-1.53) 
1.32 (1.30-1.33) 
1.25 (1.23-1.26) 
1.37 (1.35-1.38) 
1.32 (1.30-1.34) 
1.42 (1.42-1.42) 
1.36 (1.35-1.37) 
4000 
4930 
7278 
9103 
12828 
12605 
10613 
5970 
67325 
- 
Age-groups according to aggregated data analysis by HI Connections Pty Ltd 
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Discussion 
In Australia, national principal diagnosis HZ hospitalisation data to almost 9 years post VV funding 
shows no increase in age-standardised admission rates. This has occurred in the context of high 
single dose vaccine coverage by 24 months of age, increasing from 78% in 2007 to 91% in 2014 
(22, 26). However, our findings on age-standardised HZ admission rates differed from those of 
Heywood et al (58). In their previous national principal diagnosis HZ hospitalisation analysis where 
an earlier vaccine funded period of January 2006-June 2010 was compared to a pre-vaccine period 
of July 1998-December 1999, Heywood et al (58) found age-standardised HZ rates to have 
decreased significantly (from 11.0 to 10.4 per 100,000 population per year). Our study found age- 
standardised HZ admission rates between 2010/11-2013/14 to be unchanged compared to rates 
during 1998/99-1999/2000. 
Among people aged ≥80 years, HZ hospitalisation rates remained stable, whilst among the 70-79 
year old age-group, hospitalisation rates were lower in the most recent funding years of 2010/2011- 
2013/2014, compared to the pre-vaccine period of 1998/1999-1999/2000. These results are 
consistent with the previous national HZ hospitalisation analysis by Heywood et al (58). This may 
indicate that despite decreasing varicella circulation, the single-dose VV has limited influence on 
HZ hospitalisation rates among older age-groups. Another analysis of national all HZ-related 
hospitalisations in which a post-VV funded period of 2007/2008-2011/2012 was compared to a pre- 
funded VV period of 1998/1999-2004/2005 found age-specific hospitalisation rates stable across 
the two periods, except among those aged ≥80 years in which there was a significant increase from 
267 to 289 per 100,000 per year (242). However, different time periods were under comparison and 
our analysis did not include non-principal diagnoses. 
The lack of increase in HZ hospitalisation rates in people aged ≥70 years is particularly reassuring 
given that HZ incidence and severity is greatest among older people. The most common 
complication of HZ, post-herpetic neuralgia (PHN) increases with age, with the proportion of HZ 
affected patients reporting PHN increasing from 18% in those aged ≥50 years to 33% among those 
≥80 years of age (240). Increased healthcare resource use is also associated with increasing age and 
the presence of PHN (249). The lack of increase seen in the older age-groups despite high vaccine 
coverage may indicate that exogenous boosting has less of a role to play in protecting against zoster 
due to immunosenescence than previously thought. 
Unlike earlier national analyses (58, 242), our hospitalisation findings suggested there is a small (in 
terms of absolute numbers), but significant increase in HZ admissions among 40-49 year olds, with 
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the increase almost reaching significance among 60-69 year olds. Continued surveillance will be 
useful in identifying whether this trend will continue with the maturation of the VV program. 
In contrast to the hospitalisation patterns, the rates of patients receiving antiviral therapy for HZ 
increased substantially in all age-groups between 2002/2003-2005/2006 and 2010/2011-2014/2015. 
This was similar to a previous analysis, which found increased antiviral prescription rates for HZ in 
all age groups in 2006/2007-2011/2012 compared to 2002/2003-2006/2007 (242). However, the 
rates of patients receiving antiviral prescriptions for HZ may be underestimated in people ≥60 years 
of age, approximately 7% of whom may access prescriptions under the Repatriation Pharmaceutical 
Benefits Scheme (242), which is not included in this analysis. 
There may be multiple factors contributing to the increase in the rates of patients receiving antiviral 
therapy for HZ. Hospitalisation patterns are less likely to be sensitive to changes in population 
incidence of HZ, as only a small proportion of HZ cases are hospitalised. Other sources of 
Australian non-admitted patient data from emergency departments and general practice (GP) 
encounters (242) indicate a true increase in HZ incidence rate. Analysis of consultations from a 
sentinel medical deputising service in Australia also showed a significant increase in age-specific 
HZ risk people aged <60 years between 1998-99 and 2006-12 (250). However, over the same 
periods, their HZ risk remained stable among 70-79 year olds and decreased in those ≥80 years of 
age (250). 
In addition to increasing disease incidence, there may be a widespread increase in the use of 
antivirals for HZ. Previously reported data from GP consultations showed a non-significant increase 
in prescribing behaviour, with the 61.5% of GPs prescribing antivirals to new encounters for HZ 
problems in April 2000-September 2006, compared to 65.6% in October 2006-March 2013 (242). 
Increases in the proportion of antiviral prescription for HZ has been reported elsewhere; in 
Manitoba, Canada, the proportion of HZ treated with antivirals increased from 42% in 1997/1998 to 
66% in 2013/14 (251). Furthermore, increased early antiviral treatment may reduce the likelihood 
of hospitalisation by reducing HZ symptoms. 
While there is evidence of an overall increase in HZ incidence, the degree to which VV has been an 
influencing factor is unclear. HZ incidence rates were increasing prior to the introduction of VV 
programs in Australia and the United States (244, 252, 253). Recent evidence from the United 
States showed rates of HZ have increased significantly over the previous six decades with an age 
and sex adjusted rate of increase of 2.5% per year remaining stable before and after introduction of 
their childhood varicella immunisation program in 1996, suggesting changes in HZ incidence are 
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unrelated to the vaccine (246). Given the proportion of HZ cases who were immunosuppressed did 
not greatly change over the course of their study, changes in the prevalence of immunosuppression 
is unlikely to fully explain the increase in HZ (246). 
Consistent with our hospitalisation findings, VV has been associated with the reduction in HZ rates 
in children <10 years of age, among the age-group most exposed to VV in the post VV program 
years, when compared to immediately prior to VV (246, 254, 255). This suggests HZ incidence is 
lower following VV than natural infection. 
It is reassuring that almost nine years following the introduction of a single dose of childhood VV, 
there has been no increase in HZ principal diagnosis hospitalisation rates in people ≥70 years of 
age, who are most vulnerable to severe disease. However, the burden of HZ illness is high in older 
adults. Whilst Zostavax is effective at reducing the incidence of HZ and PHN (256, 257), the 
effectiveness of a single dose wanes rapidly over time (258). With the imminent public funding of 
Zostavax in Australia, monitoring of VV and Zostavax uptake and the potential impacts on HZ 
morbidity will be important. 
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Chapter 5: Rotavirus vaccine effectiveness and impact 
5.1 Impact of rotavirus vaccination on childhood gastroenteritis 
This section is presented as a published review: 
Sheridan SL, Lambert SB, Grimwood K. Impact of rotavirus vaccination on childhood 
gastroenteritis. Microbiology Australia. 2012;33(2):56-60. 
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Rotaviruses are the most common cause of severe childhood gastroenteritis worldwide. The 
recent development of safe and effective rotavirus vaccines means that the global health and 
economic burden of rotavirus disease can now be reduced. 
Disease burden and impact 
By age 5 years virtually all children will have had at least one rotavirus infection. Each year, 
rotaviruses cause more than 450,000 deaths in children aged under 5 years, comprising over a third 
of worldwide deaths due to diarrhoea and 5% of all deaths in this age group (80). Most deaths occur 
in low and middle-income countries (80). 
Whilst deaths from rotavirus infections are rare in high-income countries the incidence of disease is 
similar to children from lower income countries. This results in a substantial health system and 
economic burden, especially as rates peak each Winter and Spring during the annual respiratory 
virus season. For example, in the pre-vaccine era in Australia there were approximately 10,000 
hospitalisations, 22,000 emergency department presentations and 115,000 general practice 
consultations for rotavirus annually among children aged under 5 years (84). Importantly,  
Indigenous Australians have substantially higher rates of disease than the general population with 
approximately five times the hospitalisation rate during infancy and a longer average length of stay 
(85). 
Despite most severe disease outcomes occurring in low and middle-income countries, most 
measured costs are direct medical costs and lost parental wages in high-income countries. The pre- 
vaccine era annual health-care and societal cost in the United States was estimated at USD$893 
million for 2004 (259), while in Australia direct medical costs were AUD$30 million in 2005/2006 
(84). 
Licensed vaccines 
Rotaviruses can be classified according to two surface proteins, VP7, a glycoprotein (G-protein), 
and VP4, a protease-cleaved protein (P-protein). Both are targets for neutralising antibodies. 
However, cross-protection amongst different G and P-types might also be mediated by immune 
responses to shared epitopes amongst several viral proteins. Globally, G1-G4 and G9 are the most 
common VP7 genotypes, while P[4], P[6] and P[8] are the most prevalent VP4 genotypes (260). 
Two licensed vaccines are available currently. Each was developed according to different biological 
principles to achieve protection. Both are live-attenuated, orally administered vaccines, but vary in 
117 
their virus components and schedule (Table 5.1.1). The human strain rotavirus vaccine (RV1; 
Rotarix®, GlaxoSmithKline) contains a single live attenuated human rotavirus strain, which is 
intended to induce both homotypic and heterotypic protection. In contrast, the pentavalent rotavirus 
vaccine (RV5; RotaTeq®, Merck & Co Inc/ CSL Biotherapies) contains five human-bovine 
reassorted rotavirus strains and relies more heavily upon inducing homotypic protective immunity. 
Rotavirus vaccines were included in the publicly funded Australian National Immunisation Program 
in July 2007, with an earlier introduction in the Northern Territory in October 2006. Both vaccines 
have strict administration timetables (Table 5.1.1). Catch-up dosing is not recommended as safety 
data in older age-groups are lacking, with a theoretically increased risk of intussusception if doses 
are given beyond the recommended age-limits. Both rotavirus vaccines can be administered safely 
with other routinely delivered childhood vaccines. 
Table 5.1.1: Properties and dose schedule of currently licensed oral live-attenuated rotavirus 
vaccines (261). 
RV1 
Tradename 
Origin 
Rotarix® 
1 human strain G1P[8] 
RV5 
RotaTeq® 
5 human-bovine reassortment 
strains with human serotypes 
G1, G2, G3, G4, and P[8] 
Biological principles* 
Presentation 
Number of doses 
Administration 
Heterotypic immunity 
Oral liquid stored at 2-8°C 
2 (1.5 mL per dose) 
1st dose: 6 to <15-wks 
2nd dose: ≥4-wk interval at 10 
to <25-wks 
Homotypic immunity 
Oral liquid stored at 2-8°C 
3 (2 mL per dose) 
1st dose: 6 to <13-wks, next 
doses at 4-10 wk intervals, 
completed by <33-wks 
* RV1 relies upon a single human-derived rotavirus strain inducing protective heterotypic immunity 
against all other strains, while RV5 uses 5 bovine-human reassortant strains to induce serotype- 
specific (homotypic) immunity against the most commonly circulating strains (G1P[8], G2P[4], 
G3P[8], G4P[8] and G9P8]) worldwide. 
Efficacy 
Trials to determine the efficacy of RV5 and RV1 have been undertaken in several countries (Table 
5.1.2). Although no direct comparisons can be made between the two vaccines because of 
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differences in subject populations and clinical endpoints, both vaccines appear to perform similarly 
against different rotavirus strains in various settings. Vaccine efficacy in high and middle-income 
(Latin American) countries was highest against severe rotavirus gastroenteritis, providing 83-98% 
protection in the first rotavirus season post-vaccination and maintaining similar levels of protection 
against severe disease over the following one-to-two seasons (88-90, 262-264). The definition of 
‘severity’ varied according to study, but included severity grading according to one of two different 
clinical scoring scales (Vesikari or Clark) (265), or the need for overnight admission to hospital or 
rehydration therapy. In addition, both vaccines also provided 74-87% protection against rotavirus 
diarrhoea of any severity in the first rotavirus season post-vaccination (89, 90), and decreased ‘all- 
cause’ gastroenteritis hospitalisations by 39-72% (88-90, 263). 
Table 5.1.2: Rotavirus vaccine efficacy for severe gastroenteritis in the first year of life across 
high, middle and low-income countries (modified from WHO (266) with permission) 
Setting 
High-income 
Efficacy 
96-98% 
Main country where phase III trials performed 
North America (90), Western Europe (89, 90), 
Singapore (262), Taiwan (262), and Hong Kong (262) 
Middle-income 72-85% Latin America (88, 263), South Africa (92), and 
Vietnam (93) 
Low-income 46-64% Ghana (81), Kenya (81), Mali (91), Malawi (92), and 
Bangladesh (93) 
In contrast, vaccine efficacy was initially reduced and poorly sustained in middle and low-income 
African and Asian settings. Protection provided by RV1 against severe rotavirus gastroenteritis 
disease during infancy was 77% (95% confidence interval [CI]: 56-88) in South Africa and 49% 
(95% CI: 19-68) in Malawi (92). Meanwhile RV5 field trials in Africa and Asia demonstrated 
efficacy against severe disease of 64% (95% CI: 40-79) and 51% (95% CI: 13-73) in the first year 
of life, and 20% (95% CI: -16-44) and 45% (95% CI: 1-71) in the second year of life, respectively 
(91, 93). 
The findings from Malawi demonstrate the important distinction between efficacy and impact. 
While relative efficacy was lower in Malawi compared to South Africa, the absolute impact in 
terms of severe rotavirus gastroenteritis cases prevented, was greater in Malawi (6.7 vs 4.2 cases 
prevented per 100 vaccinees) due to a higher disease burden and year round circulation of the virus 
(92). Thus despite lower efficacy, the potential impact of rotavirus vaccine reducing morbidity and 
mortality is greatest in low-income countries. Reasons for lower immunogenicity and efficacy of 
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live-attenuated oral rotavirus vaccines in low-income settings remain unknown. These are, 
however, likely to involve multiple host and environmental factors such as interference by 
maternal antibodies in blood and breast-milk, co-existent enteric infections, chronic illness, 
malnutrition and difficulties maintaining the cold chain (226). 
Post-licensure effectiveness and impact 
Since 2006, rotavirus vaccines have been licensed in over 125 countries and included in the national 
vaccination schedules of 34 predominantly high and middle-income countries worldwide (82). A 
detailed review of published post-licensure studies is beyond the scope of this article. Tables 3 and 4 
summarise a selection of major studies describing the effectiveness and impact of rotavirus vaccines 
respectively across high and middle-income countries. Both vaccines appear to have direct and 
indirect effects on rotavirus disease patterns, with the real-world findings broadly consistent with 
the efficacy studies for different settings. As with efficacy studies, comparisons of effectiveness 
estimates are limited by differences in study design, including selection of controls, setting and 
period of observation. 
Table 5.1.3: Major post-licensure studies on effectiveness of rotavirus vaccines against rotavirus 
hospitalisation and/or emergency department visits among children under 5 years of age 
across high and middle-income countries. 
Setting 
RV1 
High-income 
Middle-income 
RV5 
High-income 
Middle-income 
89-100% 
43% 
Australia (94), France (269) and United States (270) 
Nicaragua (271) 
19-85% 
76% 
Australia (95, 96) (largely Indigenous population) 
Brazil (267) and El Salvador (268) 
Effectiveness (%) Country where study undertaken 
Studies on RV5 vaccine effectiveness in high-income settings report effectiveness of 89-100% 
against hospitalisation for rotavirus gastroenteritis (94, 269, 270). In contrast, mixed results were 
found for RV1 effectiveness in Australia. Two studies undertaken during outbreaks predominantly 
affecting Aboriginal children in Central Australia found effectiveness against hospitalisation for 
infants to be 85% during a G9P[8] outbreak, but in a subsequent outbreak of a non-vaccine related 
strain G2P[4], the vaccine was found only to provide a significant protective effect in a subset of 
infants with disease complicated by acidosis (95, 96). Interestingly, in middle-income Latin 
American countries both vaccines provided 43-76% protection against rotavirus hospitalisation 
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from various strains, including G2P[4], but as in Central Australia, this effectiveness waned after 
infancy (267, 268, 271). 
Table 5.1.4: Major post-licensure studies on impact of rotavirus vaccines across high and middle- 
income countries 
Setting Coverage Comparison of 2-3 years post-vaccine 
introduction vs pre-vaccine era: 
Impact on RV hospitalisations or ED visits 
High income 
Australia (272), 
Belgium (273), 
USA (274, 275) 
Impact on ‘all-cause’ AGE hospitalisations 
High income 
Australia (272), 
USA (274, 275) 
Middle income 
Brazil (276) 
Up to 81% of 
children <1 years 
of age 
Impact on diarrhoea-related mortality 
Middle income 
Brazil (276), 
Mexico (277) 
Up to 89% of 
children 
<2 years of age 
≥1 dose 
Abbreviations: AGE, acute gastroenteritis; ED, emergency department; RV, rotavirus. 
Introducing rotavirus vaccines into national immunisation schedules has been associated with 
substantial and significant declines in morbidity and mortality. Reductions of up to 46% of 
diarrhoea-related mortality in children under 5 years have been found in Latin American countries 
(276, 277). Declines in health care utilisation for both rotavirus and ‘all-cause’ gastroenteritis have 
been described across Europe, United States, Australia and Brazil (94, 272-276). In an Australian 
study, a reduction of 87% in nosocomial infections was identified following vaccine introduction 
(278). Whilst the impact is greatest among children under 2 years of age, herd protection is believed 
responsible for reductions among largely unvaccinated age-groups by presumably reducing 
transmission opportunities within the community (94, 271-275, 278, 279). Common across 
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Up to 90% 74-90% decline in children <2 years of age 
41-80% decline in children 2<5 years of age 
Up to 82% for 12 
month olds 
29-50% decline in children <5 years of age 
17% decline in children <5 years of age 
22-46% decline in children <5 years of age 
European, the United States and Australian settings, has been delays in onset with loss of 
seasonality and attenuation of the annual winter/spring rotavirus epidemics (273, 275, 278). 
Intussusception 
The first licensed rotavirus vaccine, RotaShield (Wyeth Laboratories) was withdrawn 
controversially after it was found to be associated with an increased risk of intussusception. The 
excess risk was approximately 1 case in 10,000 vaccine recipients (280, 281). Subsequently, the 
large-scale phase III safety trials undertaken in middle and high countries involving more than 
140,000 subjects, found no elevated risk of intussusception during the 42-day and 30-day periods 
after vaccination, with RV5 and RV1, respectively (88, 90, 262). In Australia, post-marketing 
surveillance reported no overall increase in intussusception with either vaccine, although, there was 
some evidence of increased risk in infants aged 1 to <3 months within 7 days (RV5: RR 5.3, 95% 
CI: 1.1-15.4; RV1: RR 3.5, 95% CI: 0.7-10.1) and within 21 days (RV5: RR 3.5, 95% CI: 1.3-7.6; 
RV1: RR 1.5, 95% CI: 0.4-3.9) of receiving dose 1 of either vaccine (282). A post-licensure case- 
control study involving surveillance at 69 hospitals in Mexico and Brazil found RV1 was associated 
with a short-term risk of intussusception in approximately 1 in 51,000 to 68,000 vaccinated infants 
(283). However, in the context of these countries, the absolute number of deaths and hospitalisations 
averted greatly exceeded those associated with RV1 vaccination. The risk-benefit analysis found 
RV1 resulted in an annual excess of 96 cases of intussusception and 5 associated deaths, but 
prevented approximately 80,000 hospitalisations and 1300 deaths from diarrhoea each year across 
Mexico and Brazil (283). A recent review assessing the current vaccines has led the World Health 
Organization to reaffirm its recommendation that rotavirus vaccines should be used globally (284). 
Further evidence of rotavirus vaccine safety has come from recent large cohort studies in the United 
States, which included follow up of children who received almost one million RV5 doses. Whilst 
these studies found no increased intussusception risk within 30-days of any RV5 dose received, they 
would still theoretically fail to detect a risk of intussusception of less than one in 50,000 vaccinated 
children (285, 286). 
Future 
Whilst high and middle-income countries have largely benefited from rotavirus vaccines, it is in 
lower-income African and Asian countries where greatest gains are to be made. With donor support, 
the Global Alliance for Vaccines and Immunization plans to introduce rotavirus vaccine into more 
than 40 low-income countries by 2015 (287). Nevertheless, rotavirus vaccine efficacy needs 
improvement in low-income countries. Development of rotavirus vaccines administered at birth 
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may be particularly important in these settings where primary infection occurs early in life and 
access to health care and routine immunisation services is poor. 
Ongoing surveillance is needed to ensure the expected benefits are being achieved, to monitor 
changes in rotavirus epidemiology, including duration of protection, and to ensure the continued 
safety and effectiveness of current vaccines (82). Whilst there is no substantial evidence to date of 
new strains emerging or a sustained shift in circulating strains occurring attributable to vaccine 
introduction (82, 288), ongoing surveillance is necessary to monitor rotavirus strain diversity, and 
the effectiveness of vaccines against them. Meanwhile, widespread implementation of rotavirus 
vaccines will help reduce the global morbidity and mortality associated with childhood diarrhoea. 
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5.2 Febrile seizures in the era of rotavirus vaccine 
This section is presented as a published brief report: 
Sheridan S, Ware R, Grimwood K, Lambert S. Febrile seizures in the era of rotavirus vaccine. J 
Pediatric Infect Dis Soc. 2016;5(2):206-9. 
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Abstract 
A protective association between rotavirus vaccination and childhood seizures in the year after 
vaccination was recently reported from the United States. In the state of Queensland, Australia, the 
authors found rotavirus vaccine was 35.8% and 38.0% effective at preventing emergency 
department presentation and subsequent hospitalization, respectively, for febrile seizures among 
children up to two years following vaccination. 
Key words: rotavirus vaccine; febrile seizures 
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Rotaviruses are the most common cause of severe childhood gastroenteritis worldwide resulting in 
approximately 450,000 deaths in children <5 years of age (80, 289). In addition, rotavirus-related 
illnesses are associated with both febrile and afebrile seizures (290). 
Recently, a retrospective analysis of a cohort of US children found a protective association between 
full rotavirus vaccination and childhood seizures resulting in emergency department (ED) 
presentation or hospital admission in the year following vaccination (99). Using a pre-existing 
linked dataset containing febrile, but not afebrile, seizure outcome data, we sought evidence of a 
similar effect in children in Queensland, Australia, after introduction of the publicly funded 
rotavirus vaccine, RotaTeq® (RV5; Merck & Co Inc/CSL Biotherapies), in mid-2007 into the 
State’s immunization schedule (5). 
Methods 
Using routinely collected health data, we calculated the vaccine effectiveness (VE) of rotavirus 
vaccine in preventing ED presentation and subsequent hospitalization for febrile seizures using the 
screening method described here. Our method involved comparing the proportion of children with 
febrile seizures who were vaccinated (proportion of cases vaccinated [PCV]) with the proportion of 
the target population vaccinated (PPV) (111). PPV values were obtained from the population-based 
Australian Childhood Immunisation Register (ACIR). The ACIR receives positive immunization 
notifications from the Queensland vaccination register (Vaccination Information and Vaccination 
Administration System [VIVAS]) to which Queensland vaccine service providers report 
immunizations. 
We investigated VE among three 12 month cohorts of children born between May 2007 and April 
2008 (VE calculated for 2009/2010/2011), between May 2008 and April 2009 (VE calculated for 
2010/2011), and between May 2009 and April 2010 (VE calculated for 2011) (Table). The birth 
cohorts were constructed to ensure that children were age-eligible for rotavirus vaccination (5) and 
had the opportunity to receive the full 3-dose course of RV5, with all doses due before 33 weeks of 
age, before the calendar year in which VE was assessed. As part of a larger rotavirus-based linkage 
study, we had data specific for febrile seizures (International Statistical Classification of Diseases 
and Related Health Problems, 10th Revision, code R56.0) from ED records of 25 Queensland public 
hospitals. In 2010/2011, these 25 hospitals were responsible for 80% of all non-admitted hospital 
presentations, (including ED presentations and outpatient visits) for any cause, in Queensland 
public hospitals. 
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To determine the PCV, the Queensland Health Data Linkage Unit linked vaccination (VIVAS) and 
ED presentation data using LinkageWiz data matching software, version 5.3 (LinkageWiz Inc, 
Adelaide, South Australia) to probabilistically identify potentially matching records. Weighting 
scores were assigned to matching variables, including surname, first name, date of birth, and 
address. Middle- and lower-weighted pairs were individually assessed, and higher-weighted pairs 
checked for false matching related to multiple births. 
As VE was assessed over an observation period of 1 year for 12 month birth cohorts, the age range 
of children within each observational period was 2 years. We obtained VE estimates and 95% 
confidence intervals (CIs) by fitting logistic regression models with the outcome variable as the 
vaccination status of the case and offset for the logit of PPV. To account for multiple seizures in the 
same infant, we used the robust variance estimate when assessing VE against all seizure 
presentations and hospitalizations. Separate models were constructed for each age group, for ED 
presentations and hospitalizations, and for VE against all febrile seizures and the first seizure during 
the period of analysis. When estimating the association between age group and VE, we included age 
group as a main effect. Analyses were undertaken using Stata, version 12 (Stata Corp). 
Results 
There were 2211 ED presentations for febrile seizure, 635 (28.7%) of which led to hospital 
admissions, included in the analysis. Among the youngest children aged between 8 months and 2 
years 7 months, the VE of the full 3-dose rotavirus vaccine course against any febrile seizures 
leading to ED presentation and subsequent hospitalization were 35.8% (95% CI: 26.0–44.2) and 
38.0% (95% CI: 20.1– 51.9), respectively (Table 5.2.1). We found the protective association against 
any febrile seizure resulting in ED presentation and hospitalization remained substantial in older 
children, up to 4 years after rotavirus vaccination. VE against any ED presentation was significantly 
associated with age-group (p=0.003), but VE against any hospitalization was not (p=0.210). VE 
remained statistically significant when restricting analysis to the first febrile seizure occurring 
during the period of analysis. 
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Table 5.2.1: Vaccine effectiveness (VE) of rotavirus vaccine against emergency department 
(ED) presentations and hospital admissions for febrile convulsions by age 
                                       Vaccinated 
                                       cases 
Any ED presentations/ hospital admission 
Any ED presentations 
May 2007–April 2008; 8m–2y7m1301 
May 2008–April 2009; 
May 2009–April 2010 
May 2007–April 2008; 1yr8m–3y7m 454 
May 2008–April 2009 
May 2007–April 20082y8m–4y7m 92 
Any hospital admissions 
May 2007–April 2008; 8m–2y7m 
May 2008–April 2009; 
May 2009–April 2010 
May 2007–April 2008; 1y8m–3y7m 
May 2008–April 2009 
May 2007–April 20082y8m–4y7m 
Birth cohort Age range Total 
cases 
PPV (%) VE [%] 
(95% CI) 
1530 87.7-90.9 35.8 
(26.0 – 44.2) 
34.7 
(18.1 – 48.0) 
66.2 
(51.6 – 76.4) 
38.0 
(20.1 – 51.9) 
56.4 
(35.3 – 70.7) 
62.0 
(19.2 – 82.1) 
544 
137 
86.7-90.3 
85.8 
389 460 87.7-90.9 
110 
23 
142 
33 
86.7-90.3 
85.8 
First presentation/admission in the year 
First ED presentation 
May 2007–April 2008; 8m–2y7m1065 
May 2008–April 2009; 
May 2009–April 2010 
May 2007–April 2008; 1yr8m–3y7m 384 
May 2008–April 2009 
May 2007–April 20082y8m–4y7m 78 
First hospital admission 
May 2007–April 2008; 8m–2y7m 
May 2008–April 2009; 
May 2009–April 2010 
May 2007–April 2008; 1yr8m–3y7m 
May 2008–April 2009 
May 2007–April 20082y8m–4y7m 
1266 87.7-90.9 40.3 
(30.5 – 48.6) 
35.5 
(17.6 – 49.5) 
64.2 
(46.8 – 75.9) 
44.2 
(27.2 – 57.3) 
461 
114 
86.7-90.3 
85.8 
326 392 87.7-90.9 
                                                                                  56.2 
                                                                                  (32.8 – 71.5) 
                                          202885.858.7 
                                                                                  (4.7 – 82.1) 
Abbreviations: PPV, proportion of the population vaccinated; CI, confidence interval; m, months; y, 
year(s). 
93 120 86.7-90.3 
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Discussion 
We found 3 doses of RV5 to have a protective association for febrile seizures up to 4 years after 
rotavirus vaccination. The VE estimate against any febrile seizure resulting in ED presentation for  
the youngest age group, 35.8%, is broadly consistent with the US finding of a reduction of 21.0% 
(95% CI: 12.5-28.6) of all childhood seizures requiring ED care or hospitalization in the first year 
after rotavirus vaccination (99). 
We investigated the association specifically between rotavirus vaccination and febrile seizures by 
using a pre-existing linked data set that did not contain afebrile seizure-associated diagnostic codes. 
Because many rotavirus-associated seizure events are afebrile (290), restricting our analysis to 
febrile seizures will have excluded some rotavirus-associated events. Our higher point estimates for 
VE compared to findings in US children may result from febrile seizures being more specific for 
rotavirus than for all seizures. Conversely, a 2010 study of young children presenting to a US 
hospital with a first-time seizure identified rotavirus in 8% of children with febrile seizures and 
21% of children with an afebrile illness (291). It is interesting to note that in our population, the 
protective effect appeared to endure with the highest point VE estimate in children aged between 2 
years 8 months and 5 years 7 months (2 to 4 years after vaccination). Nevertheless, the largest 
absolute impact would be expected to occur in younger children because of their higher incidence 
of both rotavirus infection and febrile seizures, with the peak incidence of febrile seizures occurring 
at 18 months of age (292). 
Our study has several limitations. The analysis was stratified according to age group; however, it is 
possible that other factors related to both receiving rotavirus vaccination and experiencing febrile 
seizures and/or seeking ED care for febrile seizures biased the results. The validity of our analysis 
depends upon the accuracy of data linkages. Incomplete data linkage of the original vaccination or 
ED presentation data sets, in which pairs of records failed to link because of incorrect or missing 
information, is more likely to have occurred than false-positive links. Incomplete data linkage 
would have led to an underestimation of the proportions of cases vaccinated and an overestimation 
of VE. The completeness of linkages may have varied with the children’s ages because of changes 
in address over time. However, because the linkages were also based on variables that were unlikely 
to change, including date of birth, gender, and name, we do not think linkage rates differed 
excessively according to age. Accuracy of the data linkages may have also varied with the 
weighting of the linkage pairs, but we were unable to investigate this potential bias because of the 
complex linking of 5 data sets in this study. Our study benefited from obtaining accurate PPV 
estimates from the ACIR, which is estimated to capture 99% of the eligible population (102). We do 
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not have information on the specificity of ICD coding for febrile convulsions in Queensland EDs. A 
lack of specificity may have biased the results, with the inclusion of seizures unrelated to infectious 
agents likely have biased VE toward the null. 
Our findings may have also been confounded by differential receipt of influenza vaccine. It is more 
likely that children vaccinated with rotavirus vaccine would have also been vaccinated against 
influenza, a common cause of febrile seizures, and a confounding effect caused by this would lead 
to an overestimation of VE. However, influenza vaccination is not publicly funded for children in 
Australia, and uptake is likely to have been modest within the target age group (293). Moreover, 
accurate coverage data are not available from which to estimate any potential confounding effect. 
Although the prognosis for children with either afebrile or febrile seizures with mild rotavirus 
gastroenteritis is good (290, 291), a reduction in seizures from rotavirus vaccination may result in 
substantial benefits to children, their parents, and the health system more broadly. A Canadian study 
of 1359 children hospitalized with rotavirus, before vaccine introduction, found that 7% had 
seizures at presentation (294), and a study in Korea found that 7.8% of 755 children hospitalized 
with mild rotavirus experienced seizures (afebrile 5.6%; febrile 2.2%) (290). Martin et al (291), in 
their study of first-time seizures among young children, found that 7 of 13 children in whom 
rotavirus was detected had afebrile seizures, and the other 6 children had febrile seizures. The 
incidence of febrile seizures (292) and proportion of seizures caused by rotavirus also vary 
according to region, with a study in Hong Kong finding that only 1.3% of children hospitalized with 
febrile seizures, before rotavirus vaccine introduction, were rotavirus positive according to an 
enzyme immunoassay (295). This number compares to 8% of children presenting with a first-time 
febrile seizure in the US, some of whom had been born shortly before or since the introduction of 
rotavirus vaccination and were therefore eligible to have received rotavirus vaccination (291). 
Our results support the recent US finding that there is substantial benefit to be gained from the 
reduction of childhood febrile seizures through rotavirus vaccination. The benefits of early 
childhood rotavirus vaccination, some of which were not obvious before introduction, continue to 
accumulate. 
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Chapter 6: Discussion 
Overview of key findings and implications 
In this thesis I aimed to assess aspects of VE and impact of three publicly funded vaccination 
programs in Australia, using routinely collected linked data. Each piece of research contributes to 
the evidence base for vaccination policy decision-making, and, where possible, reinforces 
confidence in vaccination programs among health professionals and the public. However, the 
impetus for investigation varied for each of three vaccination programs. 
Pertussis 
I undertook a comparative assessment of wP and aP vaccines, and determined the VE of aP in 
childhood in order to gain a greater understanding of the unexpected resurgence in pertussis 
notifications in the conext of an established vaccination program with high coverage. 
My work comparing the effectiveness of wP and aP contributed to the global understanding of 
pertussis epidemiology. In the first study to provide a direct comparison between vaccines among a 
single 12 month birth cohort, I demonstrated that following primary course vaccination wP 
provided greater protection than aP over the subsequent decade. This work has since been replicated 
by groups in the US (129, 130). My findings led to greater recognition of the impact of replacing 
wP with aP in countries recently experiencing resurgent pertussis and evidence to inform countries 
that were yet to transition to aP (219). This work was a part of the recent body of work undertaken 
on pertussis epidemiology that contributed to the evidence on which the WHO’s current position 
paper on pertussis vaccines is based (296). In this position paper the WHO recommends national 
programs currently using wP vaccine continue to use wP vaccine for the primary course 
vaccinations, and to only switch from wP to aP priming if additional periodic booster or maternal 
immunisation can sustainably be included in the national immunisation schedule (296). The 
replacement of wP with aP has substantial financial implications given the greater cost of aP and 
larger number of doses required with more poorly-controlled disease (296). Remaining with an 
effective wP may allow scarce resources to fund other public health interventions in lower income 
countries. 
Following the recognition of the lower effectiveness of aP compared to wP, I aimed to assess the 
current VE of the full childhood aP course during what was then the current epidemic in 
Queensland, and found that whilst initially highly effective, protection provided by aP waned 
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quickly. My research on aP effectiveness during 2009 and 2010 epidemic years in Queensland 
contributed the first assessment of aP in Australia among those who had received solely aP 
vaccination courses. The findings of this study contributed another piece of evidence to improve 
understanding of the national resurgence in pertussis. While finding that aP was highly effective in 
children aged 1-<4 years with point VE estimates between 84% and 89% against pertussis 
notification and hospitalisation, the study also demonstrated VE decreased substantially with age, 
consistent with the evidence of waning protection provided by aP reported in the US (38, 39, 45). 
Importantly, these assessments were undertaken against notified disease, rather than being 
restricted to severe disease requiring hospitalisation. The effectiveness of aP and the comparative 
effectiveness of aP and wP may vary according to the severity of pertussis disease. Furthermore, 
changes in testing practices, including increased PCR use, may have led to greater notification of 
milder pertussis, against which pertussis vaccination may be less effective. This could contribute 
to lower estimations of VE than reported prior to the widespread use of PCR. 
Together with findings from the US, my research will inform countries where aP has been fully 
implemented on what changes in pertussis epidemiology to expect as their wP only cohorts become 
older. The replacement of a highly effective wP with aP may be associated with future changes in 
pertussis epidemiology in Australia and in other countries that rely solely on aP. As the cohort of 
people vaccinated purely with aP becomes older, the incidence of pertussis in this cohort may be 
relatively higher than those primed with wP. The higher rates of pertussis reported following aP 
booster doses among those who were primed with only aP compared to those who were at least in 
part primed with wP (130, 131, 297), strongly suggests that the priming event continues to 
influence the degree of protection provided by subsequent booster doses. Previous vaccination 
schedules, adequate to control pertussis among adolescents and adults primed with wP may prove to 
be less effective and require additional boosters for the aP primed cohort (298). Surveillance of age- 
specific pertussis incidence will continue to be important in identifying new patterns of disease and 
assessing the impact of the numerous changes in vaccination schedule that have occurred since the 
beginning of the last epidemic in 2009 in an effort to control pertussis in the aP era. These changes 
have included the cocoon program, maternal vaccination, and re-introduction of the 18 month 
booster. 
My comparison of protection against pertussis by nature of primary pertussis vaccine course (aP, 
wP, or mixed aP/wP) also indicated mixed primary-course vaccine recipients had greater protection 
if they received wP rather than aP as their initial dose. This highlights the importance the first dose 
of vaccine may have on enduring protection. These findings support the immunomodulatory role of 
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pertussis vaccines and their role in non-specific effects, which may have far-reaching implications. 
While a highly effective wP is more effective than aP, the former is associated with a higher 
incidence of adverse events (21) and consequently declines in pertussis vaccination coverage. aP 
vaccines were developed to provide an alternative more acceptable pertussis vaccine with less 
frequent adverse events. Whilst there has been more of a trade-off in terms of effectiveness than 
was anticipated when aP replaced wP, no national immunisation advisory committee has 
recommended replacement of currently scheduled aP with wP vaccines. However, the addition of 
more aP doses, which are considerably more expensive than wP, to achieve a lesser degree of 
pertussis control than may be achieved with wP highlights the complex cost-effectiveness 
considerations for pertussis vaccines in countries using aP and experiencing resurgent pertussis. 
This is illustrated by the possible removal of the adolescent pertussis booster from the NIP 
following the PBAC’s request of ATAGI to review the cost effectiveness of the pertussis schedule 
(35, 36) 
Varicella 
The primary reason for researching the effectiveness of VV was to fill our gap in knowledge of the 
VE of a single dose of VV in the Australian context. My study, providing the first estimate of VE 
since public funding of VV in Australia, found a single dose of VV was 82% (95% CI: 62-91) 
effective at preventing varicella hospitalisation among Queensland children aged 19 months to 6 
years. VE against ED presentations among children 19 months to 8 years of age was 58% (95% CI: 
49-66), indicating a moderate degree of protection provided by a single VV dose and the incidence 
of breakthrough disease. I found the VV program was associated with significant reductions in 
moderate to severe varicella disease with age-standardised varicella hospitalisation rates declining 
by more than 70% in 2011-2014 compared to the pre-funded vaccine period 2000-2003. Despite the 
substantial impact the single dose VV program has had on morbidity, high coverage with a single 
dose has been insufficient to interrupt varicella transmission with varicella outbreaks continuing to 
occur in child care and school settings, as occurred in the US during their single VV dose program 
(63). To interrupt transmission and reduce the incidence of breakthrough disease in Queensland, a 
second VV dose would be necessary. The impact of the second VV dose has been demonstrated in 
the US where, 7-8 years post-second dose introduction, overall varicella incidence has declined by 
85% compared to the single VV era (68). A second dose of VV was considered and rejected by the 
PBAC in 2007 (233). Further evidence on varicella incidence and the cost of disease will be useful 
to inform future decisions on the cost-effectiveness of publicly funding a second VV dose. 
Building on previously published work (58), I also found national age-standardised HZ 
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hospitalisation rates had not increased significantly after almost 9 years of funded VV. Given the 
greater incidence and severity of HZ disease in older adults, it was particularly reassuring that there 
was no increase in hospitalisation rates among people aged 70 years and above. In contrast, a small, 
but significant increase in HZ hospitalisation rates was identified among 40-49 year olds. It will be 
important to identify whether this trend continues as the VV program matures. The increase in 
younger adults may be due to reduced exogenous boosting as a result of the VV program, though 
the lack of increase in hospitalisation rates among older adults suggest exogenous boosting may 
play less of a role in preventing HZ in older people due to immunosenescence. Modelling of the 
impact of VV in Australia and elsewhere had predicted an increase in HZ disease in older people in 
the medium term (71, 237-239). Whilst our findings have not identified an overall increase in 
severe HZ disease requiring hospitalisation, continued surveillance will be essential to identify 
changes in HZ epidemiology and the association with VV and zoster vaccine programs. Together 
the varicella and HZ findings provide a baseline of severe varicella and HZ incidence in the single 
VV dose era. These findings may inform vaccine policy decisions on inclusion of a second VV 
dose, and provide a baseline from which to assess the impact of the soon-to-be publicly funded 
adult zoster vaccine (Zostavax). 
Rotavirus 
Wherever they have been introduced into NIPs, rotavirus vaccines have had a substantial impact on 
the large burden of viral gastroenteritis internationally, including in Australia. Previous research in 
Queensland found the effectiveness of three doses of pentavalent rotavirus vaccine in preventing 
hospitalisation with a principal diagnosis of rotavirus and non-rotavirus to be 94% (95% CI: 83-98) 
and 64% (95% CI: 52-72), respectively (94). The impact of the national rotavirus vaccination 
program in reducing the burden of rotavirus illness resulting in hospitalisation has also been 
documented (299). Prompted by findings in the US, I aimed to identify whether rotavirus 
vaccination had an additional unexpected benefit of reducing risk of febrile seizures. In agreement 
with the US findings, I was able to show rotavirus vaccine was associated with moderate protection  
from febrile seizures in Queensland children, with a VE of 36% (95% CI: 26-44) at preventing ED 
presentations. This finding provides locally relevant evidence to further support the effectiveness 
and cost-effectiveness of rotavirus vaccine and to build public confidence in rotavirus vaccination. 
Strengths and limitations 
The use of routinely collected health datasets in the assessment of the real-world effectiveness and 
impact of vaccination programs enables population-based, locally relevant evidence to be gained in 
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a timely and resource efficient manner. The data sources used in the research presented in this thesis 
are well-established, enabling the description and investigation of epidemiological patterns often 
over more than a decade. The findings of my research, largely based on data from Queensland, are 
also generalisable to other regions of Australia and of international relevance. 
While double blinded RCTs are ideal for assessing vaccine efficacy, post-licensure studies are vital 
in evaluating the effectiveness of vaccination programs. Post-licensure assessments of VE 
incorporate both the direct and indirect (herd) effects of a vaccine and may vary significantly from 
vaccine efficacy estimates obtained during vaccine trials due to a number of factors (114). These 
include host factors such as age, the presence of conditions which affect immune response or 
disease susceptibility, previous exposure to the antigen, and interference due to the co- 
administration of vaccines or medications (114). Epidemiological factors which may be quite 
different in post-licensure settings include the force of infection, herd immunity, and emergence of 
new bacterial or viral variants, and the more diverse nature of the population evaluated (114). 
Additionally, logistical issues such as adherence to the recommended schedule and maintenance of 
the cold chain may vary in post-licensure compared to the strict conditions imposed by vaccine trial 
settings (114). Post-licensure VE and impact assessment provides information and evidence for 
decision-making that is not available before licensure, including herd immunity effects, such as 
those occurring post-VV introduction, the impact of waning immunity such as with aP vaccines 
(132), how the degree of matching with circulating strains influences VE, as for influenza (300), 
and in identifying changes in microbial ecology induced by vaccination, such as has occurred with 
pneumococcal conjugate vaccination (114, 301). While not the focus of this thesis, post-licensure 
surveillance also offers an important opportunity to assess vaccine safety. Population-based post- 
licensure surveillance, when vaccines are delivered to millions of people, may identify very rare 
adverse events that may otherwise go undetected due to limitations in sample size in vaccine 
efficacy trials (114). 
While the analysis of linked routinely collected health data can provide resource efficient evidence,  
it does not negate the value of more expensive and complex health research. Instead, findings from 
the analysis of routinely collected data may be useful in identifying gaps in knowledge that can be 
addressed through other forms of research. 
Much of the research included in this thesis has benefitted from the existence of the national 
population based immunisation register, ACIR. The validity of the results using the screening 
method depend upon accurate vaccination data for the population and the notified cases. It has been 
estimated that the ACIR underestimated immunisation coverage by up to 5% in the early 2000s, due 
135 
to inadequate reporting by immunisation providers (302). However, financial incentives for parents 
and immunisation providers over time have substantially improved the accuracy of the ACIR (102). 
There is still likely to be some under-reporting, for example due to vaccinations received overseas 
not being reported to the ACIR (303). In January 2016, the Australian Government extended the 
immunisation requirements for parents to be able to receive the Family Tax Benefit Part A 
supplement, Child Care Benefit, and Child Care Rebate (115). These financial incentives are now 
only paid for children and adolescents up to 19 years of age who are up to date with or medically 
exempt from immunisations according to the NIP schedule (115). With the addition of Zoster 
Vaccine Live (Zostavax) and the requirement for capturing data on adolescent immunisations for 
families to receive financial incentives, ACIR changed to a whole-of-life immunisation register and 
was renamed AIR. The AIR commenced operating on 30 September 2016. These financial 
incentives are likely to both increase reporting to AIR as well as increase immunisation uptake. 
Nevertheless, under-reporting of vaccinations may lead to underestimation of the PPV and PCV. 
Underestimation of PPV will cause VE to be underestimated, whilst underestimation of PCV would 
cause VE to be overestimated. For the purposes of this thesis, it is unknown if under-reporting of 
vaccination status has affected the VE estimates, and if so in which direction as well as whether 
there has been differential under-reporting for cases compared to the population in general. 
A further potential limitation specific for the pertussis VE assessments relates to the use of the third 
dose assumption. This is where it is assumed that a child who has their third dose of pertussis 
vaccine recorded is assumed to have received their entire primary course, regardless of whether the 
first and second dose are recorded on ACIR or VIVAS. Whilst this has been previously validated 
(118), this validation has not been repeated in the last decade. If incorrect, the third dose assumption 
would lead to overestimation of both the PPV and PCV values. Overestimation of PPV would result 
in overestimation of VE, whilst overestimation of PCV would bias VE in the opposite direction. 
The more stringent immunisation record requirements for accessing financial incentive may reduce 
underreporting of primary course pertussis vaccinations and change the validity of the third dose 
assumption. Another assessment of the third dose assumption would be useful to inform whether it 
should still be used in assessing vaccination coverage. 
A potential limitation of routinely collected passive surveillance data is biased case ascertainment. 
Studies based on passively notified cases are particularly prone to biased case ascertainment as 
people with disease may not have equal likelihood of being notified (110). It is not known to what 
extent case ascertainment was associated with vaccination status in the studies included in this 
thesis, though this is less likely to be a source of confounding when VE was assessed for more 
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severe disease, such as requiring hospitalisation. If unvaccinated groups were less likely to be 
identified as cases, due to differences in health care use (113) this would lead to an underestimation 
of VE. Differential healthcare provider testing behaviour may lead to an overestimation of VE if 
providers are less likely to suspect or test for disease in vaccinated individuals (110). It is unknown 
whether there is variability in thresholds for hospitalisation, for instance between metropolitan and 
regional or public and private contexts, across Queensland or Australia in general. Another 
limitation of using routinely collected data is the limited information on or knowledge of potential 
confounding factors. The most important potential confounder in observational VE studies is 
exposure to infection, which may vary with geography and socio-demographic factors (110). 
Differential susceptibility to disease between vaccinated and unvaccinated groups, due to reasons 
apart from vaccination is another potential confounding factor. In my VE assessments, potential 
confounding due to age was limited by either age-matching in the varicella case-control study or 
calculating VE for narrow birth cohorts in screening method assessments. These make 
substantial residual confounding due to age less likely. However, it is unknown how the VE 
assessments in this thesis have been affected by other, unrecognised residual confounding 
variables. 
The screening method is not recommended for providing precise estimates of VE, but it does 
provide evidence on whether further evaluation is required (139). Furthermore, in the context of 
high PPV, which was generally the case in the studies presented in this thesis, small changes in 
PCV result in large changes in VE estimates. As incidence of disease becomes rarer, the PCV 
becomes more sensitive to small changes in the vaccination status of cases (139, 304). 
Ecological studies, such as my research on the impact of vaccination programs, are important for 
monitoring population health and generating hypotheses for further investigation (305). However, 
findings from ecological studies require cautious interpretation, as the association found at the 
population level may not necessarily occur at the level of the individual. 
Identifying issues with data quality early is essential for accurate and efficient research. A project I 
was involved in used a large linked dataset of rotavirus outcome and vaccination status. 
Unfortunately, the specificity of the rotavirus test used at the time of the data collected in this 
dataset was unexpectedly poor (306, 307), thereby undermining the validity of vaccine impact and 
effectiveness assessment using rotavirus coded health outcomes. This highlights the importance of 
examining data, understanding the data collection process, and potential weaknesses that may affect 
data quality and interpretation. 
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A limitation of using routinely collected health outcome data is reliance upon the accuracy and 
completeness of health outcome codes. Accurate laboratory testing data, when linked to diagnostic 
codes (such as in hospitalisation data) may be used to improve the specificity of case definitions. It 
is likely that the accuracy of diagnostic coding varies by condition, context, and health practitioner. 
Codes based on clinical diagnosis in ED by less experienced clinicians, such as may occur for 
chickenpox, are likely to be less specific than conditions requiring hospitalisation and confirmed 
with laboratory investigations. Errors may also occur in the administrative coding of routinely 
collected data. Moreover, the accuracy and completeness of coding may change over time with 
changes in health care practice and improved diagnostics. These limitations require consideration 
specific for each condition when interpreting routinely collected data. 
Routinely collected data and data linkage 
The research presented in this thesis was possible because of the availability of Queensland and 
Australian health and vaccination datasets, and State Government support for the linkage of 
routinely collected data for health research. Health-related and administrative data collected from 
the public and paid for by tax payers should be used to maximise public health benefit, whilst 
protecting the privacy of individuals. For this to occur, continued public funding is required to 
ensure and improve the data quality and accessibility to linked and unlinked health-related data. The 
Population Health Research Network, an Australian Government initiative which is a network of 
collaborators developing Australia’s data linkage capacity should make a powerful contribution to 
health research in Australia (308). There has been some progress in improving the accessibility of 
ACIR for linkage with other health related datasets. Led by Drs Heather Gidding and Hannah 
Moore, a project aiming to evaluate and inform Australia’s immunisation program is being 
undertaken, which has involved the linkage of ACIR and other Commonwealth and State-based 
registers (309). 
In Queensland, vaccine service providers report in the first instance to VIVAS, and immunisation 
encounters recorded in VIVAS are routinely reported to ACIR. However, the opposite does not 
occur, and there are sometimes discrepancies between VIVAS and ACIR, such as in instances 
where children have migrated to Queensland, and their prior vaccination record has not been 
recorded on VIVAS. The completeness, data quality and usefulness of VIVAS could be improved 
through a two-way sharing of immunisation data with ACIR. The improvement in VIVAS data 
quality would enable efficient, timely and more accurate assessment of vaccination programs in 
Queensland, as well as increasing the efficiency of routine public health follow up of notified cases 
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of disease. In addition to VIVAS sharing a unique personal identifier with the Queensland 
Notifiable Conditions System, VIVAS is also being included into a master linkage file with other 
health datasets within the Queensland Department of Health. This will potentially allow more 
timely, inexpensive, and ongoing investigation of vaccination effectiveness and safety.  
Future research 
With changes to vaccine schedules and introductions of new vaccines, there is an ongoing need to 
evaluate the impact and effectiveness of vaccination programs for public and provider confidence, 
and for optimal public health outcome and efficiency. The effectiveness of vaccines may change 
over time due to changes in epidemiology or target populations (110), while disease surveillance 
will continue to be important in both prompting investigation into and providing evidence of VE  
and impact. Post-licensure surveillance also allows identification of unanticipated beneficial or 
detrimental disease-specific and non-disease specific effects of vaccination. Useful future research 
that may be undertaken in Queensland, or Australia-wide, includes investigating both the specific 
and potential non-specific effects of vaccination. 
Disease-specific effects of vaccination 
Recent changes in the pertussis immunisation schedule include re-introduction of an 18 month 
booster into the NIP (17), based upon findings of waning VE in the second and third year of life 
following the primary course vaccinations (126), and publicly funded maternal pertussis 
immunisation (31). Studies from the UK and the US provide evidence of the effectiveness of the 
maternal vaccination as a strategy in preventing and reducing the severity of infant pertussis (310- 
312), and have also demonstrated maternal vaccination to be more effective than postpartum 
vaccination (313). Maintaining pertussis surveillance and assessment of the impact and 
effectiveness of the vaccination schedule will be necessary to evaluate the success of the current 
schedule and inform the need for future changes in pertussis vaccination schedule. 
Key investigations include assessing the local effectiveness of maternal pertussis vaccination on 
protecting infants too young to be fully vaccinated against pertussis. Additionally, the longer-term 
impact of maternal vaccination needs monitoring to identify whether maternal pertussis 
immunisation is associated with differential protection in children beyond their primary course of 
pertussis immunisations. There has been concern that maternal dTpa vaccination may cause 
blunting of the immune response of infants to their primary pertussis-containing vaccination course. 
Several studies have investigated the antibody responses among infants born to mothers who 
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received maternal dTpa vaccination and compared these with those to infants born to mothers who 
did not receive a pertussis containing vaccination during pregnancy. Some blunting of pertussis 
antibody following the primary series of vaccinations has been found, with two studies finding 
resolution of this difference between groups following receipt of a fourth aP containing vaccine at 
12-18 months of age (314, 315). One study has found the persistence of some minor blunting of 
anti-PT antibodies after a 15 month dose among infants born to mothers receiving Tdap in 
pregnancy (316), but the clinical significance of this is unknown. 
For a six month period in 2005 and 2006, Queensland used the five pertussis component DTPa-IPV 
(Quadracel®, Sanofi Pasteur Toronto) for childhood vaccinations, before replacing Quadracel with 
three pertussis component DTPa-IPV (Infanrix IPV®, GlaxoSmithKline Australia). A study from 
the US identified differential protection provided by two brands of dTpa, given as booster doses to 
adolescents primed with DTPa (317). They found receipt of the 3-component dTpa (Boostrix; 
GlaxoSmithKline Biologicals, Rixensart, Belgium) was associated with greater protection from 
pertussis than receipt of the 5-component dTpa (Adacel; Sanofi Pasteur, Toronto, Canada) (317). 
However, as recognised by the authors, the effectiveness of the different brands of dTpa may be 
related to the nature of DTPa received in childhood, information which was not available for the 
cohort studied (317). To the best of my knowledge, there is no published evidence comparing the 
longer-term effectiveness of three versus 5-component DTPa pertussis containing vaccines. Using 
historical VIVAS data, in which the details of a vaccine, including batch number, are recorded, we 
have a unique opportunity in Queensland to investigate whether receipt of the three compared to the 
5-component aP for the primary course, or initial vaccine, is associated with differential protection 
against pertussis in children. 
Another useful assessment of potential differential effectiveness of different pertussis vaccine 
schedules involves comparing the effectiveness of a four-dose (at 2, 4, 6 months, and 4 years of 
age) versus a five-dose (at 2, 4, 6, 18 months, and 4 years of age) aP childhood course. This may 
indicate the expected benefit from re-introducing the 18 month aP dose into the NIP. Assessment of 
the impact and effectiveness of the re-introduced 18 month DTPa will be important to evaluate the 
recent change in vaccination schedule. 
Whilst there is evidence of the differential effectiveness of wP and aP vaccines against pertussis 
notification, comparison of the effectiveness of wP and aP vaccines on more severe pertussis 
outcomes, such as infections requiring hospitalisation, would provide new and useful findings. 
Ongoing monitoring of varicella and HZ, in the context of a maturing VV program, an ageing 
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population, and introduction of publicly funded Zostavax will be important when considering 
including a second dose of VV, and evaluating the effectiveness, impact, and timing of Zostavax. 
Evaluation of Zostavax will also inform decisions on the potential future replacement of Zostavax 
with more recently developed zoster vaccine being currently trialled (318). 
Similarly, continued evaluation of rotavirus vaccines using routinely collected data will provide 
useful information on the impact of an increasing established vaccination program. This includes 
monitoring to detect vaccine escape mutants that may threaten the ongoing success of the rotavirus 
vaccination program. 
There is great value in having VE evaluation incorporated as a core task of health departments, in 
settings where existing resources enable efficient assessment. With its own vaccination register, 
Queensland is in better position than most other Australian jurisdictions to undertake such 
assessments. For instance, using linked vaccination and public Queensland Pathology testing data, 
VE could be rapidly estimated using a test-negative design for conditions such as rotavirus, 
pertussis, and influenza. Such VE assessments could be triggered by unexpected increases in 
disease or alternatively could be part of regular and routine assessment, such as for seasonal 
influenza vaccine. Whilst multiple biases may occur in test-negative studies (319), interpreted with 
caution, such studies can add valuable insight into the performance of a vaccination program. 
Non-specific effects of vaccination 
A new paradigm in vaccinology considers not only the effect of a vaccine on the target-disease (the 
specific or homologous effect of vaccines), but also the non-specific or heterologous vaccine 
effects. As recognised by Flanagan, this shift in understanding the broader effects of vaccination 
opens a new phase in vaccine research (320). In this model, vaccines are recognised as having non- 
specific effects, which influence the immune response to subsequent exposure to unrelated 
antigenic exposures (321). The nature of the non-specific effect is considered to vary with the type 
of vaccine, the sequence in which vaccinations occur, the sex of the recipient, and whether 
micronutrients are co-administered with vaccination (321). 
There is a growing body of epidemiological evidence describing the non-specific effects of vaccines 
on non-vaccine targeted infections and all-cause mortality (321-324). It is important to identify and 
understand both specific and non-specific effects of vaccination so that vaccination schedules can 
both maximise benefits and minimise potentially detrimental effects of vaccines (321). Among the 
evidence of non-specific effects are findings from low income settings, indicating the co- 
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administration of MMR with DTPw may be associated with higher mortality than administration of 
DTPw prior to MMR (325), and that females may be more susceptible to non-specific vaccine 
effects than males (326, 327). While most of the studies of non-specific effects of vaccination have 
come from low-income settings, there is also some evidence from high-income countries. This 
includes findings from Spain indicating Bacille Calmette-Guerin vaccination (BCG) at birth may 
decrease hospitalisation rates among children up to 15 years of age for non-tuberculosis related 
respiratory infections and sepsis (328). A population-based cohort study of Danish children found 
receipt of MMR compared to DTPa-IPV-Hib as the most recent vaccine was associated with a lower 
hospitalisation rate for infections of any cause (329). In addition to vaccines influencing risk of non- 
targeted infectious diseases, there is some evidence BCG vaccination may protect against allergic 
disease (330), although other studies provide conflicting results (331). 
There are several research questions concerning potential non-specific effects of vaccination that 
may be investigated initially with linked vaccination and health outcome data in Queensland or 
Australia-wide. These include investigating whether wP and aP are associated with differential risk 
of atopy or non-pertussis infection-related hospitalisation, in addition to their differential 
effectiveness against pertussis (332). Other potential investigations include examination of 
heterologous effects associated with the change from single live to inactivated vaccines, such as 
from OPV to IPV, and changes in the vaccination schedule with regard to combined live and/or 
inactivated vaccines such as replacing MMR at 4 years of age with MMRV at 18 months of age co- 
administered with DTPa. Investigation into whether Aboriginal and Torres Strait Islander children 
who receive BCG at birth experience the same protective effects as suggested in the Spanish 
findings (328) would also be of value. If protective effects are found, this could inform changes in 
the recommended use of BCG, beyond the current recommendation to Aboriginal and Torres Strait 
Islander neonates in regions at higher risk of tuberculosis (333). A randomised controlled trial 
currently being undertaken in Melbourne by Professor Nigel Curtis, investigating whether BCG at 
birth reduces both allergy and infection in the first year of life, will provide important evidence to 
inform BCG vaccination recommendations (334). 
Conclusion 
The body of research presented in this thesis has added to our understanding of the effectiveness 
and impact of vaccination programs in Australia and has important implications for such programs 
internationally. This work highlights the importance of measuring post-licensure VE and 
undertaking impact surveillance to identify longer-term effectiveness and impacts of vaccination 
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programs that are not known at the time of vaccine introduction. Routinely collected and linked 
health data provide a powerful, resource-efficient tool to undertake the necessary monitoring of 
vaccine impact and effectiveness to inform vaccination policy decision-making. One way in which 
VE and impact studies contribute to vaccine policy decisions is by providing vital information for 
economic analyses of vaccine programs. Opportunities for further work include the sustainable 
integration of VE assessment into routine health department activity, and expanding assessments to 
include off target disease impacts. 
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 To the editor: In their recent article on the Australian immunisation registers (335) Chin et al. 
recognise the potential value of linking immunisation registers with healthcare outcome data for 
public health benefit by enabling rapid investigation of population-level vaccine safety and 
effectiveness. While the national Australian Childhood Immunisation Register (ACIR) has been 
linked on two occasions to examine vaccine safety, (282, 336) it has not been linked to health 
outcome data to investigate vaccine effectiveness. 
As Chin et al. mention, Queensland and the Northern Territory have separate jurisdiction-level 
immunisation registers. These registers, which are not subject to the same privacy legislation 
inhibiting linkage of ACIR data, have been used to calculate effectiveness for rotavirus (94, 96), 
pneumococcal (337) and pertussis-containing vaccines (unpublished data) by linking immunisation 
with outcome data such as hospitalisations and disease notifications. 
These studies demonstrate the usefulness of linking data from immunisation registers to assess 
vaccine effectiveness and the importance jurisdiction-level immunisation registers have played in 
allowing evaluation of large publicly-funded immunisation programmes. 
Individual privacy must be protected. However, data linkage does not pose a significant threat to 
privacy and has the potential to contribute efficiently and substantially to public health. One could  
argue that the ethical obligation, seen from a population as well as individual perspective, is to 
ensure routinely-collected health information is efficiently and optimally used to achieve the 
greatest public benefit, while protecting the individual’s privacy. 
In setting up jurisdictional or national immunisation registers to achieve the greatest public benefit, 
we recommend thought be given to enabling easy linkage of data, in practical and legal terms, 
between immunisation and health outcome data. 
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